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ABSTRACT
Chronic limb-threatening ischemia (CLTI) is associated with mortality, amputation, and impaired quality of life. These Global Vascular
Guidelines (GVG) are focused on deﬁnition, evaluation, and management of CLTI with the goals of improving evidence-based care and
highlighting critical research needs. The term CLTI is preferred over critical limb ischemia, as the latter implies threshold values of
impaired perfusion rather than a continuum. CLTI is a clinical syndrome deﬁned by the presence of peripheral artery disease (PAD) in
combinationwith rest pain, gangrene, or a lower limbulceration>2weeks duration. Venous, traumatic, embolic, andnonatherosclerotic
etiologies are excluded. All patients with suspected CLTI should be referred urgently to a vascular specialist. Accurately staging the
severity of limb threat is fundamental, and the Society for Vascular Surgery Threatened Limb Classiﬁcation system, based on grading of
Wounds, Ischemia, and foot Infection (WIfI) is endorsed. Objective hemodynamic testing, including toe pressures as the preferred
measure, is required to assess CLTI. Evidence-based revascularization (EBR) hinges on three independent axes: Patient risk, Limb severity,
and ANatomic complexity (PLAN). Average-risk and high-risk patients are deﬁned by estimated procedural and 2-year all-cause mor-
tality. The GVG proposes a new Global Anatomic Staging System (GLASS), which involves deﬁning a preferred target artery path (TAP)
and then estimating limb-based patency (LBP), resulting in three stages of complexity for intervention. The optimal revascularization
strategy is also inﬂuenced by the availability of autogenous vein for open bypass surgery. Recommendations for EBR are based on best
available data, pending level 1 evidence from ongoing trials. Vein bypass may be preferred for average-risk patients with advanced limb
threat and high complexity disease, while those with less complex anatomy, intermediate severity limb threat, or high patient risk may
be favored for endovascular intervention. All patients with CLTI should be afforded best medical therapy including the use of antith-
rombotic, lipid-lowering, antihypertensive, and glycemic control agents, as well as counseling on smoking cessation, diet, exercise, and
preventive foot care. Following EBR, long-term limb surveillance is advised. The effectiveness of nonrevascularization therapies (eg,
spinal stimulation, pneumatic compression, prostanoids, and hyperbaric oxygen) has not been established. Regenerative medicine
approaches (eg, cell, gene therapies) for CLTI should be restricted to rigorously conducted randomizsed clinical trials. TheGVGpromotes
standardization of study designs and end points for clinical trials in CLTI. The importance of multidisciplinary teams and centers of
excellence for amputation prevention is stressed as a key health system initiative. (J Vasc Surg 2019;69:3S-125S.)
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Rationale and goals
Chronic limb-threatening ischemia (CLTI) represents the
end stage of peripheral artery disease (PAD), a problem of
growing prevalence and increased health care costs
around the globe.1 CLTI is a highly morbid disease, incur-
ring signiﬁcant mortality, limb loss, pain, and diminished
health-relatedqualityof life (HRQL) amongthoseafﬂicted.
Multiple health care specialists are involved in the man-
agement of CLTI, yet lack of public awareness and the
frequent failure to make an early diagnosis continue to
be major obstacles to effective treatment. Variability in
practice patterns is high, contributing to a broad disparity
in the use of treatments and clinical outcomes. For
example, a study from the United States suggested that
many patients do not even receive angiography in the
year before major limb amputation.2 These data also
12S Conte et al Journal of Vascular Surgery
June Supplement 2019demonstrate a broad variation in the use of open or endo-
vascular interventions by region of the country and hospi-
tal referral center.2 More expensive (and more invasive)
care is not associated with better outcomes.3 Instead,
what is lacking is a uniform deﬁnition of clinical stages of
disease and key patient-focused outcomes, contributing
to an incomplete picture of the epidemiology of CLTI
and a limited evidence base to guide daily practice.
At the same time, rapidly evolving technologies in diag-
nostics, devices, drugs, and biologics offer new opportu-
nities to improve treatment and to address unmet needs
in this vulnerable population. A PubMed search of the
term “critical limb ischemia” revealed >5000 citations,
with a clear inﬂection point at the turn of the millennium,
demonstrating an explosion of interest. A new framework
is urgently needed to establish evidence-based medical
practices in this changing ﬁeld. The rationale for this global
guideline on the management of CLTI was based on this
nexus of factors and the recognition of its growing impact
on public health across all nations and socioeconomic
strata. Vascular specialists play a dominant role in the treat-
ment of CLTI. Accordingly, in 2013, when several leading
vascular societies determined to launch the Global
Vascular Guidelines (GVG) initiative, CLTI was considered
the ﬁrst priority disease area of focus. The primary goal of
this practice guideline on CLTI is to improve the quality of
care for all patients with CLTI as well as for those at risk for
CLTI.An important secondarygoal is to identifykey research
priorities in need of further basic, translational, clinical, and
health services investigation to advance those aims.
GVG structure
The threemajor global vascular surgical societies, theEu-
ropean Society for Vascular Surgery (ESVS), the Society for
Vascular Surgery (SVS), and the World Federation of
Vascular Societies (WFVS), joined efforts to launch the
GVG initiative. In this process, theESVS represents national
vascular societies fromEurope and the SVS represents na-
tional, regional, and local vascular societies inNorthAmer-
ica. The WFVS represents a large number of non-
European, non-North American vascular surgical societies
from across the world. These include the Australian and
New Zealand Society for Vascular Surgery, the Japanese
Society for Vascular Surgery, the Vascular Society of India,
the Vascular Society of Southern Africa, the Asian Society
for Vascular Surgery, and the Latin American Society of
Vascular Surgery andAngiology (this list is not exhaustive).
As the primary sponsors, the ESVS, SVS, and WFVS devel-
oped the organizational structure, policies on conﬂict of
interest, andcommittedﬁnancial support for theGVGpro-
gram.Allﬁnancial support for theGVGwasderiveddirectly
from the sponsoring societies and without the direct
involvement of industry or other external stakeholders.
Representatives from the three leading societies were
asked to serve as Co-Editors as well as members of the
Steering Committee to oversee all aspects of the projectand its subsequent communications. Oversight from the
societies was limited to budgetary and administrative as-
pects, including their respectivedocument reviewpolicies
before public dissemination of the ﬁnal guideline. The
Steering Committee recruited a large and diversiﬁed
writing group; developed the scope and section briefs for
the guideline; identiﬁed priority questions for commis-
sioned evidence reviews; and participated in all stages of
writing, consensus debate, and editing of themanuscript.
Conﬂict of interest policy
A primary consideration on inception of the GVG was to
create a robust yet practical approach to conﬂict of interest
to enable an unbiased effort at guideline development by
experts in the ﬁeld. A central element to this, in concert
with the exclusion of direct commercial funding sources,
was full disclosure and speciﬁc limits on relevant ﬁnancial
relationships for members of the writing group, Steering
Committee, and Co-Editors. A full description of the GVG
Conﬂict of Interest policy is provided at the beginning of
this supplement. Financial disclosures for all contributing
authors were collected and updated by the Steering Com-
mittee. They are detailed in the table of Contributing Au-
thors listed at the beginning of the guideline.
Leadership and writing group
The Co-Editors and Steering Committee were selected
by the three major sponsoring societies and were tasked
with the recruitment of a multidisciplinary, international
writing group of recognized experts. In total, the ﬁnal
writing group comprised 58 individuals from 24 countries
across 6 continents. This group represents specialists in
vascular surgery, vascular medicine, interventional cardiol-
ogy and radiology, angiology, epidemiology, podiatry, and
orthopedics as well as a methodologist with expertise in
guideline development. Authors were assigned to individ-
ual sections of the guideline, and all authors reviewed the
complete ﬁnal document before societal review.
Methodology
The Steering Committee drafted a Table of Contents
that was divided into distinct sections. Briefs were
created to outline the scope and content of each section.
Potential authors were then solicited and vetted, and
two authors were chosen to co-lead the writing effort
for each section. The co-lead authors communicated
directly with the Steering Committee on their progress
and on iterative cycles of revision as needed. All of the au-
thors of each section reviewed and approved their ﬁnal
versions before compilation of the full document.
The Steering Committee examined the state of recent
evidence reviews in the ﬁeld, including those commis-
sioned by the participating societies, and determined
the need for additional evidence reviews and updating.
These were commissioned to an external group (Mayo
Clinic Evidence-Based Practice Research Program) who
performed four systematic reviews that summarized
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studies.4-7 These systematic reviews underwent peer re-
view and were published in the Journal of Vascular Sur-
gery, one of which is published as an accompaniment
to the guideline document in this supplement.7
Consensus development during the process occurred
through conﬁdential electronic communications, tele-
conferences, and multiple in-person meetings of the
Steering Committee and members of the writing group.
The Grading of Recommendations Assessment, Develop-
ment, and Evaluation (GRADE) approach was used to
determine the quality of evidence and strength of recom-
mendations.8 A strong (Grade 1) recommendation implies
that the guideline developers are conﬁdent as to the bal-
ance of beneﬁts and harmand that this recommendation
should apply to the majority of patients. A conditional
recommendation (Grade2) implies less certainty and indi-
cates that a different course of action is reasonable. The
guideline developers used an imperative verb to denote
strong recommendations and used the term “consider”
to denote a conditional recommendation. The level of ev-
idence for each recommendation is consideredhighqual-
ity (A), moderate quality (B), or low quality (C). The
guideline also includes good practice recommendations.
These ungraded good practice recommendations are
supported by a wealth of indirect evidence but no direct
evidence, and the beneﬁt of pursuing the recommended
actions is considered to outweigh any plausible harm. The
intentionof thesegoodpractice recommendationswas to
draw attention to and remind providers of known and
noncontroversial surgical principles or principles about
general medical care. For example, there are good prac-
tice statements about performing a comprehensive his-
tory and physical examination in patients with CLTI.9
The ﬁnal grading of all guideline recommendations was
determined by the guideline developers and themethod-
ologist. After approval by the fullwritinggroup, the sections
were compiled into one document and reviewed concur-
rently by the document oversight bodies of each of the
three sponsoring societies. An open comment period was
subsequently enabled on a secure website (http://vsweb.
org/GlobalVascularGuidelines) to provide an opportunity
for external stakeholders to review the document. The Co-
Editors collated all reviews and made ﬁnal revisions to the
document,whichwas thenapprovedby thesponsoringso-
cieties before publication and dissemination.
Target population
The target population of patients includes adults with
CLTI, deﬁned as a patient with objectively documented
PAD and any of the following clinical symptoms or signs:
d Ischemic rest pain with conﬁrmatory hemodynamic
studies
d Diabetic foot ulcer (DFU) or any lower limb ulceration
present for at least 2 weeks
d Gangrene involvinganyportionof the lower limbor footSpeciﬁcallyexcludedarepatientswithpurevenousulcers,
pure traumatic wounds, acute limb ischemia (symptoms
present for 2weeks or less), embolic disease, andnonather-
osclerotic chronic vascular conditions of the lower extrem-
ity (eg, vasculitis, Buerger disease, radiation arteritis).
Target audience
The primary target audience for this guideline includes
all clinicians who are directly involved in themanagement
of patients with CLTI, to include surgeons (vascular, gen-
eral, plastic, and orthopedic), interventionalists (radiolo-
gists, cardiologists), podiatrists, wound care providers,
rehabilitation medicine specialists, orthotists and physical
therapists, and trainees in these disciplines.
Secondary audiences include referringproviders, suchas
primary care physicians, medical specialists, nurses, and
other allied health providers, who may care for the at-risk
population and who are critical for awareness and timely
specialist referral of patients with suspected CLTI. Other
key targets for this guideline are third parties with inﬂu-
ence over the current and future treatment of CLTI,
including government agencies, payers (funders), industry
stakeholders, investigators, and research organizations.
CLTI: A new paradigm for treatment and research
This clinical practice guideline (CPG) intentionally seeks
to create a new conceptual framework for the treatment
of CLTI. It encompasses nomenclature, disease staging,
and a platform for evidence-based revascularization
(EBR) thatwill allow future evolution andquality improve-
ment in the ﬁeld. A brief introduction to the key elements
introduced in this document is provided here.
Nomenclature. Consistent and meaningful nomencla-
ture is of fundamental importance for assessing the state
of evidence and guiding future research efforts. To this
end, the GVG promotes the use of the term CLTI, deﬁned
by the target population, to denote the universe of pa-
tients with advanced lower limb ischemia, wounds, neu-
ropathy, and infection who are commonly referred to
vascular specialists for evaluation and management.
Prior terms, such as “critical” and “severe” limb ischemia,
connote speciﬁc hemodynamic thresholds and fail to
recognize the full spectrum and inter-relatedness of
components beyond ischemia that contribute to major
limb amputation and long-term disability. This is
addressed fully in Section 1 of the guideline.
Disease staging in CLTI. Improved disease staging is
mandatory for designing clinical trials, conducting
comparative effectiveness research, identifying critical
gaps in knowledge, and developing effective algorithms
for treatment. CLTI represents a broad range of clinical
severity (limb threat) and anatomic complexity of dis-
ease. The GVG incorporates the SVS Lower Extremity
Threatened Limb Classiﬁcation System10 as a preferred
staging system for CLTI, which is discussed more fully in
Section 1 and other related areas of the document.
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of EBR for CLTI to improve the quality of vascular care
and to reduce disparities in treatment and outcomes.
However, the existing database to support EBR is found
to be lacking in many domains. There have been few
high-quality randomized controlled trials (RCT) or
comparative effectiveness studies in the ﬁeld. This re-
mains a major unmet need requiring broad support
from national health agencies, payers, industry, profes-
sional organizations, and research foundations. The
writing group sought the best available evidence to
generate consensus recommendations while also
providing a foundation for future iterations based on a
patient- and limb-centric approach to treatment rather
than on the prevailing lesion-focused lexicon in the ﬁeld.
The PLAN concept of EBR (Section 6) stresses a struc-
tured management approach based on Patient risk,
Limb severity, and ANatomic pattern of disease, in that
order of priority. The authors believe that adequate strat-
iﬁcation along these three independent axes is clinically
relevant and of fundamental importance to improve ev-
idence quality and to achieve EBR for patients with CLTI.
Further development of this approach requires prospec-
tive validation and reﬁnement of tools to accurately
stage patient risk, limb threat, and anatomic patterns
of disease, as discussed in detail in the document.
Global Limb Anatomic Staging System (GLASS). A
new anatomic scheme for the threatened limb is pro-
posed. Commonly used anatomic classiﬁcation schemes
for PAD are lesion or segment focused11 or aim to quan-
tify the overall burden of disease,12 rather than integrating
the complex patterns of disease found in most patients
with CLTI. Successful revascularization in CLTI, particularly
in patients with tissue loss, nearly always requires resto-
ration of in-line (pulsatile) ﬂow to the foot. Moreover, there
is a general lack of understanding of the relationships
between patterns of disease, hemodynamic improve-
ment after treatment, anatomic durability, clinical stage,
andoutcomes that continues toplague theﬁeld.With this
in mind, a new approach was developed to facilitate
clinical decision-making in CLTIdthe GLASS (Section 5).
To be most useful, GLASS incorporates a set of baseline
assumptions to avoid overcomplexity and to permit its
ready utility in everyday clinical practice and in future
research.
GLASS incorporates two novel and important concepts,
the target arterial path (TAP) and estimated limb-based
patency (LBP). Based on appropriate angiographic
imaging, the TAP is deﬁned by the treating surgeon or
interventionalist as the optimal arterial pathway to restore
in-line (pulsatile) ﬂow to the ankle and foot. It may incor-
porate either the least diseased or an angiosome-
preferred path, as chosen by the treating clinician. LBP is
deﬁned as maintenance of in-line ﬂow throughout the
TAP, from groin to ankle. LBP allows more directcomparison of anatomic outcomes across revasculariza-
tion strategies in CLTI. The complexity of disease
traversed by the TAP is integrated in the GLASS. Femoro-
popliteal (FP) and infrapopliteal (IP) arterial segments are
individually graded on a scale of 0 to 4. Using a consensus-
basedmatrix, these segmental grades are combined into
three overall GLASS (I-III) stages for the limb.
GLASS includes a simpliﬁed approach to inﬂow (aortoil-
iac [AI]) disease, a dichotomous stratiﬁcation for severe
calciﬁcation within segment, and a simple modiﬁer for
pedal (inframalleolar [IM]) disease. GLASS stages (I-III)
were deﬁned on the basis of expected technical success
and anatomic durability for infrainguinal endovascular
intervention and reﬂect the overall complexity of disease
within the TAP. The consensus process for developing
and assigning GLASS stages was informed by an
updated systematic review of revascularization out-
comes in CLTI.7 Thus, GLASS stages I to III correlate with
low-, intermediate-, or high-complexity infrainguinal dis-
ease patterns, with expected correlation to immediate
technical success and 1-year LBP for endovascular inter-
vention. The relevance of these GLASS anatomic stages
in different clinical scenarios is integrated within the
PLAN framework for decision-making. GLASS is designed
for subsequent reﬁnement, reclassiﬁcation, and valida-
tion based on data from prospective studies that employ
the scheme and report appropriate outcome measures.
A mobile app to quickly derive GLASS stage from angio-
graphic imaging in real time will be released in proximity
to the guideline publication.
End points and trial designs. Existing limitations of the
evidence base in CLTI were obvious and broadly acknowl-
edged during the GVG development process. The impor-
tance of developing consensus around key outcome
measures, with a focus on patient-oriented end points, is
critical to advancing the ﬁeld. It is anticipated that
currently enrolling RCTs, including Bypass vs Angioplasty
in Severe Ischaemia of the Leg (BASIL-2) trial, Balloon vs
Stenting in Severe Ischaemia of the Leg (BASIL-3) trial, and
Best Endovascular vs Best Surgical Therapy for Patients
with Critical Limb Ischemia (BEST-CLI), will allow impor-
tant advances in themanagement of CLTI, with signiﬁcant
overlap among these efforts.13-15 In Section 11 of the
guideline, a full consideration of this important topic is
provided as a framework, with speciﬁc recommendations
for study and RCT designs going forward.
Interdisciplinary team in CLTI. There has been growing
recognition of the value of multidisciplinary and interdis-
ciplinary team-based care to optimize the outcomes for
patients with CLTI. The components of such teams vary
considerably across centers and regions of practice, but
certain critical skill sets, expertise, facilities, and resources
are required to create a Center of Excellence for CLTI
management. Consideration of this important topic is
addressed in Section 12 of the guideline.
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revisions of the guideline
Translation of expert guidelines into clinical practice is
known to be a major obstacle to evidence-based medi-
cine. Reasons are multifactorial and include limited pro-
vider and patient engagement, lack of consensus,
economic conﬂicts, and resource constraints. The inter-
national scope of the GVG mandated an attempt to sur-
vey differences in practice patterns, resources, and
potential hurdles to implementation around the globe
(Section 13). Dissemination of the guideline by the spon-
soring societies is planned to include an array of print
media, web and social media, mobile apps, and commu-
nications at multiple national and regional meetings to
facilitate discussion. The incorporation of suggested stag-
ing systems and end points into national and multina-
tional registries will greatly facilitate use and future
reﬁnement of this effort. It is anticipated that the GVG
will be translated into the other major world languages.
To remain current and evidence based, practice guide-
lines must be periodically reviewed and updated.
Ongoing RCTs and prospective cohort studies will pro-
vide critical new evidence in the management of CLTIRecommendation
1. Deﬁnitions and nomenclature
1.1 Use objective hemodynamic tests to
determine the presence and to quantify the
severity of ischemia in all patients with
suspected CLTI.
1 (S
1.2 Use a lower extremity threatened limb
classiﬁcation staging system (eg, SVS’s WIfI
classiﬁcation system) that grades wound
extent, degree of ischemia, and severity of
infection to guide clinical management in
all patients with suspected CLTI.
1 (S
2. Global epidemiology and risk factors for CLTI
No recommendations
3. Diagnosis and limb staging in CLTI
3.1 Perform a detailed history to determine
symptoms, past medical history, and
cardiovascular risk factors in all patients with
suspected CLTI.
Go
3.2 Perform a complete cardiovascular physical
examination of all patients with suspected
CLTI.
Go
3.3 Perform a complete examination of the foot,
including an assessment of neuropathy and
a probe-to-bone test of any open ulcers, in
all patients with pedal tissue loss and
suspected CLTI.
Go
3.4 Measure AP and ABI as the ﬁrst-line
noninvasive test in all patients with
suspected CLTI.
1 (Sduring the next several years. The sponsoring societies
of the GVG recognize the importance of stewardship of
this practice guideline, both as new key evidence arises
and as a planned interval exercise.
Supporting materials
Evidence-based recommendations made in this
guideline are supported by key references listed in the
text. A summary of the relevant ﬁndings from the
studies used to support each recommendation is pro-
vided as a Supplementary Table (online only) to the
guideline.
A scientiﬁcmanuscript summarizing a commissionedev-
idence review on the outcomes of revascularization in CLTI
is also published within the guidelines supplement.7 This
manuscript underwent independent peer review by the
Journal of Vascular Surgery. The Supplementary Tables of
that document summarizing the individual source studies
and the various outcomes analyzed by time interval are





trong) C (Low) de Graaff,16 2003
Brownrigg,17 2016
Wang,18 2016





trong) B (Moderate) Lijmer,19 1996
Dachun,20 2010





3.5 Measure TP and TBI in all patients with
suspected CLTI and tissue loss (Fig 3.1 in full
guideline).
1 (Strong) B (Moderate) Aboyans,21 2008
Salaun,22 2018
3.6 Consider using alternative methods for
noninvasive assessment of perfusion, such as
PVR, transcutaneous oximetry, or skin
perfusion pressure, when ankle and toe
pressures, indices, and waveforms cannot be
assessed.
2 (Weak) C (Low) Aboyans,21 2008
Shirasu,23 2016
Saluan,22 2018
3.7 Consider DUS imaging as the ﬁrst arterial
imagingmodality in patients with suspected
CLTI.
2 (Weak) B (Moderate) Hingorani,24 2008
3.8 Consider noninvasive vascular imaging
modalities (DUS, CTA, MRA) when available
before invasive catheter angiography in
patients with suspected CLTI who are
candidates for revascularization.






3.9 Obtain high-quality angiographic imaging of
the lower limb (with modalities and
techniques to be determined by local
availabilty of facilities and expertise). This
should include the ankle and foot in all
patients with suspected CLTI who are




4.1 Evaluate cardiovascular risk factors in all
patients with suspected CLTI.
1 (Strong) B (Moderate) I.C.A.I. Group,30 1997
4.2 Manage all modiﬁable risk factors to
recommended levels in all patients with
suspected CLTI.
1 (Strong) B (Moderate) Armstrong,31 2014
Faglia,32 2014
4.3 Treat all patients with CLTI with an antiplatelet
agent.








4.4 Consider clopidogrel as the single antiplatelet
agent of choice in patients with CLTI.
2 (Weak) B (Moderate) CAPRIE,35 1996
Hiatt,36 2017
4.5 Consider low-dose aspirin and rivaroxaban, 2.5
mg twice daily, to reduce adverse
cardiovascular events and lower extremity
ischemic events in patients with CLTI.
2 (Weak) B (Moderate) Anand,37 2018
4.6 Do not use systemic vitamin K antagonists for
the treatment of lower extremity
atherosclerosis in patients with CLTI.
1 (Strong) B (Moderate) Anand,38 2007
4.7 Use moderate- or high-intensity statin therapy
to reduce all-cause and cardiovascular
mortality in patients with CLTI.















4.8 Control hypertension to target levels of <140
mm Hg systolic and <90 mm Hg diastolic in
patients with CLTI.






4.9 Consider control of type 2 DM in CLTI patients
to achieve a hemoglobin A1c of <7% (53
mmol/mol [International Federation of
Clinical Chemistry]).







4.10 Use metformin as the
primary hypoglycemic agent
in patients with
type 2 DM and CLTI.
1 (Strong) A (High) Palmer,54 2016
4.11 Consider withholding metformin immediately
before and for 24 to 48 hours after the
administration of an iodinated contrast
agent for diabetic patients, especially those
with an estimated glomerular ﬁltration
rate <30 mL/min/1.73 m2.
2 (Weak) C (Low) Nawaz,55 1998
Goergen,56 2010
Stacul,57 2011
4.12 Offer smoking cessation interventions
(pharmacotherapy, counseling,
or behavior modiﬁcation therapy)
to all patients with CLTI
who smoke or use
tobacco products.
1 (Strong) A (High) Dagenais,58 2005
Athyros,59 2013
Blomster,60 2016
4.13 Ask all CLTI patients who are smokers or
former smokers about status of tobacco use
at every visit.
1 (Strong) A (High) Kondo,61 2011
Newhall,62 2017
4.14 Prescribe analgesics of appropriate strength
for CLTI patients who have ischemic rest
pain of the lower extremity and foot until
pain resolves after revascularization.
Good practice statement
4.15 In CLTI patients with chronic severe pain, use
paracetamol (acetaminophen) in
combination with opioids for pain control.
Good practice statement
5. The Global Limb Anatomic Staging System (GLASS) for CLTI
5.1 Use an integrated, limb-based anatomic
staging system (such as the GLASS) to deﬁne
complexity of a preferred target artery path
(TAP) and to facilitate evidence-based
revascularization (EBR) in patients with CLTI.
Good practice statement
6. Strategies for EBR
6.1 Refer all patients with suspected CLTI to a
vascular specialist for consideration of limb
salvage, unless major amputation is
considered medically urgent.
Good practice statement
6.2 Offer primary amputation or palliation to
patients with limited life expectancy, poor
functional status (eg, nonambulatory), or an
unsalvageable limb after shared decision-
making.
Good practice statement
(Continued on next page)
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6.3 Estimate periprocedural risk and life
expectancy in patients with CLTI who are
candidates for revascularization.






6.4 Deﬁne a CLTI patient as average surgical risk
when anticipated periprocedural mortality
is <5% and estimated 2-year survival is
>50%.
2 (Weak) C (Low)
6.5 Deﬁne a CLTI patient as high surgical risk when
anticipated periprocedural mortality is $5%
or estimated 2-year survival is #50%.
2 (Weak) C (Low)
6.6 Use an integrated threatened limb
classiﬁcation system (such as WIfI) to stage
all CLTI patients who are candidates for limb
salvage.





6.7 Perform urgent surgical drainage and
débridement (including minor amputation
if needed) and commence antibiotic
treatment in all patients with suspected CLTI
who present with deep space foot infection
or wet gangrene.
Good practice statement
6.8 Repeat limb staging after surgical drainage,
débridement, minor amputations, or
correction of inﬂow disease (AI, common
and deep femoral artery disease) and before
the next major treatment decision.
Good practice statement
6.9 Do not perform revascularization in the
absence of signiﬁcant ischemia (WIfI
ischemiagrade0) unless an isolated regionof
poor perfusion in conjunction with major
tissue loss (eg,WIfIwoundgrade2or 3) canbe
effectively targeted and the wound
progresses or fails to reduce in size by $50%
within 4 weeks despite appropriate infection
control, wound care, and ofﬂoading.
Good practice statement
6.10 Do not perform revascularization in very-low-
risk limbs (eg, WIfI stage 1) unless the wound
progresses or fails to reduce in size by $50%
within 4 weeks despite appropriate infection
control, wound care, and ofﬂoading.




6.11 Offer revascularization to all average-risk
patients with advanced limb-threatening
conditions (eg, WIfI stage 4) and signiﬁcant
perfusion deﬁcits (eg, WIfI ischemia grades 2
and 3).
1 (Strong) C (Low) Abu Dabrh,5 2015
6.12 Consider revascularization for average-risk
patients with intermediate limb threat (eg,
WIfI stages 2 and 3) and signiﬁcant perfusion
deﬁcits (eg, WIfI ischemia grades 2 and 3).





6.13 Consider revascularization in average-risk
patients with advanced limb threat (eg, WIfI
stage 4) and moderate ischemia (eg, WIfI
ischemia grade 1).
2 (Weak) C (Low)
6.14 Consider revascularization in average-risk
patients with intermediate limb threat (eg,
WIfI stages 2 and 3) andmoderate ischemia
(eg, WIfI ischemia grade 1) if the wound
progresses or fails to reduce in size by $50%
within 4 weeks despite appropriate infection
control, wound care, and ofﬂoading.
2 (Weak) C (Low)






6.15 Obtain high-quality angiographic imaging
with dedicated views of ankle and foot
arteries to permit anatomic staging and
procedural planning in all CLTI patients who
are candidates for revascularization.
Good practice statement
6.16 Use an integrated limb-based staging system
(eg, GLASS) to deﬁne the anatomic pattern
of disease and preferred TAP in all CLTI
patients who are candidates for
revascularization.
Good practice statement
6.17 Perform ultrasound vein mapping when
available in all CLTI patients who are
candidates for surgical bypass.
1 (Strong) C (Low) Seeger,77 1987
Wengerter,78 1990
Schanzer,79 2007
6.18 Map the ipsilateral GSV and small saphenous
vein for planning of surgical bypass.
Map veins in the contralateral leg and both
arms if ipsilateral vein is insufﬁcient or
inadequate.
Good practice statement
6.19 Do not classify a CLTI patient as being
unsuitable for revascularization without
review of adequate-quality imaging studies
and clinical evaluation by a qualiﬁed
vascular specialist.
Good practice statement
6.20 Correct inﬂow disease ﬁrst when both inﬂow
and outﬂow disease are present in a patient
with CLTI.
Good practice statement
6.21 Base the decision for staged vs combined
inﬂow and outﬂow revascularization on
patient risk and the severity of limb threat
(eg, WIfI stage).
1 (Strong) C (Low)
Harward,80 1995
Zukauskas,81 1995
6.22 Correct inﬂow disease alone in CLTI patients
with multilevel disease and low-grade
ischemia (eg, WIfI ischemia grade 1) or
limited tissue loss (eg, WIfI wound grade 0/1)
and in any circumstance in which the risk-
beneﬁt of additional outﬂow reconstruction
is high or initially unclear.
1 (Strong) C (Low)
6.23 Restage the limb and repeat the
hemodynamic assessment after performing
inﬂow correction in CLTI patients with inﬂow
and outﬂow disease.
1 (Strong) C (Low)
6.24 Consider simultaneous inﬂow and outﬂow
revascularization in CLTI patients with a high
limb risk (eg, WIfI stages 3 and 4), or in
patients with severe ischemia (eg, WIfI
ischemia grades 2 and 3).
2 (Weak) C (Low)
6.25 Use an endovascular-ﬁrst approach for
treatment of CLTI patients with moderate to
severe (eg, GLASS stage IA) aorto-iliac (AI)
disease, depending on the history of prior
intervention.
1 (Strong) B (Moderate) Jongkind,82 2010
Ye,83 2011
Deloose,84 2017
6.26 Consider surgical reconstruction for the
treatment of average-risk CLTI patients with
extensive (eg, GLASS stage II) AI disease or
after failed endovascular intervention.
2 (Weak) C (Low) Ricco,85 2008
Chiu,86 2010
Indes,87 2013
(Continued on next page)
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6.27 Perform open CFA endarterectomy with patch
angioplasty, with or without extension into
the PFA, in CLTI patients with
hemodynamically signiﬁcant (>50%
stenosis) disease of the common and deep
femoral arteries.
1 (Strong) C (Low) Kang,88 2008
Ballotta,89 2010
6.28 Consider a hybrid procedure combining open
CFA endarterectomy and endovascular
treatment of AI disease with concomitant
CFA involvement (GLASS stage IB).
2 (Weak) C (Low) Chang,90 2008
6.29 Consider endovascular treatment of signiﬁcant
CFA disease in selected patients who are
deemed to be at high surgical risk or to have
a hostile groin.




6.30 Avoid stents in the CFA and do not place
stents across the origin of a patent deep
femoral artery.
Good practice statement
6.31 Correct hemodynamically signiﬁcant ($50%
stenosis) disease of the proximal deep
femoral artery whenever technically feasible.
Good practice statement
6.32 In average-risk CLTI patients with infrainguinal
disease, base decisions of endovascular
intervention vs open surgical bypass on the
severity of limb threat (eg, WIfI), the
anatomic pattern of disease (eg, GLASS), and
the availability of autologous vein.
1 (Strong) C (Low) Almasri,7 2018
6.33 Offer endovascular revascularization when
technically feasible for high-risk patients
with advanced limb threat (eg, WIfI stage 4)
and signiﬁcant perfusion deﬁcits (eg, WIfI
ischemia grades 2 and 3).






6.34 Consider endovascular revascularization for
high-risk patients with intermediate limb
threat (eg, WIfI stages 2 and 3) and
signiﬁcant perfusion deﬁcits (eg, WIfI
ischemia grades 2 and 3).
2 (Weak) C (Low)
6.35 Consider endovascular revascularization for
high-risk patients with advanced limb threat
(eg, WIfI stage 4) and moderate ischemia
(eg, WIfI ischemia grade 1) if the wound
progresses or fails to reduce in size by $50%
within 4 weeks despite appropriate infection
control, wound care, and ofﬂoading, when
technically feasible.
2 (Weak) C (Low)
6.36 Consider endovascular revascularization for
high-risk patients with intermediate limb
threat (eg, WIfI stages 2 and 3) andmoderate
ischemia (eg, WIfI ischemia grade 1) if the
wound progresses or fails to reduce in size
by $50% within 4 weeks despite
appropriate infection control, wound care,
and ofﬂoading, when technically feasible.
2 (Weak) C (Low)
6.37 Consider open surgery in selected high-risk
patients with advanced limb threat (eg, WIfI
stage 3 or 4), signiﬁcant perfusion deﬁcits
(ischemia grade 2 or 3), and advanced
complexity of disease (eg, GLASS stage III) or
after prior failed endovascular attempts and
unresolved symptoms of CLTI.
2 (Weak) C (Low)






6.38 Consider angiosome-guided revascularization
in patients with signiﬁcant wounds (eg, WIfI
wound grades 3 and 4), particularly those
involving the midfoot or hindfoot, and when
the appropriate TAP is available.





6.39 In treating femoro-popliteal (FP) disease in
CLTI patients by endovascular means,
consider adjuncts to balloon angioplasty (eg,
stents, covered stents, or drug-eluting
technologies) when there is a technically
inadequate result (residual stenosis or ﬂow-
limiting dissection) or in the setting of
advanced lesion complexity (eg, GLASS FP
grade 2-4).





6.40 Use autologous vein as the preferred conduit
for infrainguinal bypass surgery in CLTI.
1 (Strong) B (Moderate) Almasri,7 2018
6.41 Avoid using a nonautologous conduit for
infrainguinal bypass unless there is no
endovascular option and no adequate
autologous vein.
2 (Weak) C (Low) Almasri,7 2018
6.42 Perform intraoperative imaging (angiography,
DUS, or both) on completion of open bypass
surgery for CLTI and correct signiﬁcant
technical defects if feasible during the index
operation.
1 (Strong) C (Low) Mills,104 1992
Bandyk,105 1994
7. Nonrevascularization treatments of the limb
7.1 Consider spinal cord stimulation to reduce the
risk of amputation and to decrease pain in
carefully selected patients (eg, rest pain,
minor tissue loss) in whom revascularization
is not possible.
2 (Weak) B (Moderate) Ubbink,106 2013
7.2 Do not use lumbar sympathectomy for limb
salvage in CLTI patients in whom
revascularization is not possible.
2 (Weak) C (Low) Karanth,107 2016
7.3 Consider intermittent pneumatic compression
therapy in carefully selected patients (eg,
rest pain, minor tissue loss) in whom
revascularization is not possible.
2 (Weak) B (Moderate) Abu Dabrh,4 2015
7.4 Do not offer prostanoids for limb salvage in
CLTI patients. Consider offering selectively
for patients with rest pain or minor tissue
loss and in whom revascularization is not
possible.
2 (Weak) B (Moderate) Vietto,108 2018
7.5 Do not offer vasoactive drugs or deﬁbrinating
agents (ancrod) in patients in whom
revascularization is not possible.
1 (Strong) C (Low) Smith,109 2012
7.6 Do not offer HBOT to improve limb salvage in
CLTI patients with severe, uncorrected
ischemia (eg, WIfI ischemia grade 2/3).
1 (Strong) B (Moderate) Kranke,110 2015
Game,111 2016
Santema,112 2018
7.7 Continue to provide optimal wound care until
the lower extremity wound is completely
healed or the patient undergoes
amputation.
Good practice statement
8. Biologic and regenerative medicine approaches in CLTI
8.1 Restrict use of therapeutic angiogenesis to
CLTI patients who are enrolled in a
registered clinical trial.
1 (Strong) B (Moderate) Abu Dabrh,4 2015
Peeters,113 2015
9. The role of minor and major amputations
(Continued on next page)
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9.1 Consider transmetatarsal amputation of the
forefoot in CLTI patients who would require
more than two digital ray amputations to
resolve distal necrosis, especially when the
hallux is involved.
2 (Weak) C (Low) Elsherif,114 2018
9.2 Offer primary amputation to CLTI patients who
have a pre-existing dysfunctional or
unsalvageable limb, a poor functional status
(eg, bedridden), or a short life expectancy
after shared decision-making with the
patient and health care team.
1 (Strong) C (Low) Aziz,115 2015
Siracuse,116 2015
9.3 Consider secondary amputation for patients
with CLTI who have a failed or ineffective
reconstruction and in whom no further
revascularization is possible and who have
incapacitating pain, nonhealing wounds, or
uncontrolled sepsis in the affected limb after
shared decision-making with the patient
and health care team.
2 (Weak) C (Low) Reed,117 2008
9.4 Consider revascularization to improve the
possibility of healing an amputation at a
more distal functional amputation level (eg,
AKA to BKA), particularly for patients with a
high likelihood of rehabilitation and
continued ambulation.
2 (Weak) C (Low) Rollins,118 1985
Miksic,119 1986
9.5 Consider a TKA or AKA in patients who are
nonambulatory for reasons other than CLTI
(ie, bedridden patients with ﬂexion
contracture, dense hemiplegia, cancer) and
are unlikely to undergo successful
rehabilitation to ambulation.
2 (Weak) C (Low) Ayoub,120 1993
Taylor,121 2008
9.6 Involve a multidisciplinary rehabilitation team
from the time a decision to amputate has
been made until successful completion of
rehabilitation has been achieved.
1 (Strong) C (Low) Webster,122 2012
9.7 Continue to observe CLTI patients who have
undergone amputation at least yearly to
monitor progression of disease in the
contralateral limb and to maintain optimal
medical therapy and risk factor
management.
1 (Strong) C (Low) Bradley,123 2006
Glaser,124 2013
10. Postprocedural care and surveillance after infrainguinal revascularization for CLTI
10.1 Continue best medical therapy for PAD,
including the long-term use of antiplatelet
and statin therapies, in all patients who have
undergone lower extremity
revascularization.






10.2 Promote smoking cessation in all CLTI patients
who have undergone lower extremity
revascularization.
1 (Strong) A (High) Hobbs,130 2003
Willigendael,131
2005
10.3 Consider DAPT (aspirin plus clopidogrel) in
patients who have undergone infrainguinal
prosthetic bypass for CLTI for a period of 6 to
24 months to maintain graft patency.




10.4 Consider DAPT (aspirin plus clopidogrel) in
patients who have undergone infrainguinal
endovascular interventions for CLTI for a
period of at least 1 month.










10.5 Consider DAPT for a period of 1 to 6 months in
patients undergoing repeated catheter-
based interventions if they are at low risk for
bleeding.
2 (Weak) C (Low) Cassar,134 2005
Tepe,136 2012
Strobl,137 2013
10.6 Observe patients who have undergone lower
extremity vein bypass for CLTI on a regular
basis for at least 2 years with a clinical
surveillance program consisting of interval
history, pulse examination, and
measurement of resting APs and TPs.
Consider DUS scanning where available.
Good practice statement
10.7 Observe patients who have undergone lower
extremity prosthetic bypass for CLTI on a
regular basis for at least 2 years with interval
history, pulse examination, and
measurement of resting APs and TPs.
Good practice statement
10.8 Observe patients who have undergone
infrainguinal endovascular interventions for
CLTI in a surveillance program that includes
clinical visits, pulse examination, and
noninvasive testing (resting APs and TPs).
Good practice statement
10.9 Consider performing additional imaging in
patients with lower extremity vein grafts
who have a decrease in ABI $0.15 and
recurrence of symptoms or change in pulse
status to detect vein graft stenosis.
Good practice
statement
10.10 Offer intervention for DUS-detected vein graft
lesions with an associated PSV of >300 cm/s
and a PSV ratio >3.5 or grafts with low
velocity (midgraft PSV <45 cm/s) to maintain
patency.
1 (Strong) B (Moderate) Mills,138 2001
10.11 Maintain long-term surveillance after surgical
or catheter-based revision of a vein graft,
including DUS graft scanning where
available, to detect recurrent graft-
threatening lesions.
1 (Strong) B (Moderate) Landry,139 2002
Nguyen,140 2004
10.12 Consider arterial imaging after endovascular
intervention for failure to improve (wound
healing, rest pain) or a recurrence of
symptoms to detect restenosis or
progression of pre-existing disease.
2 (Weak) C (Low) Bui,141 2012
10.13 Consider reintervention for patients with DUS-
detected restenosis lesions >70% (PSV ratio
>3.5, PSV >300 cm/s) if symptoms of CLTI
are unresolved or on a selective basis in
asymptomatic patients after catheter-based
interventions.
2 (Weak) C (Low) Humphries,142 2011
10.14 Provide mechanical ofﬂoading as a primary
component for care of all CLTI patients with
pedal wounds.
1 (Strong) A (High) Elraiyah,143 2016
10.15 Provide counseling on continued protection of
the healed wound and foot to include
appropriate shoes, insoles, and monitoring
of inﬂammation.
1 (Strong) A (High) Elraiyah,143 2016
(Continued on next page)
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11. Study designs and trial end points in CLTI
11.1 Use a research framework such as the IDEAL
for gathering new data and evidence on the
surgical and endovascular management of
CLTI.
11.2 Encourage funders, journal reviewers, and
editors to prioritize prospective, multicenter,
controlled, and preferably randomized
studies over retrospective case series, studies
using historical controls, or other less
rigorous research methodologies.
11.3 When RCTs are not feasible, use the OPG
benchmarks from the SVS’s Critical Limb
Ischemia Working Group to evaluate the
efﬁcacy of novel endovascular CLTI
techniques and devices.
11.4 To facilitate sufﬁcient enrollment, limit RCT
exclusion criteria to those who are deemed
essential to trial integrity.
11.5 Design RCTs, prospective cohort studies, and
registries that are speciﬁc to CLTI.
11.6 Use an integrated, limb-based threatened
limb classiﬁcation system (eg, WIfI) and a
whole limb anatomic classiﬁcation scheme
(eg, GLASS) to describe the characteristics
and outcomes of CLTI patients who are
enrolled.
11.7 Describe outcomes in CLTI trials using a
combination of objective and clinically
relevant events, subjective PROMs and
HRQL assessments, and anatomic and
hemodynamic end points.
11.8 Require regulatory trials aimed at obtaining
premarket approval for devices for use in
CLTI to study CLTI patients and to present
data on objective and clinically relevant end
points, PROMs and HRQL assessments, and
anatomic and hemodynamic end points.
11.9 Follow up patients in trials for a time sufﬁcient
(this will usually be >2 years) to allow
appropriate comparison of the impact of the
different interventions on the natural history
of CLTI. Measure and declare completeness
of follow-up coverage to quantify risk of
attrition bias.
11.10 Include a time-integrated measure of clinical
disease severity (such as freedom from CLTI)
in the CLTI trial design to describe the total
impact of comparator CLTI interventions.
11.11 Publish all CLTI trial protocols together with
the full statistical analysis plans in peer-
reviewed journals to allow independent,
public, and transparent scrutiny and to
prevent nonreporting of negative trials.
11.12 Conduct postmarketing surveillance data
collection using well-designed, large
observational studies and registries.






11.13 Share clinical trial data to allow subsequent
individual patient data analyses, meta-
analyses, and subgroup analyses; updating
of OPGs; and validation of decision-making
tools, such as the WIfI system and GLASS.
11.14 Assess the quality of evidence in CLTI research
using frameworks such as GRADE that
consider multiple certainty domains and are
not based solely on study design.
12. Creating a Center of Excellence for amputation prevention
No recommendations
ABI, Ankle-brachial index; AI, aortoiliac; AKA, above-knee amputation; AP, ankle pressure; BKA, below-knee amputation; CFA, common femoral artery;
CLTI, chronic limb-threatening ischemia; CTA, computed tomography angiography; DAPT, dual antiplatelet therapy; DM, diabetes mellitus; DUS,
duplex ultrasound; EBR, evidence-based revascularization; FP, femoropopliteal disease; GLASS, Global Limb Anatomic Staging System; GRADE,
Grading of Recommendations Assessment, Development, and Evaluation; GSV, great saphenous vein; HBOT, hyperbaric oxygen therapy; HRQL,
health-related quality of life; IDEAL, Idea, Development, Exploration, Assessment, and Long-term study; IPC, intermittent pneumatic compression; LS,
lumbar sympathectomy; MRA, magnetic resonance angiography; OPGs, objective performance goals; PAD, peripheral artery disease; PFA, profunda
femoris artery; PROMs, patient-reported outcomes measures; PSV, peak systolic velocity; PVR, pulse volume recording; RCTs, randomized controlled
trials; SCS, spinal cord stimulation; SVS, Society for Vascular Surgery; TAP, target arterial path; TBI, toe-brachial index; TKA, through-knee amputation;
TP, toe pressure; WIfI, Wound, Ischemia, and foot Infection.
Journal of Vascular Surgery Conte et al 25S
Volume 69, Number 6S1. DEFINITIONS AND NOMENCLATURE
Deﬁning and describing the severity of PAD
The term “critical limb ischemia” (CLI) is outdated and
fails to encompass the full spectrum of patients who are
evaluated and treated for limb-threatening ischemia in
modern practice. Instead, the new term CLTI is proposed
to include a broader and more heterogeneous group of
patients with varying degrees of ischemia that can often
delay wound healing and increase amputation risk.
For development of a clearer concept of CLTI, the
following are excluded from the population as deﬁned
in this guidelines document: patients with purely venous
ulcers, acute limb ischemia, acute trash foot, ischemia
due to emboli, acute trauma, or mangled extremity
and those with wounds related to nonatherosclerotic
conditions. These include vasculitides, collagen vascular
disease, Buerger's disease, neoplastic disease, dermato-
ses, and radiation arteritis.
Previous leg ischemia deﬁnition and classiﬁcation
systems
CLI. In 1982, a working group of vascular surgeons
deﬁned CLI as ischemic rest pain with an ankle pressure
(AP) <40 mm Hg, or tissue necrosis with an AP <60 mm
Hg, in patients without diabetes.144 Patients with dia-
betes were speciﬁcally excluded because of the con-
founding effects of neuropathy and susceptibility to
infection. This deﬁnition has long been debated because
it failed to capture a large group of patients who were at
risk for amputation from a broader range ofischemia.145,146 To address this limitation, multiple and
disparate lower limb ischemia and wound/DFU classiﬁ-
cation systems have been developed and promulgated
during the past 5 decades, many of which remain in use
today. These and other commonly used classiﬁcations
and their associated components and grades of severity
are summarized in Table 1.1.10,147-158 Among vascular
surgeons, the Fontaine and Rutherford classiﬁcations
have been the most widely adopted, whereas orthope-
dists, podiatric surgeons, and diabetic foot specialists
traditionally applied the Wagner and University of Texas
classiﬁcations. The strengths and limitations of each have
been widely discussed in previous key publica-
tions.10,150,159-161 Although each of these systems has ad-
vantages, the use of multiple classiﬁcation systems has
hindered the development of optimal treatment algo-
rithms. It has also contributed to the fragmentation and
variability of care provided for patients with DFUs as well
as for nondiabetic patients across the spectrum of CLTI.
Lower extremity threatened limb classiﬁcation system
The deﬁnitions summarized in Table 1.1 were developed
primarily to describe patients suffering from pure
ischemia due to atherosclerosis. This was when the pre-
dominant risk factor was tobacco smoking and before
the global epidemic of diabetes mellitus (DM). As such,
these deﬁnitions were ischemia-dominant models of
limb threat. However, because patients with DM now
make up the majority of patients with CLTI, absolute
perfusion now needs to be considered in the context of
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June Supplement 2019neuropathy, wound characteristics, and infection. To
address this unmet need, the SVS Lower Extremity
Guidelines Committee created the SVS Lower Extremity
Threatened Limb Classiﬁcation System. This system strat-
iﬁes amputation risk according to wound extent, degree
of ischemia, and presence and severity of foot infection
(Wound, Ischemia, and foot Infection [WIfI]).10 Although
it may require some adjustments, WIfI appears to corre-
late strongly with important clinical outcomes. This in-
cludes those set forth in the SVS objective performance
goals (OPGs) that focus on limb amputation, 1-year
amputation-free survival (AFS), and wound healing time
(Table 1.2).10,68-72,162-167
The WIfI classiﬁcation system is currently being evalu-
ated in multicenter trials including the U.S. National Insti-
tutes of Health-funded BEST-CLI trial13 and the UK
National Institute for Health Research Health Technology
Assessment-funded BASIL-2 and BASIL-3 trials.14,15 WIfI is
also being incorporated into the U.S. SVS Vascular
Quality Initiative registry of lower extremity interventions.
Hemodynamic criteria
Although previous guidelines have suggested a range
of AP and toe pressure (TP) thresholds for deﬁning
limb-threatening ischemia, such thresholds must be
used with great caution and considered in the clinical
context because of multiple confounding factors and
the lack of a clear and reliable relationship to outcomes.
Patients with limb-threatening ischemia should be
deﬁned primarily in terms of their clinical presentation,
supplemented by physiologic studies that demonstrate
a degree of ischemia sufﬁcient to cause pain, to impair
wound healing, and to increase amputation risk.
In addition to patients who meet the proposed new
deﬁnition of CLTI, there are a signiﬁcant number of pa-
tients whose PAD is so severe that they are likely to be
at increased risk for development of CLTI in the foresee-
able future.168 Although data are lacking, it is logical to
suggest that such individuals should be monitored
closely for clinical disease progression.
CLTI
We propose that CLTI be deﬁned to include a broader
and more heterogeneous group of patients with varying
degrees of ischemia that may delay wound healing and
increase amputation risk. A diagnosis of CLTI requires
objectively documented atherosclerotic PAD in associa-
tion with ischemic rest pain or tissue loss (ulceration or
gangrene).
Ischemic rest pain is typically described as affecting the
forefoot and is oftenmade worse with recumbency while
being relieved by dependency. It should be present for
>2 weeks and be associated with one or more abnormal
hemodynamic parameters. These parameters include an
ankle-brachial index (ABI) <0.4 (using higher of the dor-
salis pedis [DP] and posterior tibial [PT] arteries), abso-
lute highest AP <50 mm Hg, absolute TP <30 mm Hg,
Table 1.2. One-year major limb amputation rate by Society for Vascular Surgery (SVS) Wound, Ischemia, and foot Infection
(WIfI) clinical stage
Study (year): No. of limbs at risk Stage 1 Stage 2 Stage 3 Stage 4
Cull68 (2014): 151 37 (3) 63 (10) 43 (23) 8 (40)
Zhan69 (2015): 201 39 (0) 50 (0) 53 (8) 59 (64)a
Darling71 (2016): 551 5 (0) 110 (10) 222 (11) 213 (24)
Causey70 (2016): 160 21 (0) 48 (8) 42 (5) 49 (20)
Beropoulis163 (2016): 126 29 (13) 42 (19) 29 (19) 26 (38)
Ward166 (2017): 98 5 (0) 21 (14) 14 (21) 58 (34)
Darling164 (2017): 992 12 (0) 293 (4) 249 (4) 438 (21)
Robinson72 (2017): 280 48 (2.1) 67 (7.5) 64 (7.8) 83 (17)
Mathioudakis165 (2017): 217 95 (4) 33 (3) 87 (5) 64 (6)
Tokuda167 (2018): 163 16 (0) 30 (10) 56 (10.7) 61 (34.4)
N ¼ 2982 (weighted mean) 307 (3.2) 757 (7.0) 859 (8.7) 1059 (23.3)
Median (1-year major limb amputation) 0% 9% 9.4% 29%
The number of limbs at risk in each WIfI stage is given, with percentage of amputations at 1 year in parentheses. Means in totals (in parentheses) are
weighted.
aFalsely elevated because of inadvertent inclusion of stage 5 (unsalvageable) limbs.
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Volume 69, Number 6Stranscutaneous partial pressure of oxygen (TcPO2) <30
mm Hg, and ﬂat or minimally pulsatile pulse volume
recording (PVR) waveforms (equivalent to WIfI ischemia
grade 3). Pressure measurements should be correlated
with Doppler arterial waveforms, keeping in mind that
AP and ABI are frequently falsely elevated because of
medial calcinosis, especially in people with DM and
end-stage renal disease (ESRD). For this reason, a combi-
nation of tests may be needed. In patients with DM or
ESRD, toe waveforms and systolic pressures are
preferred. One study demonstrated that AP alone failed
to identify 42% of patients with CLTI. TP and TcPO2 mea-
surements were more accurate than AP and also were
more predictive of 1-year amputation risk (TP <30 mm
Hg or TcPO2 <10 mm Hg).
169
Tissue loss related to CLTI includes gangrene of any part
of the foot or nonhealing ulceration present for at least 2
weeks. It should be accompanied by objective evidence
of signiﬁcant PAD (eg, WIfI ischemia grade $1). This deﬁ-
nition excludes purely neuropathic, traumatic, or venous
ulcers lacking any ischemic component. However, the
WIfI scheme recognizes that a wide range of ischemic
deﬁcit may be limb threatening when it coexists with
varying degrees of wound complexity and superimposed
infection. CLTI is present if either ischemic rest pain or tis-
sue loss with appropriate hemodynamics is present.
Some patients may have relatively normal hemody-
namics when the limb or foot is considered as a whole
but nevertheless suffer ulceration as a result of dimin-
ished local perfusion (ie, angiosomal or regional ischemia
without adequate collateral ﬂow). It is recognized that
such ulcers may contribute to limb threat, and current
tools to assess regional ischemia require further develop-
ment to better deﬁne such circumstances and their
treatment. The relationship between regional ischemiaand patterns of IP and pedal disease also requires
more in-depth study.12,170
The GVG recommends use of the SVS WIfI classiﬁcation
(Section 3) in a manner analogous to the TNM system of
cancer staging to stage the limb in patients with CLTI.
The WIfI classiﬁcation is intuitive and has been made
user-friendly by the availability of free online application
software provided by the SVS (SVS Interactive Practice
Guidelines; https://itunes.apple.com/app/id1014644425).
Data accrued in nearly 3000 patients to date and sum-
marized in Table 1.2 suggest that the four WIfI clinical
stages of limb threat correlate with the risk of major
limb amputation and time to wound healing. It has
also been suggested that novel WIfI composite and
mean scores may predict other clinically signiﬁcant
events as well.164 The WIfI system appears to contain
the key limb status elements needed to gauge the
severity of limb threat at presentation.
In addition, recent data suggest that WIfI can assist in
predicting which patients might fare better with open
surgical bypass compared with endovascular ther-
apy.171,172 One study reported that when endovascular
therapy alone was applied to WIfI stage 4 patients, re-
sults were worse than in lower clinical stage patients.172
Speciﬁcally, the wound healing rate was only 44%, the
major limb amputation rate was 20%, and 46% of
patients required multiple, repetitive endovascular pro-
cedures. In a nonrandomized, single-center comparison
of WIfI stage 4 patients, researchers found that
freedom from major limb amputation was superior in
patients who underwent bypass compared with those
who underwent endovascular therapy.171 If these results
can be conﬁrmed, WIfI may prove to be a useful tool in
deciding whether to offer endovascular therapy or
bypass.
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TNM staging for cancer and reassigned patients to
stages after 1 month of therapy. The investigators found
that at 1 month and 6 months, wound, ischemia, and
infection grades correlated with AFS, whereas baseline
ischemia grade did not.173 These data suggest that
restaging with WIfI at 1 month and 6 months after
intervention may help identify a cohort of patients
undergoing therapy for CLTI that remains at higher
risk for major limb amputation and may merit targeted
reintervention.
Ultimately, the optimal staging system for CLTI is ex-
pected to evolve with additional clinical application and
larger scale, multicenter, andmultinational data analysis.
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suspected CLTI.1 (Strong) C (Low) See
Table 1.22. GLOBAL EPIDEMIOLOGY AND RISK FACTORS
FOR CLTI
In 2010, estimates suggested that >200 million people
worldwide were living with PAD. This represented a
23.5% increase since 2000, an increase that is believed
to be largely attributable to aging populations and the
growing prevalence of risk factors, in particular DM.1
These ﬁgures are thought to almost certainly underesti-
mate the true burden of disease as they are largely based
on community-based studies that deﬁne PAD on the ba-
sis of reduced ABI. Although CLTI is widely believed to be
a growing global health care problem, reliable epidemi-
ologic data are extremely limited.
Men have been reported to have a higher prevalence
of PAD in high-income countries (HICs; Fig 2.1), whereas
women seem to have a higher prevalence of PAD in
low- and middle-income countries (LMICs).1 As life ex-
pectancy increases, the burden of PAD seems likely to
rise in LMIC. However, in certain geographic regions,notably in the western Paciﬁc and Southeast Asia,
most PAD cases are reported in people younger than
55 years.1
In a meta-analysis from the United States, the preva-
lence of PAD in men ranged from 6.5% (aged 60-69
years) to 11.6% (aged 70-79 years) to 29.4% (>80 years).174
There were similar age-related increases in PAD preva-
lence in women (5.3%, 11.5%, and 24.7% in these age cat-
egories, respectively).174 Given that the life expectancy of
women still exceeds that of men, the overall burden of
PAD (total number of individuals affected) is likely to
be greater in women than in men. The epidemiology of
PAD is likely to be similar in other developed countries,
such as the United Kingdom, and regions, such as the
European Union.175,176 However, as these populations
become more multicultural, differences in disease
burden between different communities within these na-
tions seem likely to become apparent, further compli-
cating the epidemiology of the condition.177
Data on the epidemiology of PAD and in particular of
CLTI in other parts of the world are even more limited. In
one Japanese community study of people older than 40
years, the prevalence of ABI <0.9 was very low (1.4%).178
In a population-based cohort of 4055 Chinese men and
women older than 60 years, the prevalence of PAD
(ABI <0.9) was 2.9% and 2.8%, respectively.179 Another
population-based cohort of 1871 individuals younger
than 65 years in two countries fromCentral Africa showed
that the overall prevalence of PAD was 14.8%.180
There is a considerable body of evidence showing that
PAD is more common among black individuals than
among whites.181-184 There is also evidence that Asians
and Hispanics have a lower prevalence of PAD than
whites do.184 It is not clear whether these differences
have a genetic basis or simply reﬂect differential expo-
sure to traditional risk factors. However, disease risk pro-
ﬁles appear to change as populations migrate,
suggesting that environment is more important than ge-
netic makeup. Another explanation may be that ABI is
intrinsically lower in black individuals, resulting in a
falsely high prevalence of PAD.185
There are far more international data on the epidemi-
ology of intermittent claudication (IC) than of CLTI. The
annual incidence of IC in 60-year-old men has been
shown to range from 0.2% in Iceland to 1.0% in Israel.186
A study using data from a large, insured U.S. population
estimated the annual incidence of PAD, deﬁned by the
presence of a diagnosis or procedure insurance claim,
to be 2.4% in a cohort of adults older than 40 years.187
Studies reporting on the epidemiology of PAD based
on ABI rather than on the presence of symptomatic dis-
ease suggest that the prevalence of asymptomatic PAD
may be similar in men and women, although IC appears
to be more prevalent in men.188,189 Differences in presen-
tation between men and women with IC may inﬂuence
the accuracy of prevalence estimates.190
Fig 2.1. Prevalence of peripheral artery disease (PAD; ankle-brachial index [ABI] <0.9) by age and sex in high-
income countries (HICs) and in low- and middle-income countries (LMICs).1
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have been comprehensively studied in HICs and include
smoking, DM, hypertension, hypercholesterolemia, and
air pollution. A global study suggested that although
these risk factors may be equally applicable to LMICs,
for most, the strength of the association was greater in
HICs. This may be because HIC studies often include a
larger number of older patients and because the expo-
sure time tends to be shorter in LMICs.1
Smoking is unarguably a signiﬁcant risk factor in the
development and progression of PAD. Nevertheless,
whereas smoking rates are falling in most HICs, this is
not the case in LMICs (Fig 2.2). DM is also strongly associ-
ated with the development of PAD, and risk increases
with the duration of DM in affected individuals. Patients
with DM are widely recognized to be at markedly higher
risk of amputation.191,192 The rapidly increasing worldwide
prevalence of type 2 DM is concerning and likely to have a
signiﬁcant impact on the future incidence andprevalence
of PAD and CLTI as well as their morbid end points.
The link between obesity and PAD is inconsistent. Many
studies have suggested the existence of an “obesity
paradox,” with lower rates of PAD being observed in pa-
tients with a higher bodymass index (BMI).186 By contrast,
other studies that have adjusted for smoking, which is
associated with a generally lower BMI,193 reported a posi-
tive correlation between BMI and PAD. Hypertension is
associated with the development of PAD and is another
common risk factor in the adult population.The association between dyslipidemia and the devel-
opment and progression of atherosclerosis has been
extensively studied. Whereas elevated levels of total
cholesterol and low-density lipoprotein cholesterol
(LDL-C) are widely accepted as risk factors for PAD,
reduced high-density lipoprotein cholesterol levels also
appear to be associated with increased mortality in
PAD patients.194 A ratio of the two may also be a useful
predictor of PAD.195 Whereas hypertriglyceridemia ap-
pears to be atherogenic,196 its role in the development
and progression of PAD remains incompletely deﬁned.
Chronic kidney disease (CKD), particularly ESRD, is a
strong risk factor for PAD and limb loss, especially in asso-
ciationwith DM. Affected patients frequently have heavily
calciﬁed arteries and a distal pattern of arterial disease.186
The association between alcohol consumption and
PAD is inconsistent, making it difﬁcult to draw any ﬁrm
conclusions.197 However, heavy alcohol consumption is
often associated with other risk factors for PAD, such as
smoking, and as with DM, the presence of alcoholic neu-
ropathy increases the risk of tissue loss for any given
perfusion deﬁcit.
Recent data suggest that air pollution from sources
such as motor vehicles, power plants, wood burning,
and some industrial processes may be associated with
increased cardiovascular morbidity and mortality.198
Likewise, chronic inﬂammation, characterized by
elevated levels of C-reactive protein and other bio-
markers, has been shown to be associated with PAD.186
Fig 2.2. Odds ratios (ORs) for peripheral artery disease (PAD) in high-income countries (HICs) and low- and
middle-income countries (LMICs). BMI, Body mass index; CRP, C-reactive protein; CVD, cardiovascular disease;
HDL, high-density lipoprotein. (Reprinted from Criqui MH, Aboyans V. Epidemiology of peripheral artery disease.
Circ Res 2015;116:1509-26.)
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PAD cohort studies, although the beneﬁts of folate sup-
plementation appear to be negligible.186,199
The signiﬁcance of family history and genetic makeup
is uncertain.200,201 Studies have yielded varying results,
with some identifying a small number of candidate
genes or even single-nucleotide polymorphisms and
others failing to identify any association at all.
Finally, people of lower socioeconomic status and
educational attainment tend to have a higher preva-
lence of IC and probably also of CLTI, although the asso-
ciation is not always strong and can often be explained in
part by their increased exposure to other risk factors,
such as smoking.180,183,202 However, there is increasing
evidence that chronic mental and psychosocial stress
may have direct effects on cardiovascular health.203
Incidence and prevalence of CLTI. As noted before,
high-quality data on the epidemiology of CLTI are lack-
ing, especially from LMICs, with many estimates being
extrapolated from the incidence and prevalence of IC,
amputation, and DM. Unfortunately, such estimates can
behighlymisleading for a number of reasons. First, ICdoes
not progress to CLTI in a predictablemanner. Second, CLTI
probably represents <10% of all PAD patients, and those
undergoing amputation for CLTI are at very high risk of
premature death (and so more likely to be absent from
population-based studies). Third, the clinical and hemo-
dynamic data required to reliably diagnose CLTI are difﬁ-
cult to obtain in large populations. This is particularly truein patients with DM, who often have incompressible ves-
sels. Thus, although it is estimated that approximately half
of all patients with a DFU in western Europe and North
America also have signiﬁcant PAD, the disease may often
appear relativelymild (not fulﬁlling the criteria for CLTI) on
hemodynamic assessment.204
For many years, the annual incidence of what has typi-
cally been termed CLI was estimated at 500 to 1000 new
cases per million individuals in Western countries.205 Un-
fortunately, there are no reliable contemporary epidemi-
ologic data that take into account recent changes in
lifestyle (such as reduced smoking rates), identiﬁcation
and medical management of cardiovascular risk factors,
prevalence of obesity and diabetes, and overall
increasing life expectancy around the world.
In 2013, a meta-analysis involving 6 studies and close to
83,000 patients showed the overall prevalence of severe
chronic limb ischemia (deﬁned by Fontaine stage,
AP <70 mm Hg, and ABI <0.60) to be 0.74% (95% conﬁ-
dence interval [CI], 0.26-1.46), with marked heterogeneity
between studies (prevalence, 0.11%-1.59%).206
In an analysis of the U.S. MarketScan database (Truven
Health Analytics, Ann Arbor, Mich), composed of approx-
imately 12 million Americans aged 40 years and older
receiving care from Medicare and Medicaid between
2003 and 2008, the prevalence and annual incidence
of CLTI were estimated at 1.33% and 0.35%, respectively.
This equates to around 3500 new cases per million indi-
viduals per year.187 The study deﬁned primary CLTI as pa-
tients with no prior PAD or subsequent PAD diagnostic
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CLTI included patients with prior PAD (or subsequent
PAD diagnostic codes within 30 days of a CLTI diagnostic
code). The annual incidence rate of primary and second-
ary CLTI was 0.19% and 0.16%. CLTI patients represented
11.08% (95% CI, 11.03%-11.13%) of total PAD patients annu-
ally. As noted before, although one might expect similar
rates of CLTI in other developed nations and regions,
data from LMICs are lacking. Even within HICs, the epide-
miology of CLTI is likely to be complex and evolving.
Amputation and CLTI. A number of studies have used
major lower limb amputation as a surrogate for CLTI on
the basis that most (>80%) are due to CLTI. However, it
can be difﬁcult to distinguish reliably between minor
(below the ankle) and major (above the ankle) amputa-
tions in some administrative data. Furthermore, the num-
ber of amputations that are performed for trauma, tumor,
or infection, including patients with DM and neuropathy
(butwithout PAD), is likely to vary considerably fromcoun-
try to country, particularly in comparing HICs and LMICs.
In the United States in 2015, an estimated 504,000 indi-
viduals (of a total estimated population of 295.5 million)
were living with a major amputation due to PAD, a num-
ber that was projected to more than double by 2050.207
In Minnesota, a state with low overall rates of cardiovascu-
lar disease (CVD), one study showed that between 2005
and 2008, the age-adjusted annual incidence of ischemic
lower limb amputation (amputations not due to trauma
or cancer) remained unchanged at 20 per 100,000.208
A systematic review found that the rate ofmajor amputa-
tion varied considerably (3.6 to 68.4 per 100,000 per year)
across the world, probably because of differences in
ethnicity, social deprivation, and, in particular, the preva-
lence of DM.209 In some countries, including England, the
incidence of amputations unrelated to DM appears to be
decreasing.210 However, inmost parts of the world, the inci-
dence of DM-related limb amputations is increasing.211
Natural history of untreated CLTI. A meta-analysis (13
studies and 1527 patients) of the natural history of un-
treated CLTI found that during a median follow-up of 12
months, both the mortality rate and the per-patient
amputation rate were 22%, although there was marked
heterogeneity between studies.5 With regard to disease
progression, one study estimated that only 5% to 10% of
patients with either asymptomatic PAD or IC went on
the develop CLTI during a 5-year period.212 However,
another meta-analysis suggested that this progression
rate may be signiﬁcantly higher at 21% (range, 12%-29%)
during 5 years.213 Approximately 50% of patients pre-
senting with CLTI have no prior history of PAD.214,215
Patients with CLTI present with a wide spectrum of clin-
ical, hemodynamic, and anatomic disease. Outcomes
depend on the availability and quality of primary and
secondary care and may be further inﬂuenced by factorssuch as social stigmatization and cultural and religious
beliefs. Those living in regions with poor access to health
care often present late with advanced disease and unsal-
vageable limbs. Indeed, it has been estimated that
approximately half of all patients with CLTI do not un-
dergo revascularization.216 Even in HICs with advanced
health care systems, such as Germany and the United
States, many patients with suspected CLTI do not receive
angiography or any attempt at revascularization.217 This
may be because patients are too sick or frail, are thought
to have no revascularization option, or present too late.
Unfortunately, whereas reasonable data are available
on amputation rates, data on processes of care that
can help explain the shortfall and differences in revascu-
larization and amputation are lacking.
The recently published VASCUNET report showed large
(almost sixfold) differences but an overall decline in ma-
jor amputation rates in 12 European and Australasian
countries between 2010 and 2014.218 DM prevalence,
age distribution, and mortality rates were also found to
vary between countries. Despite limitations inherent to
the use of registry data, these ﬁndings are important
andmay indicate disparities in access to vascular surgical
intervention across the countries studied. Further
research is clearly required to improve limb salvage in
different demographic and geographic settings.218
In patients with known PAD, the risk for development of
CLTI appears to be greater in men, in patients who have
had a stroke or are in heart failure, and in patients with
DM.187 Patients who present de novo with CLTI (no prior
diagnosis of PAD) seemmore likely to be older and male
and to have pre-existing CVD (including hypertension,
myocardial infarction, heart failure, or stroke) and renal
failure.187 Not surprisingly, because of the associated
high prevalence of neuropathy, DM had the strongest as-
sociation with a new presentation of CLTI (odds ratio
[OR], 7.45; 95% CI, 7.19-7.72). The medical management
of patientswhohave or are at risk of having CLTI is covered
elsewhere in the guideline (Section 4). Still, there is
growing evidence that aggressive medical management
of risk factors can signiﬁcantly improve the overall prog-
nosis for patients with PAD. This may in part explain the
decline in mortality observed in patients with IC and CLTI
in The Netherlands between 1998 and 2010.219
The risk of amputation is high in CLTI patients, even in
those undergoing a successful revascularization.220 Un-
surprisingly, patients who present late and with the
greatest degree of tissue loss are at highest risk. In one
analysis, the rates of amputation at 4 years were 12.1%,
35.3%, and 67.3% for Rutherford class 4, class 5, and class
6, respectively.217
Anatomic patterns of disease. CLTI is usually the result
of multilevel arterial occlusive disease. Involvement of
parallel vascular beds, such as the superﬁcial femoral
artery (SFA) and profunda femoris artery (PFA), is
Fig 2.3. Association of risk factors with the level of atherosclerotic target lesions. The red overlay on the anatomic
cartoon illustrates the association of risk factor with patterns of atherosclerotic disease.217 (Reprinted from Diehm
N, Shang A, Silvestro A, Do DD, Dick F, Schmidli J, et al. Association of cardiovascular risk factors with pattern of
lower limb atherosclerosis in 2659 patients undergoing angioplasty. Eur J Vasc Endovasc Surg 2006;31:59-63.)
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increasingly involved as the overall severity of disease
worsens. However, FP and IP disease does not always
progress in parallel. The general requirement is that
there needs to be two levels of arterial occlusive disease
to cause CLTI. However, an increasingly observed excep-
tion is diffuse disease involving the IP and pedal arteries
in patients with DM or CKD. In patients with CLTI and IP
disease, the PT artery tends to be the most diseased,
often with relative sparing of the peroneal artery. In
patients with DM, there may also be sparing of the DP
artery. A number of speciﬁc factors appear to drive the
distribution of lower limb PAD (Fig 2.3). Thus, women
may be more prone to development of FP disease,
whereas elderly male patients and those with diabetes
are more likely to develop IP disease.221 There is also
some evidence that black people and Asians are more
likely to develop distal disease.222,223
CVD and mortality risk. Despite some evidence of
recent improvements in HICs, patients who develop PAD
and CLTI remain at high risk of premature death. Thus, in
a German study, 4-year mortality was 18.9% in Ruth-
erford class 1 to class 3, 37.7% in class 4, 52.2% in class 5, and
63.5% in class 6.217 However, interestingly, up to 40%of the
deaths were not cardiovascular, perhaps because better
medical therapy and management of risk factors have
improved overall survival from CVD.224,225
In 2014, the Global Burden of Disease (2010) database
was used to estimate PAD deaths, disability-adjustedlife-years, and years of life lost in 21 regions worldwide be-
tween 1990 and 2010. In 1990, the age-speciﬁc PAD
death rate per 100,000 population ranged from 0.05
among those aged 40 to 44 years to 16.63 among those
aged 80 years or older. In 2010, the corresponding
estimates were 0.07 and 28.71. Death rates increased
consistently with age in 1990 and 2010, and the rates in
2010 were higher than they were in 1990 in all age
categories.
The overall relative change in median disability-adjusted
life-years was greater for men and women in developing
than in developed nations. The overall relative change in
the median years of life lost rate in developed countries
was larger in women than inmen. Researchers concluded
that disability and mortality associated with PAD
increased during the 20 years of the study and that this
increase in burden was greater among women than
men. In addition, the burden of PAD is no longer conﬁned
to the elderly population and now includes young adults.
Finally, the relative increase in PAD burden in developing
regions of the world is striking and exceeds the increases
in developed nations.226
Management strategies in CLTI. A study based in South
Carolina identiﬁed patients who underwent revasculariza-
tion for CLTI in 1996 and 2005 and examined the require-
ment for subsequent amputations and further
revascularizations. Although revascularization procedures
increased by 33%, the 1-year and 3-year amputation rates
did not change signiﬁcantly between 1996 (34% and 43%)
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tients who required further revascularization in the same
calendar year increased from 8% to 19%. Investigators
concluded that the shift to endovascular interventions
increased thenumberof secondaryprocedures required to
maintain limb salvage rates. Although the absolute num-
ber of amputations appeared to decrease despite the
increasing population at risk, they concluded that it could
be misleading to suggest a direct relationship to the in-
crease in revascularization rates. Thus,whereas thenumber
of amputations fell by approximately 500, the number of
revascularization procedures rose by only 187.227 As noted
before, improved risk factor management and use of best
medical therapy are likely to have been important factors.
The increased number of revascularization procedures
may also be due to the increasing availability of endovas-
cular technology and techniques. Indeed, there is some
suggestion that practitioners have become more liberal
with the use of all revascularization techniques, including
bypass and angioplasty.228 Data from the United Kingdom
suggest that an increasing number of patients are under-
going attempts at revascularization.228
Undoubtedly, there is an increase in the number and
proportion of revascularization procedures performed
using an endovascular approach. In the South Carolina
study, the endovascular approach was used in 26% of
CLTI revascularization procedures performed in 1996
compared with 51% in 2005.227 It is difﬁcult to establish
whether this change in management strategy has
resulted in the salvage of more limbs and prevention of
premature deaths. Such questions can only be answered
by RCTs. There are, however, consistent data to suggest
that more modern vascular strategies (including a
more widespread adoption of endovascular techniques
as ﬁrst- or second-line therapies) are associated with an
increased number of patients requiring repeated revas-
cularization (increasing from 8% to 19% in the South Car-
olina study).227 Alternative explanations may be that
vascular surgeons are becoming more aggressive at
retreating patients or that patients are living longer.
Summary. PAD is an increasingly common condition
worldwide. Most patients remain asymptomatic, but it
is estimated that up to 10% will progress to or present
de novo with CLTI (although that ﬁgure appears to vary
widely). The number of women with PAD continues to
increase, and women may be more likely to develop
symptomatic disease. Modiﬁable risk factors include
DM, smoking, hypertension, dyslipidemia, CKD, obesity,
and sedentary lifestyle.
Despite advances in risk factor management and best
medical therapy, PAD and especially CLTI are associated
with markedly increased cardiovascular morbidity and
mortality, especially in LMICs. Left untreated, the overall
risk of limb loss in CLTI is estimated at approximately 25%at 1 year.5 However, it will probably be much higher than
that for some groups, such as those with extensive tissue
loss at presentation. The key to preventing limb loss is
aggressive risk factor management and bestmedical ther-
apy together with timely EBR. There are major differences
in amputation rates between and within countries. An
increasing number of patients appear to be undergoing
revascularization (both endovascular and bypass surgery)
inHICs, andat least in part, thismay account for a reduction
in amputation. However, improvements in cardiovascular
risk management, processes of care, and vascular and
endovascular technology may be equally important.
Research priorities2.1 Quantify and track the incidence, prevalence,
demographics, and risk factors associated with
CLTI in different global regions.2.2 Describe the contemporary natural history of CLTI
(including risk to the limb, cardiovascular events,
and all-cause mortality in that population) in
different global regions.2.3 Describe the contemporary management strategies
used in the treatment of CLTI around the world
and the associated outcomes.2.4 Describe and monitor the incidence and prevalence
of nontraumatic lower limb amputation around
the globe (eg, the Global Amputation Study,
https://GAS.vascunet.org).2.5 Establish a reliable system to monitor the number of
major amputations in as many countries and
regions as possible. Time trends and differences
around the globe could then be studied.3. DIAGNOSIS AND LIMB STAGING IN CLTI
Diagnosis and evaluation
The diagnostic evaluation, staging, and imaging of
patients with suspected CLTI, leading to EBR, is an integral
part of successful treatment. Beyond history and examina-
tion, an important new tool is the SVS Threatened Limb
Classiﬁcation System (WIfI), which correlates with the prob-
ability of limb salvage and wound healing after
revascularization. Fig 3.1 summarizes the recommended
evaluation pathway for patients presenting with CLTI that
should be followed whenever possible. In patients who are
appropriate candidates for revascularization (Section 6),
the GLASS (Section 5) anatomic scheme can be used to
help deﬁne the optimal revascularization strategy.
Recent technologic advances have made the diagnosis
and imaging of CLTI more accurate, which in turn allows
better selection of patients and planning of revasculari-
zation. However, the authors are well aware that access
to sophisticated diagnostic modalities and vascular im-
aging varies considerably around the globe, and as ex-
pected, this leads to a wide range of different
Fig 3.1. Flow diagram for the investigation of patients presenting with suspected chronic limb-threatening
ischemia (CLTI). ABI, Ankle-brachial index; PAD, peripheral artery disease; TBI, toe-brachial index; WIfI, Wound,
Ischemia, and foot Infection.
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tings.229 As such, it would not be possible or indeed
desirable to make ﬁrm, proscriptive recommendations
in this section. Rather, the aim is to set out broad princi-
ples and considerations that can reasonably be used to
guide patient evaluation, diagnosis, limb staging, and im-
aging in most health care environments.
History
Ischemic rest pain usually affects the forefoot, is
frequently worse at night, and often requires opiate anal-
gesia for management. If present for >2 weeks and com-
bined with hemodynamic evidence of severely impaired
perfusion (eg, absolute AP <50 mm Hg, absolute TP <30
mm Hg), it is diagnostic of CLTI.230
Ischemic ulceration is frequently located on the toes
and forefoot, but other areas may be affected in patients
with diabetic neuropathy, altered biomechanics, or footdeformity. Gangrene usually occurs on the forefoot. A
range of perfusion deﬁcits may be limb threatening in
different scenarios of tissue loss and concomitant infec-
tion (Section 1). Thus, all patients presenting with signs
or symptoms of suspected CLTI should undergo a com-
plete vascular assessment.
In addition to a carefully documented history of pre-
senting limb complaints, it is important to record details
of cardiovascular risk factors, drug history, and previous
vascular and endovascular revascularization procedures
and amputations.230,231 Assessment of frailty, functional
status, and HRQL is also important.232,233
Physical examination
All patients with suspected CLTI should undergo a
complete physical examination.234,235 Palpation of lower
limb pulses can help determine the likely presence and
distribution of arterial disease.236-240 Although they can
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cle atrophy, hair loss, and dystrophic toenails are
frequently observed in patients with PAD. Buerger sign,
pallor of the foot on elevation and rubor (so-called sunset
foot) on dependency, is usually present in CLTI. The capil-
lary reﬁll time will usually exceed 5 seconds, especially
when the patient is lying supine or the leg is elevated.239
It is important not to examine the patient with sus-
pected CLTI sitting in a chair with the leg hanging
down as that may lead to false reassurance regarding
the perfusion of the foot.
Many patients with CLTI, especially those with DM, have
“glove and stocking”239 sensory, motor, and autonomic
neuropathy that may be asymptomatic or be associated
with tingling, numbness, weakness, and burning pain in
the feet and ankles. The presence of such neuropathy is
a major risk factor for tissue loss and should be carefully
sought and evaluated using monoﬁlaments and, if
available, a tuning fork (loss of vibration sense is an
early feature).241-244 Neuropathy often leads to abnormal
foot biomechanics and deformity, and neuropathic
(neuroischemic) ulcers often occur at sites of abnormal
pressure (load bearing). In patients with suspected
CLTI who have a foot ulcer, a probe-to-bone test should
be performed to assess depth and the probability of
underlying osteomyelitis.245,246
Recommendations3.1 Perform a detailed history to
determine symptoms, past
medical history, and
cardiovascular risk factors in
all patients with suspected
CLTI.Good practice
statement3.2 Perform a complete
cardiovascular physical
examination of all patients
with suspected CLTI.Good practice
statement3.3 Perform a complete
examination of the foot,
including an assessment of
neuropathy and a probe-to-
bone test of any open ulcers,
in all patients with pedal
tissue loss and suspected
CLTI.Good practice
statementNoninvasive hemodynamic tests
AP and ABI. Measurement of AP and calculation ofABI (highest AP divided by highest brachial systolic pres-
sure) is recommended as the ﬁrst-line noninvasivehemodynamic test in all patients with suspected
CLTI (Fig 3.1).19 Althoughmany patients with CLTI will have
an AP <50 mm Hg or a markedly reduced ABI
(typically<0.4), an increasingproportionwill not, especially
those with DM and CKD, who may have incompressible
crural arteries. ABI results should be reported as noncom-
pressible if the value is >1.4. However, it is important to be
aware that incompressibility can lead to artifactually
elevated readings between 0.4 and 1.4.247-249 This should
be suspected when the ABI falls in or near the normal
range but is associated with dampened, monophasic
waveforms (recognized acoustically or visually on a
screen).23 These falsely normal APs and ABI values have
been reported to be an independent predictor of major
amputation.250 In such patients, TP and toe-brachial
index (TBI) or other hemodynamic measurements, as
described next, should always be obtained.251
TP and TBI. TP is measured using an appropriately
sized mini-cuff typically placed around the base of the
great toe and attached to a standard manometer. A
photoplethysmographic or continuous-wave Doppler
ﬂow detector is then used to determine when ﬂow
returns while the inﬂated cuff is slowly deﬂated. Various
automated systems can be purchased. TPs are less often
affected by incompressibility and, if possible, should be
measured whenever falsely elevated APs or ABIs are
detected or suspected, particularly when such values are
nonconcordant with acoustic or visual waveform anal-
ysis. Studies have suggested that TP is more sensitive
than AP in the diagnosis of CLTI and more predictive of
amputation risk.21,22 Systolic TPs are generally 20 to 40
mm Hg lower than APs. TBIs <0.7 are considered
abnormal and TPs <30 mm Hg are typically associated
with advanced ischemia.22,230,252
Other methods for noninvasive diagnosis of CLTI
Alternative noninvasive testing methods can also
be used to assist in the diagnosis of CLTI (Table 3.1).
Whereas each method has its own advantages and lim-
itations, depending on local availability and expertise,
they can be used to augment APs and TPs and indices.
Segmental pressures can provide information on
anatomic localization of lower limb vascular disease in
patients with CLTI but are used infrequently today, at
least in HICs. Several other noninvasive tests, including
laser Doppler ﬂowmetry, TcPO2, skin perfusion pressure,
and plethysmography, have been used to evaluate limb
perfusion.16,253 However, these tests can be inﬂuenced
by a variety of confounding factors and are not used
routinely in most vascular laboratories around the world.
Recommendation Grade Level of evidence Key references
3.4 Measure AP and ABI as the ﬁrst-line noninvasive test in all
patients with suspected CLTI.
1 (Strong) B (Moderate) Lijmer,19 1996
Dachun,20 2010
3.5 Measure TP and TBI in all patients with suspected CLTI and
tissue loss (Fig 3.1).
1 (Strong) B (Moderate) Aboyans,21 2008
Salaun,169 2018
3.6 Consider using alternative methods for noninvasive
assessment of perfusion, such as PVR, transcutaneous
oximetry, or skin perfusion pressure, when ankle and toe
pressures, indices, and waveforms cannot be assessed.
2 (Weak) C (Low) Aboyans,21 2008
Shirasu,23 2016
Saluan,169 2018
Table 3.1. Comparison of methods of noninvasive testing in patients with chronic limb-threatening ischemia (CLTI)
Techniques Advantages Limitations
AP or ABI d Simple, inexpensive, quick, widely applicable
d Provides data to predict wound healing and limb survival
d Useful to monitor efﬁcacy of therapeutic intervention
d Because of incompressible tibial arteries,
may be falsely elevated or normal in pa-
tients with diabetes, renal insufﬁciency, or
advanced age
d Does not provide localization of the
disease
TP or TBI d Simple, inexpensive, quick
d Useful in the presence of small-vessel artery disease
d Useful in noncompressible tibial arteries
d Provides data to predict wound healing and limb survival
d Useful to monitor efﬁcacy of therapeutic intervention
d Generally requires a hallux




d Useful in initial anatomic localization of CLTI disease
d Useful in creating therapeutic plan based on disease
localization
d Provides data to predict wound healing and limb survival
d Useful to monitor efﬁcacy of therapeutic intervention
d Not accurate in noncompressible tibial
arteries
TcPo2 d Useful to assess microcirculation
d Can predict wound healing
d May be useful for monitoring efﬁcacy of revascularization
d Limited accuracy in the presence of
edema or infection
d Requires skin heating to $40C
d Time-consuming
d Limited data validation
Skin perfusion
pressure
d Useful to assess microcirculation and wound healing
potential
d May be useful for monitoring efﬁcacy of revascularization
d Can be measured in a shorter time compared with TcPo2
d Probe size and shape may affect
measurements
d Limited data validation
ABI, Ankle-brachial index; AP, ankle pressure; TBI, toe-brachial index; TcPo2, transcutaneous oximetry; TP, toe pressure.
Adapted from Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of
patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Asso-
ciation for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and
Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the
Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation;
National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.
Circulation 2006;113:e463-654.
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A number of limb and wound classiﬁcation systems
have been developed to try to improve clinical
decision-making and clinical outcomes.254-256 The WIfI
system10 is based on three key factors: wound, ischemia,
and foot infection (Tables 3.2-3.5). WIfI correlates with
limb salvage, amputation risk, and wound healing andcan identify patients who are likely to beneﬁt from
revascularization.68,69
A limb-staging classiﬁcation system, such as WIfI, should
be used in all patients presenting with suspected CLTI
(Tables 3.2-3.5). Limb staging should be repeated after
vascular intervention, foot surgery, or treatment of infection
and whenever there is suspected clinical deterioration.
Table 3.2. Wound grading in Wound, Ischemia, and foot Infection (WIfI) classiﬁcation
Grade Ulcer Gangrene
0 No ulcer No gangrene
Clinical description: ischemic rest pain (requires typical symptoms þ ischemia grade 3); no wound.
1 Small, shallow ulcer on distal leg or foot; no exposed bone,
unless limited to distal phalanx
No gangrene
Clinical description: minor tissue loss. Salvageable with simple digital amputation (1 or 2 digits) or skin coverage.
2 Deeper ulcer with exposed bone, joint, or tendon; generally
not involving the heel; shallow heel ulcer, without calcaneal
involvement
Gangrenous changes limited to digits
Clinical description: major tissue loss salvageable with multiple ($3) digital amputations or standard TMA 6 skin coverage.
3 Extensive, deep ulcer involving forefoot and/or midfoot; deep,
full-thickness heel ulcer 6 calcaneal involvement
Extensive gangrene involving forefoot and/or midfoot;
full-thickness heel necrosis 6 calcaneal involvement
Clinical description: extensive tissue loss salvageable only with a complex foot reconstruction (nontraditional transmetatarsal,
Chopart, or Lisfranc amputation); ﬂap coverage or complex wound management needed for large soft tissue defect.
TMA, Transmetatarsal amputation.
Table 3.3. Ischemia grading in Wound, Ischemia, and foot Infection (WIfI) classiﬁcation
Grade ABI Ankle systolic pressure TP, TcPo2
0 $0.80 >100 mm Hg $60 mm Hg
1 0.6-0.79 70-100 mm Hg 40-59 mm Hg
2 0.4-0.59 50-70 mm Hg 30-39 mm Hg
3 #0.39 <50 mm Hg <30 mm Hg
ABI, Ankle-brachial index; TP, toe pressure; TcPO2, transcutaneous oximetry.
Flat or minimally pulsatile forefoot pulse volume recording is grade 3. Measure TP or TcPo2 if ABI incompressible (>1.3). Patients with diabetes should
have TP measurements. If arterial calciﬁcation precludes reliable ABI or TP measurements, ischemia should be documented by TcPo2, skin perfusion
pressure, or pulse volume recording. If TP and ABI measurements result in different grades, TP will be the primary determinant of ischemia grade.
Table 3.4. Foot infection grading in Wound, Ischemia, and foot Infection (WIfI) classiﬁcation




No symptoms or signs of infection 0 Uninfected
Infection present, as deﬁned by the presence of at least two of the following items:
d Local swelling or induration
d Erythema >0.5 to #2 cm around the ulcer
d Local tenderness or pain
d Local warmth
d Purulent discharge (thick, opaque to white, or sanguineous secretion)
1 Mild
Local infection involving only the skin and the subcutaneous tissue (without involvement of deeper
tissues and without systemic signs as described below).
Exclude other causes of an inﬂammatory response of the skin (eg, trauma, gout, acute Charcot
neuro-osteoarthropathy, fracture, thrombosis, venous stasis).
Local infection (as described above) with erythema >2 cm or involving structures deeper than skin
and subcutaneous tissues (eg, abscess, osteomyelitis, septic arthritis, fasciitis) and no systemic
inﬂammatory response signs (as described below).
2 Moderate
Local infection (as described above) with the signs of SIRS, as manifested by two or more of the
following:
d Temperature >38C or <36C
d Heart rate >90 beats/min
d Respiratory rate >20 breaths/min or Paco2 <32 mm Hg
d White blood cell count >12,000 or <4000 cells/mm3 or 10% immature (band) forms
3 Severea
IDSA, Infectious Diseases Society of America; Paco2, partial pressure of arterial carbon dioxide; PEDIS, perfusion, extent, depth, infection, and sensation;
SIRS, systemic inﬂammatory response syndrome; SVS, Society for Vascular Surgery.
aIschemia may complicate and increase the severity of any infection. Systemic infection may sometimes be manifested with other clinical ﬁndings,
such as hypotension, confusion, and vomiting, or evidence of metabolic disturbances, such as acidosis, severe hyperglycemia, and new-onset
azotemia.
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Table 3.5. Clinical stages of major limb amputation risk








Very low Stage 1 W0 I0 fI0,1
W0 I1 fI0
W1 I0 fI0,1
W1 I1 fI 0
















W2 I 1 fI0,1
W2 I2 ﬁ0
W3 I0 ﬁ0,1









Clinical descriptors:Stage 1: minimal ischemia; no/minor tissue loss.-
Stages 2-4 reﬂect increasing stages of ischemia, wound, and infec-
tion.Stage 5 (not shown in table): unsalvageable foot (most often due
to wound extent or severity of infection).
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Vascular imaging shouldbeperformed in all patientswith
suspected CLTI (Table 3.6) to determine the presence,
extent, and severity of arterial disease and to help inform
decisions about revascularization. Although there have
beenhuge advances in imaging techniques in recent years,
access to these latest modalities, and so practice, varies
considerably between and even within countries.
In patients with CLTI who are candidates for revasculari-
zation (Section 6), imaging should allow complete
anatomic staging using, for example, GLASS (Section 5).
Adequate imaging of the tibial and pedal vessels is ofcritical importance, particularly in planning intervention
in patients with tissue loss. History and physical examina-
tion often help guide the optimal imaging approach. For
those with tibial disease, particularly in the setting of tissue
loss, computed tomography angiography (CTA) and mag-
netic resonance angiography (MRA) may offer useful infor-
mation but may fail to completely image the ankle and
foot vessels with sufﬁcient resolution for procedural plan-
ning. Many vascular specialists believe that digital subtrac-
tion angiography (DSA) remains the “gold standard.” CTA
offers more precise quantiﬁcation of arterial calciﬁcation
compared with MRA and DSA. Selective intra-arterial
dual-energy CTA combines the low contrast material
dose of conventional angiography with computed to-
mography; if it is available, it may allow crural artery visu-
alization in patients with renal insufﬁciency.257 This
technology is in evolution and not routinely available.
Duplex ultrasound imaging (DUS). DUS imaging is
usually the ﬁrst imaging modality of choice and in
some health care settings may be the only modality
available. DUS provides information on the anatomic
location and extent of disease as well as information
about ﬂow volume and velocity.258,259 There may be dif-
ﬁculty in directly imaging the AI segments because of
body habitus, bowel gas, and movement. However, the
presence of “inﬂow” disease can often be inferred from
common femoral artery (CFA) waveforms. In the IP
arterial segments, assessment can be technically chal-
lenging, particularly when vessel calciﬁcation and over-
lying tissue loss are present. Some vascular specialists
advocate the use of ultrasound contrast agents to
improve visualization; however, clinical studies to date
are limited.260 Although multiple studies have shown
DUS to be inferior to other imaging techniques, such as
DSA, it offers many advantages as a ﬁrst-line imaging
modality, including its noninvasive nature, low cost, no
iodinated contrast media, no ionizing radiation, and no
ﬁxed installation (mobility).25,261,262 The main disadvan-
tages of DUS are that it is time-consuming and highly
operator dependent, and it does not produce a contin-
uous lesion map. DUS is also poor at estimating collateral
blood supply and reserve. Furthermore, the stored im-
ages can be difﬁcult to interpret at a later point in time.
CTA. In recent years, CTA has advanced considerably in
terms of accuracy and acquisition times. Modern CTA
quickly generates high-resolution, contrast-enhanced
images that can be viewed in multiple planes or as
three-dimensional reconstructions.26,263-265 In a meta-
analysis comparing CTA with DSA that predominantly
included patients with IC, CTA was found to have high
sensitivity and speciﬁcity in the AI (95% and 96%,
respectively) and FP (97% and 94%) segments but was
somewhat inferior in the IP segment (95% and 91%).29
The researchers highlighted the difﬁculties encoun-
tered with blooming artifact in calciﬁed arteries (where
motion-related artifact causes calcium deposits to
Recommendation Grade Level of evidence Key references
3.7 Consider DUS imaging as the ﬁrst arterial imaging modality in
patients with suspected CLTI.
2 (Weak) B (Moderate) Hingorani,24 2008
3.8 Consider noninvasive vascular imaging modalities (DUS, CTA,
MRA) when available before invasive catheter angiography
in patients with suspected CLTI who are candidates for
revascularization.
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result in lowered accuracy of this modality in the CLTI
population, particularly in the IP segment. As such, in
many centers, CTA is primarily used to image and plan
intervention in AI and FP segments.266
Contrast-induced nephropathy can be a signiﬁcant prob-
lem,57,267,268 and patients with pre-existing renal insufﬁ-
ciency are at particular risk.269 Various guidelines have
beenwritten,270,271 andmany hospitals have local operating
policies to try to mitigate the risks. Unfortunately, practices
vary considerably, making it impossible to identify ﬁrm rec-
ommendations, outside of recognizing the risk. Finally, CTA
is associatedwith signiﬁcantdosesof ionizing radiation.26,272
MRA. MRA has the potential to produce images that
are comparable in quality to DSA images but without
exposure to ionizing radiation or iodinated contrast ma-
terial, making contrast-induced nephropathy extremely
rare.27-29,57,263-269,272-276 Time-resolved techniques can
accurately image ﬂow patterns, which can be helpful in
assessing IP runoff. In a meta-analysis, MRA also showed
improved speciﬁcity and sensitivity over CTA and DUS.276
Whereas conventional time-of-ﬂight MRA sequences may
overestimate the degree of arterial stenosis, newer tech-
niques suggest that noncontrast-enhanced MRA remains
an excellent imaging modality for patients with CLTI,
accurately assessing distal lower extremity vessels.277
However, failure of MRA to visualize vessel wall calciﬁca-
tion may underestimate the difﬁculty of surgical and
endovascular revascularization. Contrast-enhanced MRA
(CE-MRA) using gadolinium-based contrast agents is
generally preferred because of the high contrast to noise
ratio, better spatial resolution, more rapid acquisition, and
less artifact. Time-resolved MRA is particularly useful in
imaging of IP disease.274 Finally, MRA produces a three-
dimensional map of the overall arterial tree, with the pos-
sibility of additional accurate mapping of the IP and foot
vessels in more specialized centers. Other challenges of
MRA include the potential overestimation of stenoses,
problems visualizing in-stent restenosis, compatibility with
implanted devices such as pacemakers and deﬁbrillators,
longer image acquisition times, and image artifact. Pa-
tients often have a lower tolerance for MRA than for CTA
because of claustrophobia. Accurate interpretation of the
images by a dedicated subspecialist, such as a vascularradiologist, isessential inaiding revascularization strategies.
MRA equipment is expensive, although it can be used for
other nonvascular magnetic resonance-based in-
vestigations. Thus, in some developing and developed
countries, access to MRA and to dedicated subspecialists
who are available to interpret the images is scarce.229
Finally, gadolinium contrast enhancement has been asso-
ciated with cases of nephrogenic systemic ﬁbrosis, pri-
marily in individualswithanestimatedglomerularﬁltration
rate of <30mL/min/1.73 m2.278
Foot MRA. CLTI patients have a high incidence of IP
and pedal artery disease. The precise location, length,
and severity of disease as well as the patency of runoff
vessels should ideally be delineated before revasculariza-
tion planning. In highly specialized centers, compared
with DSA, foot CE-MRA yielded a sensitivity of 92% for
the detection of signiﬁcant disease in IP and pedal ves-
sels.279 Magnetic resonance perfusion imaging may have
a role in assessing overall foot perfusion before and after
intervention.280,281 As for limitations of foot CE-MRA, in
slow-ﬂow states, there may be signiﬁcant venous overlay
obscuring arterial anatomy, and the availability of the
modality is limited.
In summary, MRA is still an evolving technology with
new contrast-enhanced and noncontrast-enhanced
sequences being reported in the literature. Time will
tell whether these advances will overcome some of the
current limitations. However, access to the most modern
imaging techniques is highly variable around the world.
Recommendation3.9 Obtain high-quality angiographic
imaging of the lower limb (with
modalities and techniques to be
determined by local available
facilities and expertise). This should
include the ankle and foot in all
patients with suspected CLTI who
are considered potential
candidates for revascularization.Good practice
statementCatheter DSA. With the advent of DUS, CTA, and MRA,
diagnostic DSA is probably performed less commonly
now, but many vascular specialists still consider it the




d Quick, widely available worldwide
d Useful to monitor efﬁcacy of therapeutic
intervention
d Highly operator dependent
d Limitations to the visualization of iliac arteries
due to body habitus, bowel gas
d Calciﬁcation may produce incomplete
examination
d Most DUS studies were performed in mixed
populations; thus, the validity of DUS imaging for
CLTI patients alone is uncertain
CTA d Noninvasive
d Excellent patient acceptance
Ability to evaluate previously stented arteries
d Mostly applicable in patients with contraindica-
tions to MRA
d Image interference from calciﬁed arteries
d Potentially nephrotoxic contrast agents
Radiation exposure
d Less reliable for imaging of IP vessels
d Patients with CLTI who require a complete
assessment of their lower extremity (including
foot) arteries for planning of a revascularization are
under-represented in the current studies. The
clinical value of CTA in the CLTI target population
remains uncertain.
MRA d Noninvasive
d Eliminates exposure to ionizing radiation
d Unaffected by arterial calciﬁcation
d Three-dimensional images of the entire arterial
tree are presented in a maximum intensity pro-
jection format produced on a workstation
d Easily produced arterial map aids in planning of
revascularization strategies
d Patients with pacemakers and deﬁbrillators and
some cerebral clips cannot be scanned safely
d Tendency to overestimate stenosis
d Metal clips can cause artifacts that mimic vessel
occlusions





d Provides a complete map of the lower limb
arteries
d Images are easily displayed and interpreted by
most physicians in charge of patients with CLTI
d Selective catheter placement during lower ex-
tremity angiography enhances imaging, reduces
contrast material dose, and enhances sensitivity in
patients with CLTI
d Exposure to ionizing radiation and contrast
media
d Alternatively, carbon dioxide and magnetic
resonance contrast agents (eg, gadolinium) can be
used instead of conventional contrast media
d Complications of catheterization despite im-
provements in catheter and guidewire technology
CTA, Computed tomography angiography; DSA, digital subtraction angiography; DUS, duplex ultrasound; IP, infrapopliteal; MRA, magnetic resonance
angiography.
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pected CLTI, particularly when IP disease is likely
to be present.282 Enthusiasts for DSA will also point out
that it allows intervention at the same setting. Other
vascular specialists, however, argue that diagnostic
DSA is outdated. The DSA technique should minimize
the amount of iodinated contrast material and the
dose of ionizing radiation used while maximizing imag-
ing of the distal vasculature.268,283-285 In general, diag-
nostic DSA is widely available, and the complication rate
is low.283,286
CO2 angiography. CO2 angiography can be used in pa-
tients with an allergy to contrast material or in individuals
with severe CKD; unfortunately, it frequently causes sig-
niﬁcant discomfort of the patient. CO2 angiography is
generally considered inferior to iodinated angiography
but can still provide useful diagnostic images. There is a
general trend of imaging performance progressively
degrading down the leg.287 Power injectors may
improve safety and quality.
Perfusion angiography. This is a new technique per-
formed with use of a dedicated imaging suite and work-
station to provide time-resolved perfusion imaging of thefoot to aid in the diagnosis and impact of revasculariza-
tion techniques. Perfusion angiography provides quan-
tiﬁable information of the functional status of foot
perfusion and is a positive step toward functional imag-
ing of the foot.288
Summary
All patients presenting with CLTI should have a full his-
tory and physical examination followed by noninvasive
hemodynamic testing. These studies can be easily per-
formed in most centers around the world. The authors
recommend that all patients undergo limb staging by
a classiﬁcation system, such as WIfI, that integrates mul-
tiple key elements (eg, wound, ischemia, infection) and
correlates with the risk of amputation and the likelihood
of wound healing. The next step in appropriate candi-
dates (Section 6) is to obtain high-quality diagnostic im-
ages to guide revascularization. This will depend heavily
on the availability of equipment and local expertise
(Fig 3.2). Where it is available, DUS is the preferred ﬁrst
noninvasive imaging modality. However, for more com-
plete noninvasive anatomic imaging, either MRA or CTA
can be considered.
Fig 3.2. Suggested algorithm for anatomic imaging in patients with chronic limb-threatening ischemia (CLTI)
who are candidates for revascularization. In some cases, it may be appropriate to proceed directly to angiographic
imaging (computed tomography angiography [CTA], magnetic resonance angiography [MRA], or catheter) rather
than to duplex ultrasound (DUS) imaging.
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technique, especially below the knee. In many centers,
however, DSA is typically used only when MRA or CTA
is not available, when MRA or CTA imaging is subopti-
mal and fails to adequately deﬁne the arterial anat-
omy, or for those patients expected to proceed to
endovascular intervention. No patient with suspected
CLTI who is a suitable candidate for limb salvage
should be denied revascularization without ﬁrst under-
going complete diagnostic angiography that includes
the ankle and foot.
Research priorities3.1 Deﬁne optimal methods for measuring foot perfusion and
its correlation with stages of disease and response to
treatment.3.2 Validate contrast-enhanced ultrasound in patients with
CLTI.3.3 Deﬁne optimal strategies to reduce the incidence of
contrast-induced nephropathy in patients with CLTI.3.4 Improve noninvasive imaging of the ankle and foot
vascular tree using MRA.4. MEDICAL MANAGEMENT
CLTI is an end-stage manifestation of systemic
atherosclerosis. It is frequently accompanied by
clinically signiﬁcant CVD, resulting in exceedingly
high mortality from stroke and myocardial infarction.
In the absence of aggressive identiﬁcation and
treatment of risk factors and associated comorbid
conditions, the prognosis of CLTI is usually poor, with
a mortality rate of 20% to 26% within 1 year of
diagnosis.5,30,154,213,219,220,230,289
In a study of 574 patients with CLTI who did not
undergo revascularization after 2 years, 31.6% had
died, primarily of CVD, and 23% required major
amputation.290
The goal of treatment of patients with CLTI is not only
to salvage a functional limb but to reduce cardiovascu-
lar morbidity and mortality through aggressive risk fac-
tor modiﬁcation and best medical therapy.31,32,224
Whereas certain risk factors, such as age and sex,
cannot be modiﬁed, others can, including hyperlipid-
emia, hypertension, diabetes, smoking, and sedentary
lifestyle.
Recommendations Grade Level of evidence Key references
4.1 Evaluate cardiovascular risk factors in all patients with
suspected CLTI.
1 (Strong) B (Moderate) I.C.A.I. group,30 1997
4.2 Manage all modiﬁable risk factors to recommended levels in
all patients with suspected CLTI.
1 (Strong) B (Moderate) Armstrong,224 2014
Faglia,32 2014
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strongly recommended for all patients with symptomatic
PAD to reduce the risk of major adverse cardiovascular
events (MACE).33,34,291 The Antithrombotic Trialists’ Collab-
oration performed a meta-analysis of antiplatelet agent
trials before 1997.33 It included 135,000 patients with cere-
brovascular disease, coronarydisease, or PAD (IC)whowere
treated with antiplatelet agents and 77,000 control pa-
tients. The antiplatelet therapy group had a 22% reduction
in MACEs, and 75 to 150 mg of aspirin per day was as
effective as higher doses butwith a lower risk of bleeding.33
Amore recentmeta-analysis studied the speciﬁc beneﬁt of
aspirin in 16 secondary prevention trials comprising 17,000
patients.34 This study conﬁrmed the beneﬁt of antiplatelet
agentswith an 18.2% reduction inMACEs in bothmen and
women. The Critical Leg Ischaemia Prevention Study
(CLIPS) group compared the beneﬁt of 100 mg of aspirin
per day in 185 patients with symptoms of PAD and an
ABI <0.85 or a TBI <0.6 with placebo and reported a 64%
risk reduction in vascular events compared with a 24%
reduction in the placebo group.291
However, there is a growing body of literature indi-
cating that alternatives to aspirin, such as ticlopidine,
dipyridamole, and clopidogrel, may be more effec-
tive.35,292-294 The Clopidogrel versus Aspirin in Patients
at Risk for Ischaemic Events (CAPRIE) trial, although
not speciﬁcally designed to address CLTI, compared 75
mg of clopidogrel per day with 325 mg of aspirin per
day in patients with PAD. Researchers noted an 8.7%
decrease in MACEs with clopidogrel compared with
aspirin. There was no signiﬁcant difference in bleeding
risks between the two agents.35
Other antiplatelet agents, such as ticagrelor and
vorapaxar, have also been shown to reduce MACEs in
patients with PAD.292-294 However, beneﬁt over clopi-
dogrel has not been demonstrated.36,294-298 The Exam-
ining Use of Ticagrelor in Peripheral Artery Disease
(EUCLID) trial compared ticagrelor with clopidogrel in
13,885 patients with symptomatic PAD and an ABI
#0.8.36 Although both drugs had a similar safety pro-
ﬁle, ticagrelor was not superior to clopidogrel. The Trial
to Assess the Effects of Vorapaxar in Preventing Heart
Attack and Stroke in Patients with Atherosclerosis-
Thrombolysis in Myocardial Infarction 50 (TRA2P-TIMI
50) examined the effects of the protease-activated re-
ceptor 1 antagonist vorapaxar on secondary preventionof ischemia events in patients with stable atheroscle-
rosis, including symptomatic PAD.295 Acute limb
ischemia, a prespeciﬁed study end point, was reduced
by 41% among the PAD cohort.298 However, vorapaxar
has been associated with an increase in intracranial
hemorrhage in patients who have had a prior stroke
or transient ischemic attack.296 In a meta-analysis, vor-
apaxar added to aspirin yielded little improvement in
the reduction of MACEs in patients with atherosclerosis
and was associated with a slightly higher incidence of
intracranial hemorrhage.294 Finally, a meta-analysis
that reviewed the use of ticagrelor, ticlopidine, aspirin,
cilostazol, picotamide, vorapaxar, and clopidogrel as
single antiplatelet therapy or dual antiplatelet therapy
(DAPT) in patients with PAD found that clopidogrel
monotherapy resulted in the best overall safety and ef-
ﬁcacy (reduction of MACEs).297
The long-term use of DAPT or systemic anticoagulation
with vitamin K antagonists is not indicated for PAD.299,300
The role of direct oral anticoagulants is currently the sub-
ject of intense investigation. The Cardiovascular Out-
comes for People Using Anticoagulation Strategies
(COMPASS) trial, a multicenter randomized trial of 7470
individuals with stable, mild to moderate PAD, found
that low-dose rivaroxaban (an oral factor Xa inhibitor) in
combination with aspirin reduced MACEs (death,
myocardial infarction, or stroke) and major adverse
limb events (MALEs) compared with aspirin alone.37 Pa-
tients who had previous lower extremity revasculariza-
tion, amputation, or history of IC and ABI of <0.9 and
documented peripheral stenosis of >50% or carotid ste-
nosis of >50% were included in the study. Overall, 8.5%
of study patients had an ABI of <0.7. In this population,
there was a signiﬁcant reduction in MALEs, major ampu-
tation, and acute limb ischemia compared with aspirin
alone.301 This drug combination was associated with a
small but statistically signiﬁcant increase in clinically rele-
vant bleeding. Whereas the study results are promising,
the beneﬁts and risks of the low-dose rivaroxaban and
low-dose aspirin combination in patients with CLTI
have not yet been adequately deﬁned. In addition, this
drug combination is not globally available at this time.
The ongoing VOYAGER trial (ClinicalTrials.gov identiﬁer
NCT02504216) is comparing the same two antithrom-
botic regimens in PAD patients undergoing peripheral
revascularization.302
Recommendations Grade Level of evidence Key references




4.4 Consider clopidogrel as the single antiplatelet agent of
choice in patients with CLTI.
2 (Weak) B (Moderate) CAPRIE,35 1996
Hiatt,36 2017
4.5 Consider low-dose aspirin and rivaroxaban, 2.5 mg twice
daily, to reduce adverse cardiovascular events and
lower extremity ischemic events in patients with CLTI.
2 (Weak) B (Moderate) Anand,37 2018
4.6 Do not use systemic vitamin K antagonists for the
treatment of lower extremity atherosclerosis in
patients with CLTI.
1 (Strong) B (Moderate) Anand,38 2007
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(HPS) evaluated the effect of blood lipid lowering on car-
diovascular events in PAD and included patients with
CLTI.40 Other studies, although similar, limited inclusion
to patients with IC.41 The HPS included 20,536 high-risk
individuals with a total cholesterol concentration of at
least 135 mg/dL (3.5 mmol/L). The participants were ran-
domized to 40 mg/d of simvastatin or a placebo. In the
simvastatin group, there was a 25% (95% CI, 16%-33%)
relative risk (RR) reduction in the ﬁrst major vascular
event among patients who had no history of a coronary
event at baseline.40 In addition, lipid lowering was shown
to be most effective in patients with a blood cholesterol
concentration >135 mg/dL (> 3.5 mmol/L). There was also
a signiﬁcant reduction in cardiovascular events (P <
.0001) among a subgroup of individuals with PAD.
A Cochrane review evaluated 18 lipid-lowering trials
comprising 10,049 PAD patients.39,42 Whereas the major-
ity had IC and only some trials included CLTI, the results
appear relevant to the CLTI population. Only one study
showed a negative effect of lipid lowering. When this
study was excluded, analysis showed that lipid-lowering
therapy signiﬁcantly reduced the risk of total cardiovas-
cular events in PAD (OR, 0.74; CI, 0.55-0.98).42 This was
primarily due to a positive effect on total coronary events
(OR, 0.76; CI, 0.67-0.87).
The impact of statin agents may extend beyond their
lipid-lowering effect by reducing inﬂammation in pa-
tients with PAD.303,304 An individual-patient data meta-
analysis of 54 prospective cohort studies demonstrated
that inﬂammatory biomarkers independently predict
vascular risk with a magnitude of effect at least as large
as that of blood pressure or cholesterol.305 Even after
adjustment for age, sex, and traditional risk factors, pa-
tients with PAD are known to have increased levels of in-
ﬂammatory cytokines, acute phase reactants, and
soluble adhesion molecules.306 However, although the
attributable vascular risk associated with inﬂammation
is large and animal models using targeted anti-
inﬂammatory therapies have shown promise, it remainsunknown whether inhibiting inﬂammation alone will
lower vascular event rates.
The landmark Justiﬁcation for the Use of Statins in Pre-
vention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) examined the use of intensive statin therapy
(rosuvastatin 20 mg daily vs placebo) in a primary pre-
vention trial.307,308 In total, there were 17,802 individuals
who had low levels of LDL-C but an elevated vascular
risk based on a proinﬂammatory biomarker (high levels
of high-sensitivity C-reactive protein). Investigators
demonstrated a 44% reduction in major vascular events,
including a 54% reduction in myocardial infarction, a
48% reduction in stroke, a 46% reduction in arterial
revascularization, a 43% reduction in deep venous
thrombosis or pulmonary embolism, and a 20% reduc-
tion in mortality. The greatest absolute risk and the
greatest absolute risk reduction were observed among
those with the highest levels of high-sensitivity C-reactive
protein. There are now multiple studies showing a
decrease in cardiovascular events in patients with estab-
lished atherosclerosis treated with intensive statin ther-
apy.43,224,309,310 A large retrospective cohort study from
the U.S. Veterans Affairs population demonstrated
reduced mortality and major amputation rates among
patients with established PAD receiving intensive-dose
statins.311 Statin therapy can be associated with muscle
aching, the most common adverse effect limiting its
use. In the setting of this complication, statin dose can
be lowered to the maximum tolerated dose, and a sec-
ond nonstatin cholesterol-lowering drug can be added
to reduce cholesterol levels even further.
Recent (2013, 2018) American College of Cardiology/
American Heart Association guidelines on treatment of
blood cholesterol recommend the use of moderate- to
high-intensity statins for all individuals with established
atherosclerotic CVD including PAD.312,313 Both rosuvasta-
tin (20-40 mg) and atorvastatin (40-80 mg) have been
shown to be effective.310 The 2018 guideline describes
“very high risk” individuals to include those with symp-
tomatic PAD and at least one other high-risk condition
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coronary revascularization, DM, hypertension, CKD, cur-
rent smoking, congestive heart failure)da categoriza-
tion that applies to the overwhelming majority of
patients with CLTI. For this population, high-intensity/
maximally tolerated statin dosing is recommended,
and if on-treatment LDL-C levels remain $70 mg/dL
(1.8 mmol/L), the addition of ezetimibe is considered
reasonable.313
New lipid-lowering agents have entered the armamen-
tarium. Proprotein convertase subtilisin/kexin type 9
(PCSK9) directs the degradation of LDL receptors in the
liver and has become a drug target. The Further Cardio-
vascular Outcomes Research with PCSK9 Inhibition in
Subjects with Elevated Risk (FOURIER) RCT demon-
strated an additional beneﬁt of evolocumab (a PCSK9 in-
hibitor) in reducing MACEs in PAD patients already
receiving statin therapy.314 The composite end point of
cardiovascular death, myocardial infarction, stroke, hos-
pital admission for unstable angina, or coronary revascu-
larization was statistically reduced in PAD patients
treated with the PCSK9 inhibitor evolocumab (hazard ra-
tio [HR], 0.79; P ¼ .0040). There was also a reduction in
the risk of MALEs, including acute limb ischemia and
major amputation. Further studies will be needed in
PAD subpopulations including CLTI.
Further studies of these agents are desirable in high-risk
PAD subpopulations including CLTI.Recommendation Grade Level of evidence Key references
4.7 Use moderate- or high-intensity statin
therapy to reduce all-cause and
cardiovascular mortality in patients
with CLTI.
1 (Strong) A (High) Leng,39 2000





Rodriguez,44 2017Management of hypertension. It is universally accepted
that control of hypertension reduces MACEs in patients
with PAD. The International Verapamil-SR/Trandolapril
Study (INVEST) analyzed the impact of control of hyper-
tension on all-cause death, nonfatal myocardial infarction,
and nonfatal stroke in 22,576 hypertensive patients with
stable coronary artery disease (CAD), of whom 2699 also
had PAD.46 PAD patients had a signiﬁcantly higher inci-
dence of sustaining a primary end point MACE compared
with those without PAD (16.3% vs 9.2%). In addition,
among those with PAD, a MACE was less likely to occur in
patients with systolic blood pressure <145 mm Hg and
diastolic pressures <90 mm Hg. Further reduction of
blood pressure to below 130 mm Hg systolic and 80 mm
Hg diastolic provides even greater protection fromcardiovascular events.48 The Systolic Blood Pressure
Intervention Trial (SPRINT) compared blood pressure
control with a systolic pressure of 120 mm Hg (intensive
control) or 140 mm Hg (standard control) in 2510 patients
with a mean age of 79.9 years observed for a mean of 3.14
years.315 The study documented a signiﬁcantly lower
incidence of composite cardiovascular events of death
with intensive control. However, intensive blood pressure
control may result in greater morbidity associated with
periods of clinically signiﬁcant hypotension.45,47 Optimal
blood pressure control for patients with CLTI has not been
established, and although maintaining systolic
pressure <140 mmHg and diastolic pressure <90mmHg
is important, lower pressures may be beneﬁcial to further
reduce MACEs.
The ﬁrst-line category of oral antihypertensive does not
appear to be of signiﬁcance. Angiotensin-converting
enzyme inhibitors (ACEIs), calcium channel blockers,
and diuretics, when successful in lowering blood pres-
sure to target, reduce cardiovascular events to a similar
extent.316,317 Although the Ongoing Telmisartan Alone
and in Combination with Ramipril Global Endpoint Trial
(ONTARGET) and Heart Outcomes Prevention Evaluation
(HOPE) study suggested that in the absence of heart fail-
ure, monotherapy with an ACEI (ramipril) reduces the
rate of MACEs in high-risk patients, there is recent evi-
dence to suggest that this class of drug may result in a
higher amputation rate for patients with CLTI.318 In ananalysis of the Medicare database for 2007 to 2008, there
were 22,954 patients who underwent lower extremity
revascularization. Of these, 64.6% were treated for CLTI.
Compared with those not taking an ACEI, patients who
presented with rest pain and were taking an ACEI after
the index procedure had a higher risk of amputation.
Other studies have not noted an increased risk of
amputation associated with ACEIs but have suggested
an increased rate of reintervention. A propensity
score-matched cohort study of 17,495 Danish patients
compared those receiving ACEIs with those who were
not after vascular reconstruction. Observed for a mean
of 1.6 years, the patients treated with ACEIs had a lower
all-cause mortality (20.4% vs 24.9%) but underwent
more reintervention (24% vs 23.1%).319 Using the same
Journal of Vascular Surgery Conte et al 49S
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use of beta blockers after primary vascular reconstruction
was associated with a decrease in the incidence of major
amputation but a higher rate of myocardial infarction and
stroke without an increase in all-cause mortality.320
Globally, adequate control of hypertension remains a sig-
niﬁcantchallenge. In LMICs, theavailability of oral antihyper-
tensives is limitedandcostsarehigh, resulting inpooroverall
blood pressure control. Strategies are urgently required to
improve availability and affordability of drugs so that
vascular specialists can treat their patients to target.321
There have been concerns that drugs reducing heart
rate and blood pressure will worsen ischemia in patients
with PAD. Although beta blockade has not been directly
evaluated in CLTI, it has been the subject of several clinical
trials in IC and has been shown to be effective in lowering
blood pressure without worsening symptoms.322,323Recommendation Grade Level of evidence Key references
4.8 Control hypertension to target levels of <140 mm Hg
systolic and <90 mm Hg diastolic in patients with CLTI.




Moise,48 2016Management of diabetes. Type 2 DM is a signiﬁcant risk
factor for PAD,324,325 and the extent of vascular disease
appears related to the duration and severity of hyper-
glycemia. Glycemic control is therefore essential in all
diabetic patients with PAD. Metformin monotherapy is
generally recognized as the best initial oral hypoglyce-
mic agent. When additional therapy is needed, any other
class of oral hypoglycemic agent, including sulfonylurea,
thiazolidinedione, dipeptidyl peptidase 4 inhibitor, or a-
glucosidase, can be added with equal effectiveness.54
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors
are a newer class of agents that have been associatedRecommendations
4.9 Consider control of type 2 DM in CLTI patients to achieve a
hemoglobin A1c of <7% (53 mmol/mol [International
Federation of Clinical Chemistry]).
4.10 Use metformin as the primary hypoglycemic agent in patien
with type 2 DM and CLTI.
4.11 Consider withholding metformin immediately before and
24 to 48 hours after the administration of an iodinated
contrast agent for diabetic patients, especially those with
estimated glomerular ﬁltration rate <30 mL/min/1.73 m2.with beneﬁcial effects on cardiovascular complica-
tions, renal disease, and mortality in type 2 diabetics.
However, one large trial (10,142 subjects) demon-
strated an approximately 2-fold increased risk of
lower limb amputations associated with the use of
canaglifozin, an SGLT-2 inhibitor, prompting a “black-
box” warning.326-328 The mechanism is unclear and
may be generically related to diuretic actions in this
population.329 Caution is advised in the use of this
agent in diabetic patients with advanced PAD and/
or CLTI.
Whereas there are some data to suggest that the
dipeptidyl peptidase 4 inhibitors may reduce the risks
of myocardial infarction and stroke, the impact on PAD
in patients with CLTI has not yet been deﬁned.330 The
goal for most adults with DM is to maintain a glycosy-
lated hemoglobin A1c level of <7% (equivalent to Interna-tional Federation of Clinical Chemistry units of 53 mmol/
mol).49-52 However, less stringent goals (eg, hemoglobin
A1c level <8%) may be appropriate for individuals with
advanced vascular complications or limited life
expectancy.53
Type 2 DM patients with abnormal renal function
treated with metformin may be at higher risk for
contrast-induced nephropathy and lactic acidosis.
Whereas the matter is the subject of continued debate,
it is reasonable to withhold metformin for 24 to 48 hours
after the administration of an iodinated contrast
agent.55-57,270,271Grade Level of evidence Key references
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factors as discussed, it is important to encourage
CLTI patients to adopt a healthier lifestyle. Stopping
smoking (tobacco and other recreational drugs)
completely and permanently, adopting a healthy
diet and weight control, and regular exercise must
be stressed as extremely important for both life and
limb.331,332
Tobacco. The adverse impact of tobacco use on car-
diovascular health has been well established. Despite
the use of best medical therapy, male and female
smokers (even those smoking 1-10 cigarettes per day)
have a signiﬁcantly higher rate of disease progression
and MACEs.58-60 Thus, all patients presenting with
CLTI should be asked about smoking and referred to a
smoking cessation program if they are still smoking.
To encourage compliance with advice to stop smok-
ing, patients should be challenged about smoking at
every medical encounter.61,62 The safety of electronic
cigarettes has not been established, including for pa-
tients with PAD, and until more evidence becomes
available should not be considered in patients with
CLTI.333Recommendations Grade Level of evidence Key references
4.12 Offer smoking cessation interventions (pharmacotherapy,
counseling, or behavior modiﬁcation therapy) to all patients
with CLTI who smoke or use tobacco products.
1 (Strong) A (High) Dagenais,58 2005
Athyros,59 2013
Blomster,60 2016
4.13 Ask all CLTI patients who are smokers or former smokers about
status of tobacco use at every visit.
1 (Strong) A (High) Kondo,61 2011
Newhall,62 2017Diet and exercise. Although diet and exercise have not
been speciﬁcally evaluated in CLTI, there is compelling
evidence that they affect the progression of atheroscle-
rosis. Diets that are high in carbohydrates and saturated
fats are associated with a higher risk of MACEs.334 A diet
that reduces the intake of saturated fats and increases
the intake of monounsaturated fats, omega-3 fatty acids,
antioxidants, and other natural plant sterols and stanols
is associated with a reduction in plaque burden and
MACEs.335-337 Patients should be encouraged to adopt a
low-fat or Mediterranean diet.338 Unfortunately, fruits and
vegetables are not always available or affordable, espe-
cially in LMICs.339Although CLTI studies are not available, numerous trials
have conﬁrmed the beneﬁts of supervised exercise in
IC.340 Exercise-based cardiac rehabilitation reduces the
risk of subsequent myocardial infarction and cardiovas-
cular mortality.341 It therefore seems reasonable to
suggest that a postrevascularization walking-based exer-
cise program would also beneﬁt CLTI patients who are
cleared for full weight-bearing.
Management of pain. Although pain is an important
issue for most CLTI patients, it is often poorly managed.
Poor pain control can reduce HRQL levels to those seen
in patients with terminal cancer and has a major adverse
impact on functional capacity.
As no RCTs have been conducted in CLTI, good practice
recommendations have to be extrapolated from other
conditions in which severe pain is a major factor. The
management of ischemic pain in CLTI is often compli-
cated by the coexisting neuropathic pain, particularly in
patients with DM. However, the management of neuro-
pathic pain is not covered here.
Guidelines usually recommend a tiered approach to
pain management, with a “tradeoff” between beneﬁts
and harms (eg, constipation, drowsiness).342,343Patients should be offered paracetamol (acetamino-
phen) in combination with opioids and in proportion
to the severity of pain. All patients receiving opioids
should also be offered laxatives and antinausea medi-
cation. If the maximum tolerated analgesic dose does
not produce adequate pain relief, alternative ap-
proaches should be considered. These include tricyclic
antidepressants, gabapentin, and pregabalin, all of
which are used effectively for neuropathic pain. How-
ever, if the clinician is unfamiliar with the use of these
compounds, early referral to a pain management ser-
vice for patients with pain not controlled by opioids is
required.
Recommendations
4.14 Prescribe analgesics of appropriate strength for CLTI patients who have ischemic rest pain of
the lower extremity and foot until pain resolves after revascularization.
Good practice statement
4.15 In CLTI patients with chronic severe pain, use paracetamol (acetaminophen) in combination
with opioids for pain control.
Good practice statement
Research priorities
4.1 Deﬁne the optimal antithrombotic regimen (safety and efﬁcacy) in patients with CLTI to reduce cardiovascular and limb-
speciﬁc events.
4.2 Deﬁne treatment targets and optimal dosing for lipid-lowering agents in the CLTI population.
4.3 Identify biomarkers predictive of clinical events in the CLTI population that may serve as targets for therapy.
4.4 Identify effective smoking cessation strategies for patients with advanced PAD and CLTI.
4.5 Identify the type of analgesia that is most effective in patients with chronic pain secondary to CLTI.
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SYSTEM (GLASS)
Rationale. An accurate assessment of limb threat and
stratiﬁcation of the anatomic pattern of disease are the
foundations of EBR. This is true not only in everyday prac-
tice but also in outcomes assessment and research. The
authors propose a new, clinically oriented framework
for classifying the pattern of arterial disease in CLTI. The
GLASS is a fundamental departure from current ap-
proaches used in PAD and more analogous to the SYN-
TAX system for CAD.344,345
Current PAD anatomic classiﬁcation schemes either
describe the location and severity of individual arterial le-
sions11,156 or quantify the overall burden and morphologyTable 5.1. Key deﬁnitions and assumptions in the Global
Limb Anatomic Staging System (GLASS)
Restoration of in-line ﬂow to the ankle and foot is a primary
goal.
Target arterial path (TAP): the selected continuous route of in-
line ﬂow from groin to ankle. The TAP typically involves the
least diseased IP artery but may be angiosome based.a
Limb-based patency (LBP): maintained patency of the TAP
Inﬂow disease (AI and CFA) is considered separately and
assumed corrected when using the infrainguinal staging
system for clinical decision-making.
Grade within segment is determined by presence of any one
of the deﬁned descriptors within that grade (ie, the worst
disease attribute within the segment deﬁnes grade).
Calciﬁcation is considered only if severe; increases within
segment grade by 1.
IM disease (pedal) modiﬁer: describes status of IM vessels
(including terminal divisions of the peroneal artery)
providing outﬂow into the foot.
AI, Aortoiliac; CFA, common femoral artery; IM, inframalleolar; IP,
infrapopliteal.
aThe generic case of rest pain is used as a default for deﬁning TAP as
the least diseased IP artery, or a speciﬁc IP target artery based on
clinical circumstances (eg, angiosome directed in setting of wounds)
may be selected by the clinician.of disease.12,151,170 Lesion- or segment-based grading sys-
temsareuseful for comparingendovasculardeviceperfor-
mance in well-deﬁned clinical situations. They are not,
however, useful for deﬁning EBR strategies in CLTI, espe-
cially given thecomplex,multilevel, and increasingly distal
disease patterns typically seen in current clinical practice.
Successful revascularization in CLTI, particularly in pa-
tients with tissue loss, nearly always requires restoration
of pulsatile in-line ﬂow to the foot. Because individual
lesion-based schemes correlate poorly with effective
revascularization in CLTI, vascular specialists must inte-
grate approaches for arterial segments into a manage-
ment strategy for the whole limb. Factors that determine
a successful anatomic outcome are intrinsically different
for bypass grafting and endovascular intervention. Bypass
surgery requires adequate inﬂow and outﬂow and,
perhaps most important, a suitable autologous conduit.
By contrast, the success of endovascular intervention is
largely deﬁnedby the complexity of atherosclerosiswithin
the anticipated target arterial path (TAP) that provides in-
line ﬂow to the foot. When the TAP includes multipleTable 5.2. Aorto-iliac (inﬂow) disease staging in GLASS
I Stenosis of the common and/or external iliac artery, chronic
total occlusion of either common or external iliac artery
(not both), stenosis of the infrarenal aorta; any
combination of these
II Chronic total occlusion of the aorta; chronic total occlusion
of common and external iliac arteries; severe diffuse
disease and/or small-caliber (<6 mm) common and
external iliac arteries; concomitant aneurysm disease;
severe diffuse in-stent restenosis in the AI system
A, no signiﬁcant CFA disease; B, signiﬁcant CFA disease
(>50% stenosis)
AI, Aortoiliac; CFA, common femoral artery.
A simpliﬁed staging system for inﬂow (AI and CFA) disease is sug-
gested. Hemodynamically signiﬁcant disease (>50% stenosis) of the
CFA is considered a key modiﬁer (A/B).
Fig 5.1. Inframalleolar (IM)/pedal disease descriptor in Global Limb Anatomic Staging System (GLASS). Repre-
sentative angiograms of P0 (left), P1 (middle), and P2 (right) patterns of disease.
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for the limb as a whole must be estimated as a product
function of each lesion traversed.
GLASS is based ondeﬁning the TAP in each individual pa-
tient by high-quality imaging and requires selection of a
preferred infrapopliteal (IP) artery. The TAP is generally
selected on the basis of the least diseased crural artery
providing runoff to the foot. It can also be selected on the
basis of other relevant factors, such as angiosome prefer-
ence or avoidance of a previously instrumented vessel.
Whereas the relationship between the pattern of occlusive
disease, patency of the chosen intervention, and clinical
success in CLTI is a complex one, an integrated limb-
based anatomic staging system like GLASS is critical to
deﬁne it. The preferred TAP for endovascular intervention
and the preferred target artery for open bypass surgery
may not always be the same; clinical decision-making
thus hinges on a comparative estimate of risk and success
for each. Like SYNTAX, GLASS stage is designed to correlate
primarily with endovascular outcomes. As such, it does not
incorporate factors like venous conduit quality or distal
runoff that are more directly relevant for bypass grafting.
GLASS provides a basis for clinical practice and supports
future research in CLTI. When it is combinedwith tools for
stratiﬁcationofpatient risk andseverityof limbthreat (Sec-
tions 1 and 3), GLASS facilitates the development of spe-
ciﬁc evidence-based revascularization (EBR) guidelines
in CLTI (Section 6). In developing GLASS, thewriting groupwas informed by a commissioned systematic review of
revascularization outcomes in CLTI and expert opinion.
Still, the authors acknowledge that the new grading sys-
tem requires prospective validation in a variety of patient
populations and health care environments. The system is
expected to undergo revisions as outcomes are reported.
Important factors for reﬁnement include the current state
of limited high-quality evidence in the ﬁeld, ongoing
changes inbothepidemiology and technology, anddiffer-
ences in disease patterns and practice around the world.
Assumptions and approach. As CLTI is usually the
result of complex multilevel occlusive disease, certain
simplifying assumptions are required to develop a usable
anatomic staging system (Table 5.1). First, because exist-
ing schemes for AI disease appear adequate, the focus of
GLASS is on infrainguinal disease (a simpliﬁed inﬂow
disease scheme is presented in Table 5.2). In GLASS, the
CFA and PFA are seen as inﬂow arteries, and the
infrainguinal system begins at the origin of the SFA. This
is justiﬁed by the distinct approaches used in the treat-
ment of CFA and PFA disease (Section 6) and long-term
results that are similar to those for AI interventions.
For GLASS to be useful in everyday clinical practice and
to form the basis of practice-changing research, it is
important that it does not rely on complex methods of
lesion characterization. With regard to vessel calciﬁca-
tion, GLASS adopts a dichotomous subjective scale in
which severe calciﬁcation (eg, >50% of circumference;
Fig 5.2. Femoropopliteal (FP) disease grading in Global Limb Anatomic Staging System (GLASS). Trifurcation is
deﬁned as the termination of the popliteal artery at the conﬂuence of the anterior tibial (AT) artery and tibio-
peroneal trunk. CFA, Common femoral artery; CTO, chronic total occlusion; DFA, deep femoral artery; Pop,
popliteal; SFA, superﬁcial femoral artery.
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Fig 5.3. Infrapopliteal (IP) disease grading in Global Limb Anatomic Staging System (GLASS). AT, Anterior tibial;
CTO, chronic total occlusion; TP, tibioperoneal.
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Table 5.3. Assignment of Global Limb Anatomic Staging System (GLASS) Stage
Infrainguinal GLASS stage (I-III)
FP Grade
4 III III III III III
3 II II II III III
2 I II II II III
1 I I II II III
0 NA I I II III
0 1 2 3 4
IP Grade
NA, Not applicable.
After selection of the target arterial path (TAP), the segmental femoropopliteal (FP) and infrapopliteal (IP) grades are determined from high-quality
angiographic images. Using the table, the combination of FP and IP grades is assigned to GLASS stages I to III, which correlate with technical
complexity (low, intermediate, and high) of revascularization.
Fig 5.4. Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage I disease patterns.
The target arterial path (TAP) is outlined in yellow. Left panel, TAP includes the anterior tibial (AT) artery. Femo-
ropopliteal (FP) grade is 0. Infrapopliteal (IP) grade is 2 (3-cm chronic total occlusion; chronic total occlusion of AT
artery and total length of disease <10 cm). Right panel, TAP includes the peroneal artery. FP grade is 2 (chronic
total occlusion <10 cm; total length of disease <2/3 ). IP grade is 0.
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within-segment grade by one numeric level. This is a sub-
jective determination made by the treating physician
that the severity of calciﬁcation signiﬁcantly increases
technical complexity (and expected technical failure
rates) for endovascular intervention. Alternative ap-
proaches for quantifying arterial calciﬁcation in PADhave been suggested but are more complex, and none
of these has been validated for discriminating clinical
outcomes.346,347 With regard to IM disease, GLASS em-
ploys a three-level modiﬁer (Fig 5.1) to describe the status
of arteries crossing the ankle (including the terminal divi-
sions of the peroneal artery) and the pedal arch.
Currently, the IM disease modiﬁer is not considered
Fig 5.5. Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage II disease patterns.
The target arterial path (TAP) is outlined in yellow. Left panel, TAP includes the anterior tibial (AT) artery. Femo-
ropopliteal (FP) grade is 1 (superﬁcial femoral artery [SFA] occlusion <5 cm). Infrapopliteal (IP) grade is 2 (two focal
stenoses of AT artery, total length <10 cm). Right panel, TAP includes the peroneal artery. FP grade is 0 (no sig-
niﬁcant stenosis). IP grade is 3 (chronic total occlusion of peroneal artery, 3-10 cm).
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given the absence of strong evidence on how it affects
treatment outcomes. It should, however, be captured in
future studies to better deﬁne how to incorporate pedal
outﬂow disease into anatomic staging in CLTI.
GLASS also makes the following assumptions:
d Restoring durable (pulsatile) in-line ﬂow to the
affected part, particularly in patients with tissue loss,
is a primary goal of revascularization in CLTI.
d Using high-quality imaging (Section 3), the vascular
specialist chooses and deﬁnes a TAP that is most likely
to achieve that in-line ﬂow.
d The TAP will usually involve the least diseased IP
artery.
d Other IP arteries (not selected for the TAP) are equally
diseased or more so.In addition, although it is an important research ques-
tion, the current version of GLASS does not consider mul-
tivessel IP revascularization because evidence of its role is
still lacking. Where the clinician is considering such
revascularization, GLASS staging is based on the primary
IP target, as deﬁned by the clinician before the
intervention.
In deﬁning infrainguinal anatomic stages (I-III), GLASS
combines grades (0-4) for the FP (origin of the SFA to the
origin of the anterior tibial [AT] artery; Fig 5.2) and IP (origin
of the tibioperoneal trunkand theATartery to themalleoli;
Fig 5.3) segments in series. Stages were developed to
correlate with estimated LBP, deﬁned as maintenance of
in-line ﬂow through the entire length of the TAP, from
the SFA origin to the malleoli. LBP is considered to be
lost when any one of the following occurs:
Fig 5.6. Representative angiograms of Global Limb Anatomic Staging System (GLASS) stage III disease patterns.
The target arterial path (TAP) is outlined in yellow. Left panel, TAP includes the peroneal artery. Femoropopliteal
(FP) grade is 4 (superﬁcial femoral artery [SFA] disease length, 10-20 cm; popliteal stenosis <5 cm; heavily calci-
ﬁed). Infrapopliteal (IP) grade is 2 (stenosis of tibioperoneal trunk and proximal peroneal <10 cm). Right panel, TAP
includes the anterior tibial (AT) artery. FP grade is 4 (popliteal chronic total occlusion extending into trifurcation).
IP grade is 3 (chronic total occlusion of target artery origin).
Table 5.4. Descriptive summary of Global Limb Anatomic Staging System (GLASS) stages of infrainguinal arterial disease
Stage
Estimated PVI outcomes
Anatomic patternTechnical failure 1-year LBP
I <10% >70% Short- to intermediate-length FP disease and/or short-length IP disease; no
or minimal popliteal disease
II <20% 50%-70% Intermediate- to long-length FP disease; may include popliteal stenosis and/
or short- to intermediate-length IP disease
III >20% <50% Extensive FP or IP occlusions, alone or in combination with any disease in the
other segment; popliteal CTO
CTO, Chronic total occlusion; FP, femoropopliteal; IP, infrapopliteal; LBP, limb-based patency; PVI, peripheral [endo-]vascular intervention.
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Fig 5.7. Flow chart illustrating application of Global Limb
Anatomic Staging System (GLASS) to stage infrainguinal
disease pattern in chronic limb-threatening ischemia (CLTI).
FP, Femoropopliteal; IP, infrapopliteal; PLAN, patient risk
estimation, limb staging, anatomic pattern of disease; TAP,
target arterial path;WIfI,Wound, Ischemia, and foot Infection.
Recommendation
5.1 Use an integrated, limb-based anatomic
staging system (such as the GLASS) to
deﬁne complexity of a preferred TAP and
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vention affecting any portion of the deﬁned TAP; or
2. Hemodynamic failure: a signiﬁcant drop in ABI ($0.15)
or TBI ($0.10), or identiﬁcation of $50% stenosis in the
TAP, in the presence of recurrent or unresolved clinical
symptoms (eg, rest pain, worsening or persistent tissue
loss).LBP is an important new concept allowing more direct
comparison between revascularization approaches in
CLTI. Estimating LBP after surgical or endovascular inter-
vention is central to the development of EBR (Section 6).
The writing group deﬁned three GLASS stages based on
the likelihood of immediate technical failure (ITF)347 and
1-year LBP after endovascular intervention of the selected
TAP. GLASS stages for the limb thus reﬂect a gradient of
infrainguinal disease complexity:
d Stage I: low-complexity disease: expected ITF < 10%
and 1-year LBP > 70%
d Stage II: intermediate-complexity disease: expected
ITF < 20% and 1-year LBP 50% to 70%
d Stage III: high-complexity disease: expected ITF >
20%; or 1-year LBP < 50%
Consensus process and assignment of limb stages. To
assign GLASS stages (I-III) in the two-dimensional matrix
shown in Table 5.3, a multinational, multispecialty group
of vascular specialists (GVG writing group and invited
external experts) as well as evidence summaries7 and
other published material79,160,348-404 were surveyed.
Representative examples of GLASS stage I to stage III
disease are illustrated in the angiograms depicted in Figs
5.4 to 5.6. Table 5.4 provides a descriptive summary of the
three GLASS stages.
Managing CLTI with GLASS. Use of the GLASS system
involves the following steps (Fig 5.7):
1. Obtain high-quality angiographic imaging to include
the ankle and foot (Section 3).
2. Identify the TAP.
3. Determine the FP GLASS grade (0-4) (Fig 5.2).
4. Determine the IP GLASS grade (0-4) (Fig 5.3).
5. Decide whether there is severe calciﬁcation (eg, >50%
of circumference; diffuse, bulky, or coral reef plaques
likely to compromise endovascular outcomes) within
the FP and IP segments of the TAP. If present, increase
the segment grade by one.
6. Combine FP and IP grades to determine the overall
GLASS stage (Table 5.3).
7. Use the pedal modiﬁer (P0, P1, or P2) to describe the
status of IM arteries.
For the individual patient with CLTI, an EBR strategy (Sec-
tion 6) is based on the full integration of
1. estimated patient risk and long-term survival;
2. severity of limb threat (eg, using WIfI) (Sections 1
and 3); and
3. anatomic pattern and severity of disease in the
affected limb (eg, GLASS).
Research priorities
5.1 What are the expected procedural, hemodynamic, and clinical outcomes of revascularization across the spectrum
of infrainguinal disease severity? Better evidence is needed to validate the GLASS, particularly for endovascular strategies in
intermediate (II) and severe (III) stages of infrainguinal disease.
5.2 What is the effect of severe IM and pedal arch disease on revascularization outcomes in CLTI? Is there a clinically useful way
to grade this level of disease?
5.3 Is there evidence that other measures, such as outﬂow bed resistance or below-knee runoff scores, are predictive of
procedural or clinical outcomes? How do these compare with target path lesion complexity assessed by angiography?
5.4 Is there a simple, reproducible method for quantiﬁcation of calciﬁcation that has predictive value for infrainguinal
interventions?
5.5 Are there speciﬁc patient factors (eg, demographic or comorbidity) associated with anatomic patterns of disease in CLTI?
5.6 Are there anatomic patterns of disease in which an endovascular approach is futile?
5.7 How does lesion morphology (eg, concentric vs eccentric) inﬂuence treatment success for different endovascular
interventions?
5.8 Is there a correlation between GLASS stage and clinical presentation (WIfI)?
5.9 What is the comparative value of direct (angiosome based) vs indirect revascularization in the setting of tissue loss, and how
should it drive selection of the preferred TAP? Is this speciﬁc to wound location or WIfI stage?
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edge the limitations of the available data in developing
this initial version of GLASS. Severe calciﬁcation, particu-
larly in the tibial arteries, is a negative predictor of tech-
nical success for intervention and signiﬁes a higher risk
for amputation.405,406 However, a simpliﬁed and vali-
dated scoring system for calciﬁcation that is associated
with procedural outcomes is still lacking.346 At the same
time, pedal artery disease appears to be increasing in
both prevalence and importance, particularly in CLTI
patients experiencing major tissue loss or infection (WIfI
stage 4).407,408
Pedal interventions remain relatively uncommon, and
data on outcomes are extremely limited. Patients with
no IM revascularization target are placed in a high-risk
subgroup, although they are assigned a simpliﬁed mod-
iﬁer (P2) in the current version of GLASS. In the future, it is
anticipated that better data will allow a more sophisti-
cated incorporation of calciﬁcation and pedal disease.
Other important issues, including the beneﬁts of revascu-
larizing multiple IP arteries, the relative quality of runoff
distal to the revascularization and extending to the
wound-related artery or angiosome, and the complex
relationship between hemodynamic and clinical success,
also require further study.
In assigning GLASS stages, the authors assume that pre-
procedural decision-making is frequently driven by the
estimation of the anticipated technical and clinical suc-
cess after endovascular intervention. As a result, the
preferred TAP for endovascular intervention and bypass
surgery may not always be the same. Thus, treatment out-
comes for surgical bypass should also be reported and
analyzed on the basis of the actual procedure performed,
including inﬂow artery, outﬂow artery, and conduit used.6. STRATEGIES FOR EBR
Effective revascularization is the cornerstone of limb
salvage in CLTI. Althoughmultiple techniques are available,
there are limited high-quality data to support EBR. A new,
systematic paradigm is required to improve decision-
making, clinical outcomes, and cost-effectiveness.
To aid clinical decision-making in everyday practice and
to facilitate future EBR research in CLTI, the authors pro-
pose a three-step integrated approach (PLAN; Figs 6.1
and 6.2) based on
d Patient risk estimation
d Limb staging
d ANatomic pattern of disease
PLAN: Patient risk estimation. The ﬁrst step involves
assessing the patient for candidacy for limb salvage, peri-
procedural risk, and life expectancy.
CLTI is associated with advanced age, multiple comor-
bidities, and frailty. The goals of treatment include relief
of pain, healing of wounds, and preservation of a func-
tional limb. However, revascularization may incur signiﬁ-
cant morbidity and mortality, requiring multiple
hospitalizations, prolonged outpatient care, and thus
considerable health and social care costs. Whereas the
majority of patients with CLTI should be considered can-
didates for limb salvage, some may be appropriately
treated with primary amputation or palliation after
shared decision-making. Patients, families, and care-
givers should have access to appropriate expertise in
making these challenging decisions. Although mainte-
nance of independent ambulatory status is an important
goal, predicting functional outcomes after revasculariza-









1 (Strong) C (Low)
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June Supplement 2019severely deconditioned. Palliative care consultants,
where available, may be a valuable resource to optimize
symptom management in patients with limited goals of
care.






6.4 Deﬁne a CLTI patient
as average surgical
risk when
2 (Weak) C (Low)Refer all patients with suspected
CLTI to a vascular specialist for
consideration of limb salvage,
unless major amputation is









mortality is <5% and
estimated 2-year
survival is >50%.
6.5 Deﬁne a CLTI patient
as high surgical risk
2 (Weak) C (Low)Offer primary amputation or
palliation to patients with
limited life expectancy, poor
functional status (eg,
nonambulatory), or an




mortality is $5% or
estimated 2-year
survival is #50%.Palliative therapy should rarely include revasculariza-
tion except in special circumstances, such as
d treatment of hemodynamically signiﬁcant inﬂow
disease, if needed to improve the likelihood of a
successful amputation at the most distal possible
level; and
d relief of intractable pain or to improve wound healing
after shared decision-making with the patient, family,
and vascular treatment team.
Estimation of operative risk and life expectancy plays a
critical role in EBR. Tradeoffs between risk, invasiveness,
hemodynamic gain, and anatomic durability of the
vascular intervention are commonly made in everyday
practice. Risk stratiﬁcation tools can assist by providing
objective criteria for such decisions. Multiple tools have
been developed and applied to the CLTI population
(Table 6.1).63-67,225,409-412 End points modeled have
included all-cause mortality, major amputation, AFS,
and perioperative events. The list of predictors identiﬁed
in these models includes advanced age (>75 or 80 years),
CKD, CAD, congestive heart failure, DM, smoking, cere-
brovascular disease, tissue loss, BMI, dementia, and func-
tional status. Frailty, a recently identiﬁed functional
measure, is also of clear importance in the CLTI popula-
tion.413,414 Patients with ESRD are at the highest risk in
many reports and yet have been speciﬁcally excluded
in some CLTI studies.415,416 All of these tools have been
developed retrospectively using data from patients who
have undergone revascularization, thereby excluding
those who were managed conservatively or selected for
primary amputation. Whereas some were validated inexternal data sets of similar patients, none has been pro-
spectively tested across the spectrum of CLTI presenting
for initial evaluation and treatment. As such, no speciﬁc
tool and model can be recommended in preference to
others.
Speciﬁc recommendations about preoperative cardiac
and anesthetic evaluation before limb revascularization
are beyond the scope of this document. The reader is
referred to Section 4 and to other published
guidelines.417,418
PLAN: Limb staging. CLTI patients present with a broad
spectrum of disease severity. Staging of the limb is central
to EBR (Section 3), and use of the SVS Threatened Limb
Classiﬁcation System (WIfI) is recommended (Section
1).10,68-72,171 This is the only system that fully integrates
wound severity, ischemia, and infection to stage CLTI.
The severity of ischemia and the beneﬁts of revascu-
larization do not map in an exclusively concordant
fashion with amputation risk across the spectrum of
CLTI, as expressed in the original WIfI consensus docu-
ment.10 Expert opinion, now supported by reports from
institutional series,69,70,72 suggests that the presumed
beneﬁt of revascularization in CLTI is linked to both
the severity of ischemia and the degree of limb threat
Fig 6.2. PLAN framework of clinical decision-making in chronic limb-threatening ischemia (CLTI); infrainguinal
disease. Refer to Fig 6.4 for preferred revascularization strategy in standard-risk patients with available vein conduit,
based on limb stage at presentation and anatomic complexity. Approaches for patients lacking suitable vein are
reviewed in the text. GLASS, Global Limb Anatomic Staging System; WIfI, Wound, Ischemia, and foot Infection.
Fig 6.1. Paradigm for evidence-based revascularization (EBR) in the treatment of chronic limb-threatening
ischemia (CLTI). Patient risk, Limb severity, and ANatomic stage are integrated in the PLAN approach. WIfI,
Wound, Ischemia, and foot Infection.
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Table 6.1. Comparison of risk stratiﬁcation tools for the chronic limb-threatening ischemia (CLTI) population
Tool End points Critical factors Reference
Taylor et al Mortality, ambulatory failure (median
follow-up of 2 years)
Age, race, ESRD, CAD, COPD, DM, dementia,
baseline ambulatory status
Taylor,409 2006
Finnvasc Perioperative (30-day) mortality, limb
loss
DM, CAD, gangrene, urgent operation Biancari,63 2007
PREVENT III AFS (1 year) ESRD, tissue loss, age >75 years, CAD, anemia Schanzer,64 2008
BASIL Survival (2 years) Age, CAD, smoking, tissue loss, BMI, Bollinger
score, serum creatinine concentration, AP
(number measured and highest value), prior
stroke/TIA
Bradbury,65 2010
CRAB Perioperative (30-day) mortality,
morbidity
Age >75 years, prior amputation or
revascularization, tissue loss, ESRD, recent
MI/angina, emergency operation, functional
dependence
Meltzer,66 2013
Soga et al Survival (2 years) Age, BMI, nonambulatory status, ESRD,
cerebrovascular disease, tissue loss, left
ventricular ejection fraction
Soga,225 2014
VQI AFS (1 year) Age, tissue loss, DM, CHF, serum creatinine
concentration, ambulatory status, urgent
operation, weight, bypass conduit used
Simons,67 2016
VQI Survival (30 days, 2 and 5 years) Age, CKD, ambulatory status, CAD, CHF, COPD,
tissue loss, diabetes, smoking, beta-blocker
use
Simons,412 2018
AFS, Amputation-free survival; AP, ankle pressure; BASIL, Bypass vs Angioplasty in Severe Ischaemia of the Leg; BMI, body mass index; CAD, coronary
artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRAB, Comprehensive Risk Assessment for Bypass; DM,
diabetes mellitus; ESRD, end-stage renal disease; MI, myocardial infarction; PREVENT III, Project of Ex-vivo Vein graft Engineering via Transfection III;
TIA, transient ischemic attack; VQI, Vascular Quality Initiative.
Fig 6.3. The beneﬁt of performing revascularization in
chronic limb-threatening ischemia (CLTI) increases with
degree of ischemia and with the severity of limb threat
(Wound, Ischemia, and foot Infection [WIfI] stage). WIfI
stage 1 limbs do not have advanced ischemia grades,
denoted as not applicable (N/A).
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WIfI grade 3) ischemia should undergo attempted
revascularization, presuming they are appropriate can-
didates for limb salvage.5 In settings of advanced tissue
loss or infection (eg, WIfI stage 4 limbs), revasculariza-
tion may also be of beneﬁt in the presence of moderate
ischemia (eg, WIfI ischemia grades 1 and 2). Conversely,
patients with lesser degrees of tissue loss or infection
(eg, WIfI stages 1 to 3) and mild to moderate ischemia
are often successfully treated with infection controland wound and podiatric care. Revascularization may
be considered selectively in these patients if their
wounds fail to progress (or regress) despite appropriate
limb care after 4 to 6 weeks or if they have signs or
symptoms of clinical deterioration. In such cases, all el-
ements of the initial staging and treatment plan,
including treatment of underlying moderate ischemia,
should be re-evaluated. Whenever possible, the limb
should be restaged after surgical drainage or débride-
ment and after the infective component is stabilized.
During the course of treatment, periodic restaging of
the limb is important in guiding subsequent decisions,
particularly when there is lack of progress in healing or
any deterioration of symptoms.
WIfI also provides a useful and necessary tool through
which one can compare and contrast the quality of
different revascularization strategies in CLTI. This has
become an issue of critical importance as an ever-
increasing array of technologies and treatment strategies
are being used. The magnitude and durability of
increased perfusion required to resolve the clinical situa-
tion, and to maintain satisfactory limb health (eg, preser-
vation of a functional foot, freedom from recurrent CLTI),
will vary considerably across the spectrum. The extent of
beneﬁt for revascularization (Fig 6.3) is also linked to
anatomic durability of the selected intervention. These
concepts are central to PLAN and to the development




6.6 Use an integrated threatened limb classiﬁcation system
(such as WIfI) to stage all CLTI patients who are
candidates for limb salvage.





6.7 Perform urgent surgical drainage and débridement
(including minor amputation if needed) and
commence antibiotic treatment in all patients with
suspected CLTI who present with deep space foot
infection or wet gangrene.
Good practice statement
6.8 Repeat limb staging after surgical drainage,
débridement, minor amputations, or correction of
inﬂow disease (AI, common and deep femoral artery
disease) and before the next major treatment
decision.
Good practice statement
6.9 Do not perform revascularization in the absence of
signiﬁcant ischemia (WIfI ischemia grade 0), unless an
isolated region of poor perfusion in conjunction with
major tissue loss (eg, WIfI wound grade 2 or 3) can be
effectively targeted and the wound progresses or fails
to reduce in size by $50% within 4 weeks despite
appropriate infection control, wound care, and
ofﬂoading.
Good practice statement
6.10 Do not perform revascularization in very-low-risk limbs
(eg, WIfI stage 1) unless the wound progresses or fails
to reduce in size by $50% within 4 weeks despite
appropriate infection control, wound care, and
ofﬂoading.




6.11 Offer revascularization to all average-risk patients with
advanced limb-threatening conditions (eg, WIfI stage
4) and signiﬁcant perfusion deﬁcits (eg, WIfI ischemia
grades 2 and 3).
1 (Strong) C (Low) Abu Dabrh,5 2015
6.12 Consider revascularization for average-risk patients with
intermediate limb threat (eg, WIfI stages 2 and 3) and
signiﬁcant perfusion deﬁcits (eg, WIfI ischemia grades
2 and 3).





6.13 Consider revascularization in average-risk patients with
advanced limb threat (eg, WIfI stage 4) and moderate
ischemia (eg, WIfI ischemia grade 1).
2 (Weak) C (Low)
6.14 Consider revascularization in average-risk patients with
intermediate limb threat (eg, WIfI stages 2 and 3) and
moderate ischemia (eg, WIfI ischemia grade 1) if the
wound progresses or fails to reduce in size by $50%
within 4 weeks despite appropriate infection control,
wound care, and ofﬂoading.
2 (Weak) C (Low)
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availability). Although secondary to the broader context
of patient risk and limb threat severity, the anatomic
pattern of arterial occlusive disease is a dominant consid-
eration in EBR. The overall pattern and severity of disease
in the limb (eg, as described by GLASS; Section 4) helpdeﬁne the optimal strategy for vascular intervention.
Furthermore, the availability and quality of autologous
vein conduit (especially the great saphenous vein
[GSV]) are key considerations for bypass surgery and
should be deﬁned before revascularization decisions
are taken in average-risk patients.13,77,79
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anatomically suitable for revascularization, and establish-
ing direct in-line ﬂow to the foot is the primary technical
goal. One important exception is ischemic rest pain, for
which correction of inﬂow disease alone or treatment of
FP disease even without continuous tibial runoff to the
foot may provide relief of symptoms. This may also be
the case in patients presenting with minor degrees of
tissue loss (eg, WIfI stage 2). Thus, the deﬁnition of a no-
option anatomic pattern of disease is dependent on
clinical context. Lack of a target artery crossing the ankle
and absence of a suitable pedal or plantar artery target
(eg, GLASS P2 modiﬁer) may be considered no-option
disease patterns in patients with advanced CLTI (eg,
WIfI stages 3 and 4). Angiography may occasionally fail to
detect a patent distal artery target, and there are reports
of successful tibial and pedal bypass grafting based on
exploration of an artery identiﬁed on Doppler ultrasound
examination that was not identiﬁed on contrast arteri-
ography.419,420 Careful selection and experienced surgical
judgment are required before proceeding to surgery in
such instances.
EBR strategies in CLTI. The technical options for treat-
ing complex patterns of disease in a minimally invasive
fashion have increased markedly in recent years and
led some to advocate an “endovascular-ﬁrst” approach
for most or all patients with CLTI, reserving bypass sur-
gery as a secondary option. However, existing evidence
argues strongly for a selective revascularization algorithm
based on speciﬁc clinical and anatomic scenarios, as
described here. Currently enrolling RCTs are eagerly
awaited to provide higher quality data in support of
EBR in patients with CLTI.13-15
The Bypass vs Angioplasty in Severe Ischaemia of the
Leg (BASIL) trial (now called BASIL-1) remains the only
multicenter RCT to have directly compared an
endovascular-ﬁrst with a bypass surgery-ﬁrst strategy in
limb-threatening ischemia due to infrainguinal dis-
ease.159,421 BASIL was conducted across 27 hospitals in
the United Kingdom and enrolled 452 participants be-
tween 1999 and 2004. All but six patients in the endovas-
cular arm received plain balloon angioplasty (PBA) alone;
approximately 25% of the bypasses were prosthetic;
around one-third of the procedures were IP; and just
more than 50% of patients were observed for >5 years.
Considering the follow-up period as a whole, an
intention-to-treat analysis showed no signiﬁcant differ-
ence between the two arms in terms of AFS and overall
survival. However, for the approximately 70% of patients
who lived for >2 years, HRs for overall survival (0.65; P ¼
.009) and AFS (0.85; P ¼ .108) were better for those
treated initially with bypass surgery. An analysis by treat-
ment received showed that prosthetic bypasses per-
formed very poorly (worse than PBA) and that patients
having bypass after failed PBA had a highly signiﬁcantlyworse AFS and overall survival compared with those pa-
tients who received bypass as their ﬁrst allocated
treatment.160
A systematic review comparing open and endovascular
treatments for CLTI found only nine studies meeting
standard criteria, three of which were RCTs (among
which only BASIL met all of the study quality bench-
marks).6 Researchers concluded that low-quality evi-
dence (due to heterogeneity and imprecision)
suggested similar mortality and amputation outcomes
but better expected patency for bypass surgery. Other
comparative reviews have yielded broadly similar conclu-
sions.227,422-425 OPGs for endovascular interventions in
CLTI based on open surgical data from high-quality sour-
ces have been suggested and provide minimum stan-
dards of safety and efﬁcacy until direct comparative
data become available.162
To obtain updated data on outcomes after endovascu-
lar and open bypass surgery in CLTI, a review was con-
ducted of comparative studies and noncomparative
studies that met more inclusive criteria.7 These criteria
included prospective study design, 50 or more patients
with critical or severe limb ischemia (Rutherford class
4-6 deﬁnition), infrainguinal procedure, minimum
follow-up of 1 year, at least 50 procedures of each sub-
type (endovascular or open), and adequate anatomic
description of lesion location and types of subinterven-
tions (eg, percutaneous transluminal angioplasty, stent,
atherectomy) employed. In total, 44 studies enrolling
8602 patients were reviewed in detail and results tabu-
lated to display outcomes across anatomic subsets and
from 30 days to 5-year follow-up intervals. Most of the
studies were assessed as having moderate to high risk
of bias, and the study quality was variable.
Review of the attributes of these studies revealed
several notable limitations: few studies of SFA interven-
tion were included because of inadequate numbers of
CLTI patients (vs those with IC); the majority of FP bypass
studies included prosthetic grafts; and although a good
number of studies (20) addressed endovascular interven-
tion for IP disease, the severity of disease was generally
mild to moderate (GLASS IP grades 1 and 2), with no
studies including GLASS IP grade 4 disease. Thus, the cur-
rent state of evidence in CLTI remains severely limited,
particularly for assessing endovascular outcomes in
commonly encountered, complex (especially distal) dis-
ease patterns. Caveats aside, the compendium of data
suggests similar mortality, amputation, and AFS rates
for endovascular and bypass surgery at 1 year, with
improved patency for bypass using vein compared with
endovascular interventions or prosthetic bypass grafts
at 1 year and beyond.
Additional evidence, including a larger body of retro-
spective studies and registries, provides further insights
into speciﬁc factors associated with inferior outcomes
for individual techniques and informs current vascular
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Volume 69, Number 6Spractice.79,365,366,369,372,373,376,385,391,393,395,402,407,426-438 Sur-
gical bypass with nonautologous conduits to IP targets
in CLTI performs poorly. Similarly, patency rates for endo-
vascular intervention are poor in settings of diffuse tibial
disease and popliteal and trifurcation occlusions and are
diminished in small, diffusely diseased or heavily calciﬁed
FP arteries. Several studies suggest that endovascular
outcomes for advanced tissue loss (eg, gangrene, WIfI
stage 4, WIfI ischemia grade 3, or foot infection grades
2 and 3) are inferior, with high early rates of major ampu-
tation.171,439 Patients with ESRD experience higher rates
of limb loss across all interventions. These factors must
be carefully considered in each individual case, evalu-
ating the available treatment options against the patient
risk, limb stage, functional status, and presumptive
importance of a hemodynamically durable intervention
for resolving the clinical scenario at hand.
Finally, a nonselective endovascular-ﬁrst approach
carries some risk of both clinically ineffective and cost-
ineffective treatment and potential for harm. Whereas a
signiﬁcant percentage of CLTI patients are appropriate
candidates for endovascular intervention, those with se-
vere anatomic patterns and higher stages of limb threat
may not be well served by a nonselective approach forRecommendations Grade Level of evidence Key references
6.15 Obtain high-quality angiographic imaging with
dedicated views of ankle and foot arteries to permit
anatomic staging and procedural planning in all CLTI
patients who are candidates for revascularization.
Good practice statement
6.16 Use an integrated limb-based staging system (eg,
GLASS) to deﬁne the anatomic pattern of disease and
preferred TAP in all CLTI patients who are candidates
for revascularization.
Good practice statement
6.17 Perform ultrasound vein mapping when available in all
CLTI patients who are candidates for surgical bypass.
1 (Strong) C (Low) Seeger,77 1987
Wengerter,78 1990
Schanzer,79 2007
6.18 Map the ipsilateral GSV and small saphenous vein for
planning of surgical bypass.
Map veins in the contralateral leg and both arms if
ipsilateral vein is insufﬁcient or inadequate.
Good practice statement
6.19 Do not classify a CLTI patient as being unsuitable for
revascularization without review of adequate-quality
imaging studies and clinical evaluation by a qualiﬁed
vascular specialist.
Good practice statementseveral reasons. First, ineffective revascularization can
lead to poor symptom relief, limited durability of beneﬁt,
delayed wound healing, inadequate clearance of infec-
tion, or progression of tissue loss in the foot. There are
both patient and system costs to inadequately treated
CLTI. Another important consideration is the potential ef-
fect of endovascular failures on the outcomes of second-
ary bypass surgery in CLTI. Although data in this regardare limited, several multicenter data sets including
BASIL160 and large regional registries440,441 suggest that
the outcomes of bypass surgery in patients who have un-
dergone failed endovascular interventions are signiﬁ-
cantly inferior to those in patients who underwent
primary bypass surgery. The inferior outcomes associated
with “secondary bypass” are similar whether the initial
failure was percutaneous or a prior bypass graft. This
may be a particularly high penalty to pay if clinical suc-
cess of the initial procedure was short-lived. These
studies cannot establish causality vs association, but
they strongly suggest that the success of the initial
vascular intervention is of importance in CLTI and that
endovascular failure, like open bypass failure, carries con-
sequences. Thus, an important consideration is to avoid
risking potential loss of bypass targets in performing
endovascular interventions. Conversely, surgical bypass
may incur signiﬁcant morbidity and mortality despite
the potential attractiveness of greater durability. Factors
that may increase the risk of wound complications,
graft failure, or other major postoperative complications
must be carefully weighed. These considerations
informed the consensus recommendations on speciﬁc
EBR strategies.EBR: Treatment of inﬂow disease. Inﬂow disease is
deﬁned here as proximal to the origin of the SFA and
meeting one or more of the following criteria:
d absent femoral pulse
d blunted CFA waveform on Doppler ultrasound
d >50% stenosis by angiography in the aorto-iliac
arteries or CFA
d aortatoCFAsystolicpressuregradient>10mmHgatrest
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ization for patients with combined inﬂow and outﬂow
disease is individualized on the basis of severity of limb
threat (especially presence of tissue loss), anatomic
complexity, and patient risk. In settings of rest pain and
minor tissue loss, inﬂow correction alone may sufﬁce to
achieve the desired clinical outcome. As procedural
complexity increases, perioperative morbidity and mor-
tality rise as well. Most patterns of AI disease may be suc-
cessfully treated using an endovascular approach,
frequently employing bare-metal or covered stents.82-84
Surgery is often reserved for extensive occlusions or after
failure of endovascular procedures. The choice of an
open surgical inﬂow procedure should be based on pa-
tient risk, anatomic pattern of disease, and other clinical
factors. Direct anatomic bypass (eg, aortofemoral) graft-
ing may be preferred to extra-anatomic reconstruction
in average-risk patients with severe ischemia (WIfI
ischemia grades 2 and 3) because of greater anatomic
and hemodynamic durability.85-87
CFA endarterectomy can be performed with low
morbidity and excellent long-term durability.88,89 ItRecommendations
6.20 Correct inﬂow disease ﬁrst when both inﬂow and
outﬂow disease are present in a patient with CLTI.
6.21 Base the decision for staged vs combined inﬂow and
outﬂow revascularization on patient risk and the
severity of limb threat (eg, WIfI stage).
6.22 Correct inﬂow disease alone in CLTI patients with
multilevel disease and low-grade ischemia (eg, WIfI
ischemia grade 1) or limited tissue loss (eg, WIfI wound
grade 0/1) and in any circumstance in which the risk-
beneﬁt of additional outﬂow reconstruction is high or
initially unclear.
6.23 Restage the limb and repeat the hemodynamic
assessment after performing inﬂow correction in CLTI
patients with inﬂow and outﬂow disease.
6.24 Consider simultaneous inﬂow and outﬂow
revascularization in CLTI patients with a high limb risk
(eg, WIfI stages 3 and 4) or in patients with severe
ischemia (eg, WIfI ischemia grades 2 and 3).
6.25 Use an endovascular-ﬁrst approach for treatment of
CLTI patients with moderate to severe (eg, GLASS
stage IA) AI disease, depending on the history of prior
intervention.
6.26 Consider surgical reconstruction for the treatment of
average-risk CLTI patients with extensive (eg, GLASS
stage II) AI disease or after failed endovascular
intervention.remains the optimal approach to treatment of hemody-
namically signiﬁcant CFA disease, which often includes
bulky calciﬁc plaque. In some cases, femoral interposi-
tion grafting may be preferred. In all cases, durable in-
line PFA ﬂow should bemaximized. CFA endarterectomy
may be combined with proximal intervention to treat
combined disease in a “hybrid” fashion.90 Although
long-term outcome data are sparse, reports suggest
that endovascular treatment of CFA disease may be a
safe alternative in selected patients (eg, high surgical
risk, hostile groin anatomy).91-94
Surgical treatment (eg, profundaplasty or bypass graft-
ing) of PFA disease is an important component of CLTI
revascularization with a major impact on the long-term
prognosis for the limb. The indications for and optimal
approaches to treatment of nonoriﬁcial (ie, not in conti-
nuity with the CFA) or long-segment PFA disease are
not established. There is limited evidence regarding the
use of endovascular interventions for PFA disease. How-
ever, it may be considered a secondary approach in set-
tings of hostile groin anatomy or in other high-risk
circumstances.Grade Level of evidence Key references
Good practice statement
1 (Strong) C (Low)
Harward,80 1995
Zukauskas,81 1995
1 (Strong) C (Low)
1 (Strong) C (Low)
2 (Weak) C (Low)
1 (Strong) B (Moderate) Jongkind,82 2010
Ye,83 2011
Deloose,84 2017




Recommendations Grade Level of evidence Key references
6.27 Perform open CFA endarterectomy with patch
angioplasty, with or without extension into the PFA, in
CLTI patients with hemodynamically signiﬁcant
(>50% stenosis) disease of the common and deep
femoral arteries.
1 (Strong) C (Low) Kang,88 2008
Ballotta,89 2010
6.28 Consider a hybrid procedure combining open CFA
endarterectomy and endovascular treatment of AI
disease with concomitant CFA involvement (eg,
GLASS stage IB inﬂow disease).
2 (Weak) C (Low) Chang,90 2008
6.29 Consider endovascular treatment of signiﬁcant CFA
disease in selected patients who are deemed to be at
high surgical risk or to have a hostile groin.




6.30 Avoid stents in the CFA and do not place stents across
the origin of a patent deep femoral artery.
Good practice statement
6.31 Correct hemodynamically signiﬁcant ($50% stenosis)
disease of the proximal deep femoral artery whenever
technically feasible.
Good practice statement
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patients. Outﬂow (infrainguinal) disease starts at the SFA
origin (Section 5). An average-risk patient is deﬁned as
one in whom the anticipated periprocedural mortality
is <5% and the anticipated 2-year survival is >50%
(Recommendation 6.4). These patients are potential
surgical or endovascular candidates, depending on in-
dividual clinical and anatomic factors.
Fig 6.4 provides a summary of preferred infrainguinal
revascularization strategies for an average-risk patient
with available vein conduit based on the presenting
combination of limb stage (WIfI) and anatomic
pattern of disease (GLASS). Open bypass surgery
and endovascular therapy have complementary roles,
with notable lack of consensus across the intermedi-
ate ranges of clinical and anatomic complexity.
Comparative effectiveness studies employing these
staging schemes are urgently needed to improve the
quality of evidence for interventions in speciﬁc clinical
scenarios.Recommendation
6.32 In average-risk CLTI patients with infrainguinal disease, ba
endovascular intervention vs open surgical bypass on the
threat (eg, WIfI), the anatomic pattern of disease (eg, GL
availability of autologous vein.Patients lacking adequate autologous (GSV) conduit
must be considered separately as this is a critical factor
in determining the likely success and durability of bypass
surgery. For those with no suitable venous conduit, pros-
thetic or venous allografts are the only options. Given the
inferior performance of these conduits in CLTI, endovas-
cular intervention is preferred when possible.160 Use of
prosthetic or biologic conduits (eg, cryopreserved vein al-
lografts) for infrainguinal bypass in CLTI may be reason-
able in highly selected cases, such as in patients with
untreatable anatomy for endovascular intervention or
prior endovascular failure, with acceptable runoff, and
in patients who are able to tolerate aggressive antith-
rombotic therapy.
In many patients lacking GSV, arm/spliced vein bypass
conduits may be an option. However, the results of
arm/spliced vein bypass are highly dependent on the op-
erator’s training and experience. The determination of
when and how to employ these alternative vein conduits








1 (Strong) C (Low) Almasri,7 2018
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vein bypasses perform better than nonautologous grafts
to distal targets and are inferior to autologous GSV con-
duits.7,79,442,443 However, these higher risk vein grafts
require closer surveillance and more reinterventions to
maintain primary assisted patency.444
EBR: Treatment of infrainguinal disease in high-risk
patients. A high-risk patient is deﬁned as one in whom
the anticipated perioperative mortality is >5% or the
anticipated 2-year survival is <50%. Because endovas-
cular intervention can be performed with reduced
morbidity, it may often be preferred in high-risk patients
who are otherwise candidates for functional limb
salvage. Shared decision-making is of great importance
in high-risk patients to allow the patient, family, and
other stakeholders to express value judgments on the
tradeoffs between risk and effectiveness in relation to the
desired goals.Recommendations
6.33 Offer endovascular revascularization when technically
feasible for high-risk patients with advanced limb
threat (eg, WIfI stage 4) and signiﬁcant perfusion
deﬁcits (eg, WIfI ischemia grades 2 and 3).
6.34 Consider endovascular revascularization for high-risk
patients with intermediate limb threat (eg, WIfI stages
2 and 3) and signiﬁcant perfusion deﬁcits (eg, WIfI
ischemia grades 2 and 3).
6.35 Consider endovascular revascularization for high-risk
patients with advanced limb threat (eg, WIfI stage 4)
and moderate ischemia (eg, WIfI ischemia grade 1) if
the wound progresses or fails to reduce in size by
$50% within 4 weeks despite appropriate infection
control, wound care, and ofﬂoading, when technically
feasible.
6.36 Consider endovascular revascularization for high-risk
patients with intermediate limb threat (eg, WIfI stages
2 and 3) and moderate ischemia (eg, WIfI ischemia
grade 1) if the wound progresses or fails to reduce in
size by $50% within 4 weeks despite appropriate
infection control, wound care, and ofﬂoading, when
technically feasible.
6.37 Consider open surgery in selected high-risk patients
with advanced limb threat (eg, WIfI stage 3 or 4),
signiﬁcant perfusion deﬁcits (ischemia grade 2 or 3),
and advanced complexity of disease (eg, GLASS stage
III) or after prior failed endovascular attempts and
unresolved symptoms of CLTI.EBR: Infra-malleolar disease. Severe IM disease creates
407a major challenge to effective revascularization. The
P2 modiﬁer in GLASS describes the circumstance in
which no named artery crosses the ankle into the foot
and there is no suitable target for bypass surgery.
Although technically successful endovascular in-
terventions in the pedal arch have been reported, their
durability and hemodynamic and clinical effectiveness
remain unknown.438 Diabetic patients often have a
segment of preserved pedal artery that may be a target
for bypass. Open bypass surgery has also been success-
fully employed to tarsal and plantar arteries, but again,
techniques and outcomes are not established. Given the
technical difﬁculty and the likely reduced hemodynamic
impact and durability, the appropriate role for in-
terventions at this level is not determined. The impact of
IM disease on the success of proximal revascularization,
whether open or endovascular, is likewise unknown.
Although the presence of an intact pedal arch appearsGrade Level of evidence Key references
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Fig 6.4. Preferred initial revascularization strategy for infrainguinal disease in average-risk patients with suitable
autologous vein conduit available for bypass. Revascularization is considered rarely indicated in limbs at low risk
(Wound, Ischemia, and foot Infection [WIfI] stage 1). Anatomic stage (y-axis) is determined by the Global Limb
Anatomic Staging System (GLASS); limb risk (x-axis) is determined byWIfI staging. The dark gray shading indicates
scenarios with least consensus (assumptionsdinﬂow disease either is not signiﬁcant or is corrected; absence of
severe pedal disease, ie, no GLASS P2 modiﬁer).
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in the presence of signiﬁcant IM disease. The severity of
limb threat (tissue loss or infection) is likely to be a critical
modiﬁer of the relationship between IM disease severity





6.38 Consider angiosome-guided revascularization in patients with signiﬁcant
wounds (eg, WIfI wound grades 3 and 4), particularly those involving the
midfoot or hindfoot, and when the appropriate TAP is available.




Jongsma,99 2017EBR: Role of angiosome-guided revascularization.
Whereas few would argue about the desirability of maxi-
mizing perfusion at the site of tissue loss, there is consid-
erable debate about the utility of angiosome-guided
revascularization.445,446 First, unambiguous assignment
of foot wounds to an individual angiosome is possible in
only a minority of cases.447 Toe lesions, which typically
represent more than half of the lesions encountered,
have a dual blood supply (AT and PT), although for more
proximal foot lesions, unique angiosome assignment
may be achieved in up to 75% to 80% of patients. Then
there is the practical question of whether the desired
target artery for the angiosome is available and the
comparative hemodynamic and clinical effectiveness of
“direct” vs “indirect” revascularization. Tibial and peroneal
bypasses perform equally well for limb salvage, and DP
bypass can be effective for some hindfoot lesions.448
Systematic reviews have yielded conﬂicting results,96-99
and data are inextricably confounded by the quality ofthe pedal arch and the nature of the revascularization
performed.95,449 Whereas wound healing may be
improved when direct revascularization is achievable,
major amputation rates and patency are not consistently
different. To date, none of the analyses take into accountthe confounding effect of limb staging, for example, us-
ing WIfI. In summary, angiosome-guided revasculariza-
tion may be of importance in the setting of endovascular
intervention for midfoot and hindfoot lesions but is likely
to be irrelevant for ischemic rest pain and of marginal
value for most forefoot lesions and minor ulcers. The role
of multivessel (tibial) revascularization is also currently
unknown. However, it may be reasonable in selected
patients with advanced limb threat (eg, WIfI stages 3 and
4) undergoing endovascular therapy if it can be safely
accomplished without risking loss of a bypass target or
compromising runoff to the foot.
EBR: Preferred endovascular techniques for infrain-
guinal disease. PBA, drug-coated balloon (DCB) angio-
plasty, stent placement (bare-metal stent, drug-eluting
stent [DES], or covered stent), and atherectomymay all be
reasonable options in speciﬁc circumstances and lesion
anatomies. However, unfortunately, there are few high-
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endovascular approach in CLTI.7,380,387-389,396,450-455
PBA may be inferior to DCB angioplasty and stents for
the treatment of intermediate-length SFA disease (FP
grades 2-4) in patients with IC and possibly rest
pain.100-103 However, there are inadequate data to sup-
port a preferred endovascular approach for FP disease
in CLTI.
PBA remains a reasonable primary endovascular
approach for anatomically suitable IP disease as cur-
rent evidence is inadequate to support other, more
expensive techniques. Atherectomy is not superior to
PBA and is associated with greatly increased costs.453
Combination approaches, such as atherectomy fol-
lowed by DCB angioplasty, add signiﬁcant cost and
lack high-quality comparative data. Several modest-
sized trials suggest potential short-term beneﬁt for
DESs in short (ie, <3 cm) tibial lesions, but one cannot
generalize these data to the population of CLTI pa-
tients as a whole, who typically present with much
more extensive disease.7,456 DES may be a preferred
endovascular “bailout” after technical complications
(eg, dissection) or failed PBA for short, proximal IP le-
sions. Although early studies suggested a potential
advantage for DCBs in tibial arteries, an RCT showed
no beneﬁt of DCB angioplasty over PBA, with a nonsig-
niﬁcant higher rate of amputations in the DCB angio-
plasty group.396 The results of further, ongoing studies
are awaited. In summary, PBA currently remains the
standard of care for the endovascular treatment of IP
disease in CLTI.
Technical advances in endovascular intervention
include improved wires, low-proﬁle catheters, and retro-
grade access to allow treatment of complex disease
patterns down to the distal calf and foot. Specialized
catheters may facilitate crossing of difﬁcult chronic total
occlusions and ensure re-entry into the true lumen.
Retrograde access techniques using either ﬂuoroscopic
or ultrasound guidance may increase the ability to cross
chronic total occlusions at the IP and popliteal levels.
The “pedal loop technique” has been described to
achieve complete arch reconstitution in the presenceRecommendation
6.39 In treating FP disease in CLTI patients by
endovascular means, consider adjuncts to balloon
angioplasty (eg, stents, covered stents, or drug-
eluting technologies) when there is a technically
inadequate result (residual stenosis or ﬂow-
limiting dissection) or in the setting of advanced
lesion complexity (eg, GLASS FP grade 2-4).of IM disease, and some reports suggest that it may be
of value in highly selected patients.438,457 The clinical ef-
ﬁcacy of these techniques remains to be deﬁned in CLTI
as hemodynamic durability remains the primary limita-
tion of endovascular interventions in high-complexity
target path anatomy.
EBR: Preferred approaches for infrainguinal bypass. An
acceptable target for bypass surgery in CLTI should pro-
vide adequate runoff to the lower limb and foot to
resolve the clinical situation. In the setting of WIfI stages
3 and 4, it is recommended that the selected target ar-
tery provide continuous in-line ﬂow to the ankle and
foot.
Good-quality GSV is the optimal autologous conduit for
infrainguinal bypass surgery. Alternative (small saphe-
nous vein or arm vein) or spliced veins are acceptable
bypass conduits, although there is a higher frequency
of reinterventions, and durability is inferior to single-
segment GSV grafts. There is no evidence to support a
preferred conﬁguration (reversed, nonreversed translo-
cated, in situ) for vein bypass grafting.
Prosthetic conduits may be useful in selected patients
lacking other revascularization options. Heparin-
bonded expanded polytetraﬂuoroethylene grafts may
be superior to standard expanded polytetraﬂuoroethy-
lene grafts for below-knee bypass.458,459 Other adjuncts,
such as a distal vein cuff, may also improve patency of
prosthetic bypass to tibial targets, although the data
are limited in scope and quality.460 In general, clinical
outcomes of prosthetic grafting in CLTI are highly sen-
sitive to runoff and severity of limb presentation.
Bypass using nonautologous conduit to poor-quality
tibial or pedal targets in CLTI is discouraged as patency
rates are extremely poor. Deﬁning the optimal
approach for below-knee bypass in patients lacking
venous conduit remains a major challenge in the ﬁeld;
if these patients are not suitable for endovascular inter-
vention, the individual surgeon’s experience may
dictate practice. Further advances in bioengineered
arterial conduits are needed to meet this clinical
dilemma.Grade Level of evidence Key references





Recommendations Grade Level of evidence Key references
6.40 Use autologous vein as the preferred conduit for infrainguinal
bypass surgery in CLTI.
1 (Strong) B (Moderate) Almasri,7 2018
6.41 Avoid using a nonautologous conduit for bypass unless there
is no endovascular option and no adequate autologous vein.
2 (Weak) C (Low) Almasri,7 2018
6.42 Perform intraoperative imaging (angiography, DUS, or both)
on completion of open bypass surgery for CLTI and correct
signiﬁcant technical defects if feasible during the index
operation.
1 (Strong) C (Low) Mills,104 1992
Bandyk,105 1994
Research priorities
6.1 In patients presenting with the full spectrum of CLTI, prospectively validate and reﬁne patient risk stratiﬁcation models.
6.2 Conduct comparative effectiveness studies directly comparing strategies of revascularizationdand speciﬁc techniques and
technologiesdin well-deﬁned subgroups of patients (eg, WIfI and GLASS stages) with CLTI.
6.3 Deﬁne the circumstances in which angiosome-targeted or multivessel revascularization provides clinical beneﬁt in CLTI.
6.4 Develop and test strategies for the management of no-option CLTI patients.
6.5 Conduct appropriately controlled prospective trials to determine the safety and efﬁcacy of drug-eluting technologies
speciﬁcally in the CLTI population, with adequate (at least 2 year) long term follow up.
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THE LIMB
Although the optimal treatment of CLTI is undoubtedly
revascularization, unfortunately, a signiﬁcant proportion
of patients are not suitable for revascularization for
anatomic or physiologic reasons. Whereas major ampu-
tation may be suitable for some of these patients, there
is clearly a signiﬁcant number who might beneﬁt from
nonrevascularization-based treatments.
There is, however, a paucity of strong evidence
regarding these treatment options. The majority of
studies are low quality and uncontrolled, combined
with considerable study heterogeneity, making system-
atic review and meta-analysis difﬁcult or even impos-
sible. This heterogeneity is reﬂected by large variations
in patient factors, lesions of interest, intervention proto-
cols, study designs, and end points (limb salvage, AFS,
target lesion patency, pain relief, quality of life determi-
nants, ulcer healing, and evolution of tissue lesions).4
This section reviews nonrevascularization interventions,
pharmacotherapy, and conservative management.
Interventional nonrevascularization treatments
Spinal cord stimulation (SCS).
Mechanism of action. SCS, originally used to treat
chronic pain, was ﬁrst described by Cook et al461 in the
treatment of PAD. In SCS, electrodes are implanted in
the lumbar epidural space and connected to a generator
to stimulate sensory ﬁbers.462 SCS promotes activation of
cell signaling pathways that cause the release of vaso-
dilatory molecules, leading to a decrease in vascular
resistance and relaxation of smooth muscle cells.462 This
improved peripheral microcirculatory status has beenshown to result in increased capillary ﬂow and density of
perfusing capillaries, higher skin temperature and local
TcPO2, normalization of pulse wave morphology, and
improved skin nutrition.106 In addition, SCS suppresses
sympathetic vasoconstriction and pain transmission.462
Evidence. A 2013 Cochrane review analyzed data from
444 patients in six controlled studies investigating the
use of SCS in CLTI.106,463-468 The general quality of
studies was good, and all studies used limb salvage as
the primary end point (major AFS at 12 months). When
the results were pooled, limb salvage rates were found to
be signiﬁcantly higher in the SCS group (RR for major
amputation, 0.71; 95% CI, 0.56-0.90).106 Results were
better when patients were selected on the basis of
their initial TcPO2. Signiﬁcant pain relief was also found in
both treatment groups, although the SCS group
required less analgesia. In addition, there was no signiﬁ-
cant effect on ulcer healing. Overall mortality was not
evaluated, but the overall complication rate was 17%
(95% CI, 12-22%). Implantation problems occurred in 9%
(95% CI, 4%-15%), reintervention for changes in stimula-
tion occurred in 15% (95% CI, 10%-20%), and infection of
a lead or pulse generator pocket accounted for 3% (95%
CI, 0%-6%).106
Researchers concluded that SCS offered a modest pos-
itive effect on pain relief and an 11% reduction in the
amputation rate compared with conservative manage-
ment at 1 year.106 They stress, however, that the positive
beneﬁts should be weighed against the high cost and
possible complications. In fact, the Cochrane review
found the cost to be signiﬁcantly higher in the SCS group
by $8824. Klomp et al469 calculated the number needed
to treat to save one limb as 13, at $111,705 per limb saved
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concluded that SCS is not a cost-effective treatment of
CLTI.
Lumbar sympathectomy (LS)
Mechanism of action. Sympathetic denervation of the
lumbar sympathetic ganglia is performed either through
open or laparoscopic retroperitoneal access or through
percutaneous chemical blockade. LS increases blood
ﬂow to the lower limb by inducing vasodilation of the
collateral circulation and shunting of blood through
cutaneous arteriovenous anastomoses by its reduction
of sympathetic tone. This, in turn, improves tissue
oxygenation and decreases tissue damage and pain.
Pain is also decreased by interruption of sympathetic
nociceptive coupling and by a direct neurolytic action
on nociceptive ﬁbers.470
Evidence. In their systematic review, Sanni et al470 re-
ported that RCTs failed to identify any objective beneﬁts
for LS in patients with CLTI. They concluded, however,
that LS may be considered an alternative to amputation
in patients with otherwise viable limbs because it is
minimally invasive and cost-effective, with a low
complication rate.470 Chemical sympathectomy and
surgical sympathectomy also appear to perform equally
well, with some suggestion that LS can beneﬁt diabetic
patients.
Of the three RCTs that focus on LS in PAD, only two re-
ported on its use in CLTI,471,472 with the third reporting on
its use in IC.473 Cross et al472 found that chemical sympa-
thectomy provided relief of rest pain in 67% of patients
undergoing LS compared with 24% of controls at 6
months. However, in a contrasting study, Barnes et al471
found that LS combined with AI revascularization did
not provide any additional beneﬁts compared with
revascularization alone. In fact, the majority of cohort
studies reporting LS in CLTI474-483 consistently demon-
strate subjective improvements in approximately 60%
of patients with regard to pain relief and ulcer healing.470
Moreover, a Cochrane systematic review was unable to
ﬁnd any RCTs that evaluated the effect of LS (open, lapa-
roscopic, or chemical) compared with no intervention in
CLTI due to nonreconstructible PAD.107 Overall, data are
limited, but there is no evidence to suggest that LS re-
duces the risk of major amputation in patients with
CLTI. It remains unclear whether any subgroup of CLTI
patients may have improved pain control or ulcer heal-
ing with LS.
Intermittent pneumatic compression (IPC)
Mechanism of action. In patients treated with IPC,
arterial blood ﬂow is increased in the distal limbs by an
increase in the arteriovenous pressure gradient, which
stimulates the endothelial vasodilators, thus suspending
the venoarteriolar reﬂex and stimulating collateral artery
growth.484 As a result, the arterial ﬂow, peak systolicvelocity (PSV), end-diastolic velocity, and pulse volume
are all increased.485
Several methods of lower limb IPC use various proto-
cols. These include the ArtAssist (ACI Medical, San Mar-
cos, Calif) device, which provides sequential
compression to the foot and calf; the Aircast ArterialFlow
(DJO Global, Vista, Calif) device, which compresses the
calf; and devices that deliver leg compression synchro-
nized with ventricular contraction of the heart (Syncar-
bon [Contilabo, Saint Gobain, France] and Vascular
Pump [Rheomedix, Philadelphia, Pa]).484
Evidence. Two controlled studies486,487 and several
case series488-495 have been published regarding IPC, but
there is no robust evidence from high-quality trials. In
one, investigators entered 171 patients with CLTI into a 3-
month IPC program.494 They reported improved pain
relief, increased TPs by a mean of 15 mm Hg, and
increased popliteal artery ﬂow by a mean of 20 cm/s. The
median AFS was 18 months, with 94% limb salvage at 3.5
years. They determined that IPC is a cost-effective inter-
vention at a cost of $4454 per patient.494 In a retrospec-
tive observational study involving 107 patients,
researchers from the Mayo Clinic found 40% wound
healing at 6 months.493
In another study, a non-RCT involving 48 patients, inves-
tigators found that 58% of patients who underwent IPC
beneﬁted from complete healing and limb salvage
compared with 17% in the control group (OR, 7.00; 95%
CI, 1.82-26.89).486 In a prospective trial, changes in quality
of life were reviewed before and after IPC treatment.495
Researchers reported a signiﬁcant improvement in
pain, physical functioning, and general health percep-
tion. Another systematic review found that IPC might
be associated with improved limb salvage, wound heal-
ing, and pain management as well as with a low risk of
complications.484 However, this review also noted a
high risk of bias in these studies, with large variations in
the type of compression and optimum parameters
used.484
Wound healing varied considerably (4%-96% at 3
months) in studies that used the same IPC device. In
contrast, mortality rates were more consistent.484 It has
been suggested that outcomes with IPC may be worse
for patients with renal failure, with the prognosis for
this group being worse for both limb salvage and
mortality.484
Guidelines on nonrevascularization interventions
The TransAtlantic Inter-Society Consensus II (TASC II)
document on the management of PAD concluded
that there is low-level evidence available for the recom-
mendation of SCS.156 Likewise, guidelines from the ESVS
state that the beneﬁt of SCS is unproven, with insufﬁ-
cient evidence to recommend its use in the treatment
of CLTI.496
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the treatment of CLTI, it did mention its potential role
in the management of complex regional pain syn-
drome.156 The ESVS guidelines conclude that LS should
not be considered an option to prevent amputation
but can be considered in patients who are not amenable
to revascularization to relieve symptoms.496 The Amer-
ican Heart Association’s guidelines on the management
of PAD do not mention LS.496 Finally, the international
guidelines make no reference to IPC at all.Recommendations Grade Level of evidence Key references
7.1 Consider SCS to reduce the risk of amputation and
to decrease pain in carefully selected patients (eg,
rest pain, minor tissue loss) in whom
revascularization is not possible.
2 (Weak) B (Moderate) Ubbink,106 2013
7.2 Do not use LS for limb salvage in CLTI patients in
whom revascularization is not possible.
2 (Weak) C (Low) Karanth,107 2016
7.3 Consider IPC therapy in carefully selected patients
(eg, rest pain, minor tissue loss) in whom
revascularization is not possible.
2 (Weak) B (Moderate) Abu Dabrh,4 et al 2015Pharmacotherapy
Prostanoids.
Mechanism of action. Prostanoids include a family of
inﬂammatory mediators, mainly prostaglandin E1
(PGE1), prostacyclin (PGI2), and iloprost. Prostanoids act
by inhibiting the activation of platelets and leukocytes,
by inhibiting the adhesion and aggregation of platelets,
and by promoting vasodilation and vascular endothelial
cytoprotection through antithrombotic and proﬁbrino-
lytic activities.108,497,498
Evidence. Ameta-analysis evaluating the use of PGE1 vs
placebo in the treatment of 254 patients with CLTI
demonstrated favorable results at 6 months, with ulcer
healing or pain reduction (47.8% vs 25.2% placebo) and
reduction in major amputation or death (22.6% vs 36.2%
placebo) associated with PGE1 use.499 Subsequently, a
2018 Cochrane paper reviewed 33 prostanoid studies
with various formulations, doses, and administration
routes.108 These included intravenous (IV) administration
of PGE1 (synthetic form, alprostadil) for 21 days and an
intra-arterial administration; IV administration of PGI2 for
4 to 7 days; IV administration of iloprost (synthetic
analogue of PGI2) for 14 to 28 days, oral administration for
28 days to 1 year, and low-dose infusion; IV administration
of lipoecaprost for 50 days; and IV administration of
ciprostene (a PGI2 analogue) for 7 days.
108,497 Compared
with placebo, prostanoids appeared to have some efﬁ-
cacy for treating rest pain (RR, 1.30; 95% CI 1.06 to 1.59)
and ulcer healing (RR, 1.24; 95% CI 1.04 to 1.48). As a
group, however, prostanoids did not have a signiﬁcant
impact on amputations or mortality, although not all
studies deﬁned major vs minor amputations.498 Prosta-
noids were associated with a statistically signiﬁcantincrease in side effects (RR, 2.35; 95% CI, 1.99-2.78).498 The
side effects were mostly minor, including headache,
facial ﬂushing, nausea, vomiting, and diarrhea.
The authors of the Cochrane systematic review
concluded that there is no strong evidence on the efﬁ-
cacy and safety of prostanoids in patients with CLTI on
the basis of a high-quality meta-analysis of homoge-
neous, long-term RCTs.497 They also called on the need
for further high-quality trials.498 A subgroup analysis of
the Cochrane meta-analysis, however, suggested that ilo-prost appeared to reduce major amputation (RR, 0.69;
95% CI, 0.52-0.93) and fared better with rest pain (RR,
1.54; 95% CI, 1.19-1.99) and ulcer healing (RR, 1.80; 95%
CI, 1.29-2.50). The authors stated that whereas previous
meta-analyses of iloprost had been more positive,500
only a few of the studies used in those previous meta-
analyses could be included in the Cochrane review
because of study methodology issues. In fact, in clinical
practice, iloprost appears to beneﬁt approximately 40%
of patients in whom revascularization is not
possible.156,500
Since the Cochrane review was published, a newer RCT
comparing a placebo with the use of PGI2 analogue tap-
rostene intravenously for 2 weeks failed to demonstrate
any difference in pain relief, ulcer size improvement, or
prevention of amputation.501 There are no data to sup-
port the use of prostanoids to reduce the risk of major
amputation in CLTI patients in whom revascularization
is not possible.
Vasoactive drugs.
Naftidrofuryl. A Cochrane review of eight RCTs exam-
ined the IV administration of naftidrofuryl in 269 pa-
tients.109 The treatment tended to reduce rest pain and
to improve skin necrosis, but this was not statistically
signiﬁcant. The studies were found to be of low meth-
odologic quality, with varying levels of severity of CLTI,
varying lengths of duration of treatment (from 3 to 42
days), and different measures of effect. This resulted in
varying end points that precluded a meaningful pooling
of results.109 Thus, there is currently insufﬁcient evidence
to support the use of naftidrofuryl in the treatment of
CLTI.498
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increasing red blood cell deformity and decreasing vis-
cosity. A European RCT involving 314 patients found a sig-
niﬁcant reduction in rest pain, sleep disturbance, and
analgesia requirements.502 In a separate Norwegian
study using the same dosing regimen, there was no
statistically signiﬁcant difference either in pain-free levels
or in absolute walking distance between the two
groups.503 Researchers concluded that further investi-
gation is necessary to evaluate the role of pentoxifylline
in the treatment of patients with CLTI. Thus, there is
currently a lack of consistent evidence to recommend
the use of pentoxifylline in the treatment of CLTI.498
Cilostazol. This drug has been well studied in claudi-
cants but not as much in CLTI. One small study demon-
strated that cilostazol improves microvascular circulation
and skin perfusion pressure in ischemic limbs.504
Another uncontrolled study that used cilostazol in
conjunction with endovascular revascularization re-
ported higher rates of AFS and limb salvage but not
higher rates of survival or freedom from further revascu-
larization.505 In the absence of RCTs in patients with CLTI,
there is insufﬁcient evidence that cilostazol improves
clinical outcomes in patients with CLTI.504,505
Vasodilators
Because vasodilators can cause shunting of blood away
from ischemic areas to nonischemic areas, they are of no
value to patients with CLTI.156
Deﬁbrinating agents
Two small RCTs compared ancrod, a deﬁbrinating
agent, with placebo in CLTI.506,507 Although one study
showed positive changes in APs and TPs, both studies
failed to demonstrate any improvements in clinical
outcome.
Hyperbaric oxygen therapy (HBOT)
There are numerous plausible mechanisms for HBOT to
have a therapeutic role in CLTI. These include increased
oxygen transport capacity of plasma (independent of
red blood corpuscle number and function), improved
function of the leukocyte oxygen-dependent peroxidase
system, reduced tissue edema due to the osmotic effect
of oxygen, stimulation of progenitor stem cell mobiliza-
tion and angiogenesis, and improved ﬁbroblast func-
tion.508 If there is superimposed infection, HBOT also
inhibits bacterial growth (particularly anaerobes), gener-
ates free radicals that destroy bacterial cellular struc-
tures, and improves the oxygen-dependent transport of
antibiotics.509
In 2015, a Cochrane review of the role of HBOT in heal-
ing of chronic wounds was published,110 involving 12 trials
and 577 patients. Ten of the 12 trials studied the effect of
HBOT on ulcer healing in patients with diabetes. The
2015 review concluded that HBOT increased the rate of
ulcer healing in DFUs at 6 weeks but not at longerterm follow-up, with no signiﬁcant difference in the risk
of major amputation.110
Three other studies involved patients with ischemic
ulcers, but each study used varying deﬁnitions of
ischemia.510-512 Abidia et al511 randomized 18 patients with
an ABI of <0.8 or TBI of <0.7 and found improvement in
woundhealing in the treatmentgroup. Löndahl etal512 ran-
domized 94 patients with adequate distal perfusion
or nonreconstructible arterial disease. They found that
57% of patients had a TP of <60 mmHg (median, 52 mm
Hg). Complete ulcer healing occurred in 52% of the
patients treated with HBOT compared with 29% of
controls at 12 months (P < .02). Stratiﬁcation based on
TPs did not appear to affect healing rates. A subsequent
publication by this group demonstrated that preinterven-
tion TcPO2 correlated with ulcer healing and that individ-
uals with a TcPO2 of <25 mm Hg did not heal.
513 There
was no signiﬁcant difference in major amputations
between the two groups, with three amputations in the
HBOT cohort and one in the control cohort.
One study randomized 70 patients with DFUs to either
HBOT or standard care.510 The mean ABI and TcPO2 were
0.65 and 23 mm Hg in the HBOT cohort and 0.64 and 21
mm Hg in the non-HBOT group. All patients with an
ABI <0.9 or TcPO2 <50 mm Hg were considered
ischemic, underwent an iloprost infusion, and were
examined for possible revascularization. Thirteen pa-
tients in each group underwent a revascularization pro-
cedure. At the completion of the therapy, resting TcPO2
increased by a mean of 12.1 in the HBOT group and 5.0
in the control group (P < .0002). There was a signiﬁcant
reduction in major amputations in the HBOT group
(P < .016).510
A large longitudinal cohort study using data from a
wound healing group in the United States61 included pa-
tients with DFUs and adequate foot perfusion as deter-
mined by clinicians. A total of 793 patients underwent
HBOT. Propensity scoring was used to compensate for
the lackof randomization. The study found that individuals
treatedwith HBOTwere less likely to have healing of ulcers
(HR, 0.68; 95% CI, 0.63-0.73) and more likely to undergo
lower limb amputation (HR, 2.37; 95% CI, 1.84-3.04).514
A subsequentmulticenter RCT (Does ApplyingMore Ox-
ygen Cure Lower Extremity Sores? [DAMO2CLES]) under-
taken in 25 hospitals in the Netherlands and Belgium
randomized 120 patients with an ischemic foot wound
and diabetes to standard care with or without a course
of HBOT. Ischemia was deﬁned as AP <70 mm Hg,
TP <50 mm Hg, or TcPO2 <40 mm Hg. All patients were
assessed for revascularization, and when applicable, this
was generally performedbeforeHBOT. Primary outcomes
were limb salvage, wound healing at 12months, and time
to wound healing. Mortality and AFS were also analyzed.
Limb salvage (47/60 in the standard care cohort and 53/
60 in the standard care with HBOT cohort), index wound
healing at 12 months (28/60 in the standard care cohort
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60 in the standard care cohort vs 49 in the standard care
with HBT cohort) were not signiﬁcantly different between
the twogroups. Ahighproportion (35%) of those allocated
to HBOT were unable to undergo HBOT or did not com-
plete at least 30 treatments,mostly formedical comorbid-
ities or logistical reasons, reinforcing the signiﬁcant
medical comorbidities present in these patients.112
Overall, whereas controversy remains, there may be a
role for the use of HBOT to accelerate ulcer healing in
diabetic patients with nonhealing neuropathic ulcers
and low-grade ischemia who have failed to respond to
conventional wound care. However, HBOT does not pre-
vent major limb amputation and should not be used as
an alternative to revascularization in patients with CLTI.
Guidelines on nonrevascularization pharmacotherapy
The TASC II document notes that although previous
studies with prostanoids in CLTI suggested improved
healing of ischemic ulcers and reduction in amputation,
trials do not demonstrate a beneﬁt for prostanoids in
promoting AFS.156 The current PAD guidelines and rec-
ommendations of the American College of Cardiology
Foundation and the American Heart Association state
that parenteral administration of PGE1 or PGE2 may be
considered to reduce pain and to improve ulcer healing
in CLI but that the beneﬁcial effect is likely to occur only
in a small subset of patients.515
Finally, international guidelines do not address vasoactive
drugs, vasodilators, or deﬁbrinating agents. However, the
TASC II guideline advocated for considering HBOT in
selected patients who have not responded to revasculariza-
tion.156Recommendations Grade Level of evidence Key references
7.4 Do not offer prostanoids for limb salvage in CLTI
patients. Consider offering selectively for
patients with rest pain or minor tissue loss and
in whom revascularization is not possible.
2 (Weak) B (Moderate) Vietto,108 2018
7.5 Do not offer vasoactive drugs or deﬁbrinating
agents (ancrod) in patients in whom
revascularization is not possible.
1 (Strong) C (Low) Smith,109 2012
7.6 Do not offer HBOT to improve limb salvage in CLTI
patients with severe, uncorrected ischemia (eg,
WIfI ischemia grade 2/3).




7.7 Continue to provide optimal wound care until the lower extremity wound is
completely healed or the patient undergoes amputation.
Good practice
statementConservative management
Wound care. CLTI is associated with a markedly short-
ened life expectancy, and not surprisingly, patients with
unreconstructed CLTI experience poorer outcomes in
terms of survival and limb salvage. In a retrospective studyinvolving 105 patients with unreconstructed CLTI, 46% of
patients lost the limb and 54% died within 1 year.516 Of
the patients with a nonamputated leg, 72% were dead
within 1 year. Thus, despite advances in revascularization
techniques and anesthetics, endovascular or surgical
revascularization may not be appropriate in some pa-
tients, even if it is technically possible, because of signiﬁ-
cant comorbidities and reduced life expectancy.
A group of 169 patients with stable tissue loss who were
unsuitable for revascularization based on medical and
anatomic reasons were entered into a dedicated wound
management program.290 At 1 year, 77% of patients
remained amputation free, 52% had ulcer healing, and
only 28% required minor amputation. Investigators
concluded that conservative management might serve a
subset of CLTI patients. In fact, circumstances other than
revascularization have been identiﬁed as important for
conservative management, including adequate nutrition,
absence of infection, removal of mechanical features
interfering with wound healing (by surgical débridement,
hydrotherapy, or larvae therapy), negative dressing ther-
apy, and noncontact low-frequency ultrasound.517
More recently, a group of 602 diabetic patients with foot
ulcers and lowTPsorAPswereobserved.518During thevar-
iable follow-up period of 1 to 276 weeks, 38% of patients
had healed primarily, 12% had minor amputation, 17%
healed after major amputation, and 33% died unhealed.CONCLUSIONS
Despite the lack of evidence to support nonrevascula-
rization methods in CLTI, they are still widely used in
real-world practice. In a mail-in questionnaire of
vascular surgeons in the United Kingdom publishedin 2009, 75% believed that LS had a role in clinical prac-
tice for inoperable PAD,519 although in current practice
LS is rarely used for CLTI. Similarly, in a report on out-
comes in patients with nonreconstructible CLTI, 88%
received prostanoid infusions, 14% low-molecular-
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HBOT, and 69% wound treatment. In addition, 13% of
patients underwent toe or other foot-sparing amputa-
tions; at 24 months, the major amputation rate was
9.3%, with a mortality rate of 23.2%.520 It is possible
that these examples of real-world nonevidence-based
practice represent the desire to help this challenging
population of patients when traditional methods either
are unsuitable or have failed. Still, these treatments are
mostly unsupported by evidence and should be
considered alternatives only on an individual basis
and after careful consideration of beneﬁt and risks.
Research priorities7.1 Assess whether pneumatic compression is effective in
improving AFS and resolution of rest pain in patients
with CLTI.7.2 Better deﬁne individuals with CLTI who are likely to
beneﬁt from nonrevascularization therapies.7.3 Deﬁne the role of exercise therapy for the
nonrevascularization treatment of patients with CLTI.7.4 Deﬁne the population of CLTI patients who experience
beneﬁt from HBOT in terms of wound healing, pain
relief, or other meaningful outcomes.8. BIOLOGIC AND REGENERATIVE MEDICINE
APPROACHES IN CLTI
Biologic or regenerative medicine therapies include
gene therapy and cellular therapy. These treatments
offer the potential to promote wound healing and to
prevent amputation in patients who otherwise have no
options for revascularization.
Therapeutic angiogenesis is deﬁned as the growth of
new blood vessels from pre-existing blood vessels in
response to growth factor stimulation. This has been
shown to occur in animal models of hind limb ischemia
and can be induced either by angiogenic proteins such
as vascular endothelial growth factor or by cellular ther-
apy using stem cells or bone marrow aspirate. The
concept of angiogenesis was introduced into the clin-
ical realm by Jeffrey Isner in the early 1990s.521 Various
growth factors, including vascular endothelial growth
factor, hepatocyte growth factor (HGF), and ﬁbroblast
growth factor (FGF), have been shown to promote
angiogenesis in animal models. The short half-life of
these proteins has led to the use of gene therapy to
maintain sustained expression in the ischemic limb.
Most clinical trials to date have used intramuscular in-
jection of either a gene or cellular therapy. In the case
of gene therapy, expression of the protein is maintained
for 2 to 6 weeks. Ongoing research in this arena in-
cludes alternative vectors to safely enhance long-term
gene expression.The putative mechanism of cellular therapy involves
either the differentiation of stem cells into vascular cells,
after injection into the hypoxic extremity, or induction of
angiogenic growth factor expression, again due to relative
tissuehypoxia in the ischemicextremity.General concerns
about the safety of angiogenic therapy have been related
to the potential for “off-target” angiogenesis, which can
result in promotion of occult tumor growth or accelerated
progression of diabetic proliferative retinopathy. To date,
these concerns have not occurred in angiogenic clinical
therapy trials that have been completed.Trials of gene and stem cell therapy in CLTI
Gene therapy.
Fibroblast growth factor (FGF). This has been exten-
sively studied in the context of severe limb ischemia.
The TALISMAN phase 2 trial (NCT00798005) enrolled
125 patients and reported a signiﬁcant improvement in
AFS at 12 months of 73% in patients treated with FGF
plasmid compared with 48% in placebo-treated pa-
tients with no options for revascularization (P ¼ .009).522
Complete ulcer healing at 6 months occurred in 14% of
the placebo group and 20% of the treatment group (not
signiﬁcant).522 In a separate study, the investigators
demonstrated proof of concept of gene therapy when
they identiﬁed the FGF plasmid, messenger RNA, and
protein in the amputation specimens of patients with
CLTI who received FGF plasmid injections before
amputation.523
These ﬁndings led to a phase 3 trial, the TAMARIS trial
(NCT00566657).524 This trial enrolled 525 patients from
30 countries who had either an ischemic ulcer or minor
gangrene. However, the TAMARIS trial failed to show adif-
ference in AFS compared with placebo in patients with
CLTI (63% in the treatment group vs 67% in the placebo
group).524 The AFS for both groups was similar to that for
the FGF-treated patients in the phase 2 TALISMAN trial
(Table 8.1). The likely explanation for the different results
observed in the phase 2 TALISMAN and phase 3 TAMARIS
trials is a type II error in the earlier study.
Hepatocyte growth factor (HGF). Several clinical trials
have evaluated HGF plasmid in the treatment of patients
with CLTI and no option for revascularization. Early phase
2 trials (NCT00189540, NCT00060892) have shown that
HGF plasmid gene therapy can improve TcPO2 and pain
scores in patients with CLTI compared with placebo,
but this did not result in improved AFS.525,526 A Japa-
nese trial of 40 patients demonstrated a signiﬁcant
improvement in a composite end point of improvement
of rest pain in patients without ulcers or reduction in
ulcer size in those with ulcers at 12 weeks (70.4% vs
30.8%; P ¼ .014).527 The AFS at 12 months was not re-
ported. There are currently no U.S. Food and Drug
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AFS, Amputation-free survival; BMMNCs, bone marrow mononuclear cells; FGF, ﬁbroblast growth factor; HGF, hepatocyte growth factor; JUVENTAS,
Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation; MOBILE, MarrowStim treatment of limb ischemia in
subjects with severe peripheral arterial disease; TBI, toe-brachial index; TcPo2, transcutaneous oximetry.
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treatment of patients with CLTI.
Stem cell therapy. Preclinical studies using animal hind
limb ischemiamodels have shown that stem cells injected
intramuscularly into the hind limb can promote improved
blood ﬂow through an angiogenic mechanism. Early
studies in humans have similarly shown improved vascu-
larity in the treated extremity, as measured by ABI,
although the mechanism by which this occurs in humans
is unknown. Cellular therapies can be divided intoautologous and allogeneic. Several phase 1 and phase 2 tri-
als have recently been completed, including ones from
Harvest Technologies (NCT00498069) and Biomet
(NCT01049919).528,529 Both of these report promising early
results of phase 1 trials using autologous bone marrow
mononuclear cells (BMMNCs) in the treatment of
CLTI.528,529 In addition, both companies have developed
point-of-care cell preparation systems. After bone marrow
harvest, the BMMNCs are extracted for direct intramus-
cular injection into the ischemic limb.
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tients treated with intramuscular bone marrow concen-
trate, there was a 64% AFS at 6 months compared with
65% in the control group. The treated patients had a sig-
niﬁcant improvement in pain relief and TBI.528,530
Another trial of 152 patients found little difference in
AFS between the treatment group and control group
at 6 months (80% vs 69%; P ¼ .224).529,531 Both of these
phase 3 trials are being conducted through investigator
device exemptions from the Center for Devices and
Radiological Health of the FDA.
Another trial, the RESTORE-CLI (phase 2) trial, used
expanded autologous stem cell therapy, ixmyelocel-T,
in the treatment of CLTI patients for whom revasculariza-
tion was not an option.532 Bone marrow aspirate (50 mL)
was taken from study patients and sent to the sponsor,
where the cells were cultured in a bioreactor and
expanded during a 2-week period; when expanded, the
cell population is enriched with mesenchymal precur-
sors and alternatively activated macrophages. It was
then returned to the trial site for intramuscular injection
into the ischemic limb of the patient. The trial enrolled 72
patients with either ischemic rest pain or tissue loss. At 12
months, 40% of patients who were treated with
ixmyelocel-T experienced one or more treatment failure
events (deﬁned as death, major amputation, doubling of
wound size from baseline, or new-onset gangrene)
compared with 67% of placebo-treated patients (P ¼
.045, Fisher exact test). There was no difference in
AFS.532 Treatment failure events were particularly pro-
nounced in patients who presented with tissue loss at
baseline. In the subgroup of patients presenting with
wounds, 45% of patients treated with ixmyelocel-T expe-
rienced a treatment failure event compared with 88% of
control patients (P ¼ .01).532
In a small study of 28 patients with CLTI, Losordo et al533
completed a placebo-controlled trial to compare CD34-
positive cells selected by leukopheresis after mobiliza-
tion with granulocyte colony-stimulating factor. The in-
vestigators showed a trend toward reduction in all
amputations (both major and minor). At 12 months,
31% of treated patients underwent amputation
compared with 75% of placebo-treated patients (P ¼
.058). There was no difference between the two groups
when only major amputation was evaluated, although
the number of patients in the trial was small.533
In another small trial, the Bone Marrow Autograft in
Limb Ischemia (BALI) study randomized 38 patients with
CLI to treatment with bonemarrow-derivedmononuclear
cells vs placebo at seven centers in France.534 A single
treatment employing 30 separate intramuscular injec-
tions in the ischemic limb was performed. There was no
statistical difference in major amputation at 6 or 12months or in ulcers or pain relief at 6 months. Interest-
ingly, TcPO2 values increased in both treated and placebo
patients. Using a “jackknife” method of logistic regression,
the authors suggest some beneﬁt inmajor amputation for
the treated group. However, the total number of patients
and events in this trial was small, and the results can be
considered only exploratory at best.
The Rejuvenating Endothelial Progenitor Cells via
Transcutaneous Intra-arterial Supplementation
(JUVENTAS) trial randomized 160 patients with severe
limb ischemia to three intra-arterial infusions of either
BMMNCs or placebo, 3 weeks apart.535 No major differ-
ences were found in major amputations at 6 months
(19% in patients receiving BMMNCs vs 13% in the placebo
cohort) or in AFS at 6 months (77% in patients receiving
BMMNCs vs 84% in the placebo group). No differences
were found in the safety outcomes or secondary out-
comes of the two groups.535
The recently completed phase 1 allogeneic cell therapy
trial sponsored by Pluristem (NCT00951210) has shown
promising safety and potential efﬁcacy (personal
communication). This open label trial of allogeneic
placental stem cells (PLX-PAD cells) will be entering
phase 2 placebo-controlled trials. The PLX-PAD cells are
mesenchymal-like stromal cells derived from the full-
term placenta and are expanded using the sponsor’s
proprietary bioreactor. The cells are believed to be im-
mune privileged and would potentially offer an “off-the-
shelf” treatment option.
Finally, a meta-analysis of randomized placebo-
controlled trials of stem cell therapy involved 499 pa-
tients in 10 trials.113 Follow-up in all of the included trials
was <12 months, and only three studies observed pa-
tients for at least 6 months. This meta-analysis demon-
strated no improvement in major amputation rates or
AFS associated with stem cell therapy. Secondary out-
comes (ABI, TcPO2, and pain scores) were signiﬁcantly
better in the treatment group.113
Safety of therapeutic angiogenesis
Early concerns about off-target angiogenesis and the
potential for progression of diabetic proliferative retinop-
athy or occult tumor growth previously resulted in signif-
icant restrictions in the inclusion and exclusion criteria
for entry into these studies. As early studies demon-
strated an acceptable safety record for this therapy and
potential concerns about off-target angiogenic compli-
cations lessened, these restrictions have since decreased.
Unanswered questions in the ﬁeld
Trial design and completion hurdles. Trials involving
CLTI patients face multiple hurdles that have resulted
in delays in completion. The overall comorbid burden
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study. Likewise, the heterogeneous nature of CLTI results
in a highly variable natural history. Patients with ischemic
tissue loss have a major amputation rate at 1 year of up to
35% compared with <10% in patients with rest pain. In
addition, the FDA recommends that AFS should be the
primary efﬁcacy end point in a phase 3 CLTI trial. This
has resulted in studies with an expected enrollment
requirement of at least 500 patients. The reason for
these large numbers in a phase 3 trial is that biologic
treatment of CLTI is a limb-sparing procedure. As such,
it is not expected to signiﬁcantly inﬂuence mortality,
although mortality is a component of the primary end
point. Consequently, because of the heterogeneous and
frail nature of the population of CLTI patients, larger
numbers of patients are needed to complete a clinical
trial that can detect any potential efﬁcacy on amputation
at 1 year.
Selection of patients. Many trials have recruited indi-
viduals who are considered to have no option for revas-
cularization. Unfortunately, there is no consistent
deﬁnition of no-option CLI. Published studies referred
to in this section have broadly included individuals who
were considered poor candidates for surgical or endo-
vascular revascularization. This was due to either tech-
nical factors (inadequate venous conduit; unfavorable
anatomy, such as absence of a patent artery in the calf
that is in continuity with the foot) or patient-related
factors (poor operative risk, but pain or tissue loss was
unlikely to require amputation within 4 weeks). In several
studies, imaging was assessed by an independent
vascular specialist.
The development of advanced endovascular tech-
niques gives many patients who were previously consid-
ered to have no option for revascularization a new
opportunity to be considered potentially suitable for
endovascular intervention. Nonetheless, there are few
data supporting many of these techniques. Novel
methods to measure circulating stem or progenitor cells
before therapy may prove helpful in serving as compan-
ion diagnostics to identify those individuals who may or
may not respond to angiogenic therapy.536
Conclusions
There have been promising early safety and efﬁcacy
trial data for both gene and cellular therapies in patients
with CLTI. Despite these early promising results, no phase
3 trials have shown this therapy to be effective. Still, cur-
rent trial design has improved, and there are multiple
phase 3 clinical trials that either are actively enrolling or
are in early stages of development. These involve poten-
tially disruptive technologies that, if proven effective,could dramatically alter how patients with CLTI are cared
for in the future. Until further evidence is available, these
therapies should be considered investigational.Research priorities8.1 Identify surrogate markers (biomarkers, imaging) that
would assist in understanding the possible
mechanisms of action of gene- and cell-based
therapies in CLTI.8.2 Determine whether gene- or cell-based therapies can
serve as an adjunct to revascularization to improve
clinical outcomes in subsets of CLTI patients.9. THE ROLE OF MINOR AND MAJOR
AMPUTATIONS
CLTI is associatedwitha reduced life expectancy, a signif-
icant curtailment in ambulation, and a high likelihood of
limb loss. Preservation of a patient’s ability to walk is an
important aspect of care in CLTI, and vascular reconstruc-
tion is the most direct method for achieving functional
limb salvage in these often critically ill patients. When
properly applied, open surgical and endovascular
techniqueshaveproveduseful and successful for thepres-
ervation of limb function. A successful limb salvage inter-
vention is associated with low postprocedural morbidity
and mortality, preservation or restoration of independent
ambulation, improved quality of life for the patient, and
lower cost to the health care system. Although most pa-
tients require a single procedure to accomplish this,
many will need minor amputations to remove distal
necrotic or infected tissue to achieve a completely healed
and functional extremity. This is especially true of dia-
betics, who have a lifetime risk of foot ulceration of 25%,
with 50% of ulcers becoming infected.154 Treatment of
these patients requires both in-line pulsatile ﬂow to the
foot and wound débridement or minor amputation.537
Minor amputations. Minor amputations of the foot
include digital and ray amputation of the toe, transme-
tatarsal amputation of the forefoot, and Lisfranc and
Chopart amputations of the midfoot. Each of these
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selected patients. Although there is a signiﬁcant risk of
need for reamputation at a higher level in diabetics,
the use of minor amputations, including single-digit
and ray amputations, can preserve foot function in
the majority of patients.538-540 There are some in-
stances in which transmetatarsal amputation may be a
better ﬁrst procedure, including necrosis of the great
toe requiring long ray amputation or ray amputation of
the ﬁrst and ﬁfth toes, but ensuring adequate distal
perfusion and appropriate ofﬂoading of the forefoot
are the major principles for preservation of foot
function.114,541
There are, however, situations in which an aggressive
attempt at limb salvage would be unlikely to succeed,
would pose too great a physiologic stress on the patient,
or would be of limited value because of other causes of
limb dysfunction. For these patients, major amputation
may be considered a reasonable option. Because a
well-planned primary amputation can often result in a
high likelihood of independent ambulation for many pa-
tients, this procedure should not be considered a failure
of vascular surgery. Rather, it should be viewed as
another path to the goal of preserving the walking ability
in carefully selected patients or for resolution of ischemic
pain, ulceration, and infection.
Primary amputation. Primary amputation in patients
with CLTI is deﬁned as lower extremity amputation
without an antecedent open or endovascular attempt
at limb salvage. There are four major goals of primary
amputation for patients with CLTI: (1) relief of ischemic
pain; (2) removal of all lower extremity diseased,
necrotic, or grossly infected tissues; (3) achievement of
primary healing; and (4) preservation of independent
ambulatory ability for patients who are capable. In
addition, there are ﬁve major indications for primary
amputation.
1. Nonreconstructible arterial disease, as conﬁrmed by
clear distal imaging studies that fail to identify pat-
ent distal vessels needed for a successful interven-
tion. In the setting of severe distal ischemia, in
particular in association with ischemic ulceration,
gangrene, or infection, the inability to improve
straight-line distal perfusion often results in major
amputation even with a patent bypass graft. By-
passes to arteries that do not have at least large, an-
giographically apparent collateral vessel outﬂow
provide little additional ﬂow to the foot for distal
limb salvage.542 Patients without any appropriate
targets for successful distal revascularization are
frequently better served with a primary major
amputation.
2. Destruction of the major weight-bearing portions of
the foot, rendering it incompatible with ambulation.The weight-bearing portions of the foot consist of
the calcaneus, the ﬁrst and ﬁfth metatarsal heads,
and a functional arch. Patients with gross destruction
of the calcaneus and overlying skin should be consid-
ered for primary amputation because a functional
foot can infrequently be salvaged. After aggressive
heel ulcer excision and extensive calcanectomy, com-
plete wound healing is infrequent and chronic pain is
common.543,544
3. Nonfunctional lower extremity due to paralysis or
unremediable ﬂexion contractures. These patients
are unlikely to beneﬁt from attempts at revasculariza-
tion, and there will be little change in quality of life
despite a successful intervention.
4. Severe comorbid conditions or limited life expec-
tancy due to a terminal illness. The goal of treatment
for these patients is relief from ischemic pain, if pre-
sent, and an improvement in the remaining quality
of life. Extensive distal revascularization, prolonged
hospitalization, and protracted recovery should be
avoided. Assessment of the patient’s frailty may
be of value to determine whether primary major
amputation is more appropriate than distal
revascularization.545,546
5. Multiple surgical procedures needed to restore a
viable lower extremity. As the technology and tech-
niques of vascular surgery have improved, surgeons
have advanced beyond revascularization to complex
vascular and soft tissue reconstruction. This
approach usually involves multiple surgical proced-
ures to increase distal ﬂow, removal of all necrotic
tissue, and reconstruction of these areas with free
ﬂaps. The course of treatment is prolonged, involving
multiple returns to the operating room, long periods
of inactivity, and a difﬁcult recovery. For these pa-
tients, if multiple procedures with high morbidity
are required, primary amputation should be strongly
considered to permit early ambulation. A detailed
discussion with the patient to develop a compre-
hensive treatment plan with shared decision-
making is important for such advanced vascular
disease.
For all patients considered for primary amputation, also
consider revascularization to improve inﬂow in an
attempt to reduce the level of the amputation.118,119 For
example, those patients with extensive infrainguinal arte-
rial occlusion, including the common and proximal PFA,
might beneﬁt from restoration of ﬂow into the deep
femoral system to reduce the amputation level from
the upper thigh to the level of the knee. In such cases,
despite some additional risk, proximal revascularization
has the potential to offer a tangible and signiﬁcant
beneﬁt to the patient.
Secondary amputation. For those in whom one or
more attempts at revascularization have failed and
the likelihood of a successful and durable redo
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rehabilitation to independent ambulation should be
considered.
Level of amputation. Selecting the level of amputa-
tion that will heal primarily is critical to successful pros-
thetic rehabilitation and maximal functional mobility.
Thus, a great deal of consideration must go into select-
ing the initial level of amputation. Preoperative tissue
perfusion assessment can make it possible to lower
the level of amputation, although there is no accurate
method to predict the optimal level of amputation.547
In addition, whereas assessment of preoperative tis-
sue perfusion can aid in decision-making, it still re-
mains largely a clinical decision. Many techniques to
evaluate tissue perfusion have been tried, including
laser Doppler ﬂowmetry, thermography, skin perfusion
pressure, ﬂuorometric quantiﬁcation of a ﬂuorescein
dye, TcPO2, and indocyanine green ﬂuorescence angi-
ography. In particular, TcPO2 has been extensively
evaluated, and it has been shown that wound com-
plications increase as TcPO2 levels fall below 40 mm
Hg.547 Currently, there is still no single deﬁnitive
method of evaluating tissue perfusion that can accu-
rately predict the wound healing potential or failure at
the site of amputation.
Healing rates of amputations and reamputations.
Achieving primary healing is challenging in ischemic
lower limbs, and it is difﬁcult to predict early failure
(Table 9.1). Multiple débridements and reamputations
are required in 4% to 40% of patients, depending on the
level of amputation.548-550 Likewise, readmission rates of
20% have been reported even after minor amputations
(toe and distal forefoot), with the majority of ream-
putations occurring within 1 month.548-550 Reported
long-term healing rates after transmetatarsal amputa-
tions are approximately 53%.551 These amputations
should not be offered to patients who have poor reha-
bilitation potential.
The role of partial foot or midfoot (eg, Lisfranc, Chopart)
amputations remains controversial. Prosthetic specialists
discourage the use of these procedures as they have
higher rates of delayed healing, require more revisions,
and develop deformities and ulcers, and patients often
struggle to achieve their full rehabilitation potential.
Conversely, these amputations preserve a weight-
bearing heel and allow amputees the ability to mobilize
for short distances without prostheses.552
Transtibial amputation (below-knee amputation [BKA])
and transfemoral amputation (above-knee amputation
[AKA]) are performed with an almost equal frequency
in patients with CLTI. Reports have shown primary heal-
ing rates for BKA of approximately 60%, with 15% leadingto a transfemoral amputation.121,548 The transfemoral
amputation has the highest probability of successful pri-
mary healing and therefore has been the amputation of
choice in individuals who are less likely to ambulate with
a prosthesis.
Recent data from the American College of Surgeons
National Surgical Quality Improvement Program show
improved results with a 12.6% early failure rate for BKA
compared with 8.1% for AKA.553 A similar trend is found
in data from the National Vascular Registry of the United
Kingdom, which show that one in eight AKAs and one in
six BKAs remain unhealed at 30 days.554
Knee disarticulation. The biomechanical advantages
of a knee disarticulation or through-knee amputation
(TKA) compared with an AKA are well recognized,
although it remains an infrequently performed ampu-
tation. A well-performed TKA offers healing rates that
are comparable to those of AKA and provides
bedridden and wheelchair-bound patients with a
higher level of mobilization and transfer, counterbal-
ance, and reduced potential for contractures. Even in
patients who have rehabilitation potential, the current
prosthetic technology permits excellent functional
mobility, making TKA a good amputation choice when
a BKA is unlikely to heal. The aesthetic disadvantage of
a TKA is that the prosthetic knee will be marginally
distal to the normal contralateral knee in a sitting
position.
Mortality. Survival after major lower limb amputation is
poor, as seen in a systematic review that reported 30-day
postoperative mortality rates of 4% to 22%.555 Even after
minor amputations, the 1-year and 5-year mortality rates
are reported to be 16% and 25%, respectively, for those
with limb ischemia.556 Mortality rates for minor ampu-
tations are higher in diabetics, with type 2 diabetics
having a 5-year mortality of >50%.557 The 5-year mortality
after major amputations varies from 30% to 70% and is
signiﬁcantly worse for AKA than for BKA.558,559 The mor-
tality is even higher in bilateral lower limb amputees,
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rates demonstrate the high rate of comorbidities and the
frailty of this group of patients.
In patients with diabetes who have had major ampu-
tations, survival is often worse than in some malignant
diseases. Survival rates have been reported as 78% at 1
year, 61% at 3 years, 44% at 5 years, and 19% at 10
years.561
In 2010, recognizing the need to do more to reduce
perioperative mortality, the Vascular Society of Great Brit-
ain and Ireland introduced a quality improvement
framework to reduce mortality from amputation surgery
to <5% by 2015, which was later revised to <10% in
2016.562 Recent data from the United Kingdom’s Na-
tional Vascular Registry showed mortality rates of 11.6%
for AKA and 6.1% for BKA by establishment of dedicated
multidisciplinary amputation services that provided
expeditious and comprehensive preoperative and post-
operative care.550 These rates are similar to results from
the American College of Surgeons National Surgical
Quality Improvement Program of 12.7% for AKA and
6.5% for BKA, with an overall 9.1% mortality of 6389 pa-
tients studied.563
Fate of contralateral limb after lower extremity
amputation. Published reports of the risk of contralat-
eral amputation vary from 2.2% to 44%, with a lower
risk if the index amputation is a minor amputation.124
In most patients, the reason for contralateral amputa-
tion is disease progression, although the medical
management of unilateral amputees can also be
suboptimal, with one-third of patients not prescribed a
statin and an antiplatelet agent.123 Continued follow-
up of these patients at least yearly after ampu-
tation with attention to the contralateral limb is
important.124
Prosthetic rehabilitation, mobility, and quality of life.
When an amputation is inevitable, and whenever
possible, a prosthetic specialist should be involved in
decision-making with the surgical team regarding the
optimal level of amputation that will ensure the best
opportunity for healing, survival, and maximum func-
tional mobility. Advances in prosthetics have resulted in a
prosthesis for every stump. However, to use the pros-
thesis effectively, the stump must be created to truly
function as a dynamic sensorimotor end organ and not
simply as an inert ﬁller in the socket.
Muscle-stabilizing procedures can help create a stump
with its proprioception intact and any of the procedures
can be used, including myoplasty, myodesis, and osteo-
myoplasty. The stump evolves with time, and the pros-
thetic requirements continue to change. The patient
requires regular adjustments in the prosthesis and oftencomplete revisions. A poorly ﬁtting prosthesis can be as
disabling as the actual amputation.
The quality of life after amputation is signiﬁcantly inﬂu-
enced by pain, social isolation, depression, and the pa-
tient’s lifestyle before amputation. Mobility has a direct
effect on quality of life. It is a key determinant to the so-
cial reintegration of the amputee and has a beneﬁcial ef-
fect on late mortality.
Energy expenditures of ambulation increase with
ascending levels of amputation. Energy consumption
during ambulation is increased by 10% to 40% after
BKA and by 50% to 70% after AKA.564 The potential
for rehabilitation is better with BKA than with AKA.
Therefore, it is worthwhile to try to salvage a BKA in a
patient who has the potential to ambulate fully. In
studies involving >100 patients, ambulatory status at 6
to 12 months after amputation varies from 16% to
74%.551 At 2 years, only 40% of BKA patients achieve
full mobility.121
Maintaining ambulation is one of the most important
factors in preserving independence. A signiﬁcant
amount of evidence is available to suggest that early
postsurgical prosthetic ﬁtting leads to early mobility.565
However, to achieve and to maintain daily functional
ambulation, multidisciplinary inputs are needed from
physiotherapists, occupational therapists, prosthetists,
social workers, recreational therapist nurses, psycholo-
gists, and the surgeon. Despite initial successful pros-
thetic rehabilitation, prosthetic use deteriorates over
time, and most patients eventually become household
walkers only.566
Delivery of amputation service. Based on current inter-
national practice,562,566 the following best practice rec-
ommendations will help decrease mortality and improve
functional outcomes:
1. The indication for any nonurgent amputation
should be discussed at a multidisciplinary team
meeting after a full functional and vascular
assessment.
2. Patients should be informed as to the rationale of any
amputation as well as the postamputation care
pathway.
3. Patients should have access to a second opinion (by a
vascular specialist from another institution).
4. A preoperative assessment by a rehabilitation and
occupational physiotherapist as well as by a prosthetic
specialist should be organized.
5. Procedures should be performed on an elective list
(within 48 hours of the decision).
6. Amputations should be performed by or in the pres-
ence of a board-certiﬁed consultant surgeon.
7. A named discharge coordinator should ensure that
there is a deﬁned postamputation care pathway.
Recommendations Grade Level of evidence Key references
9.1 Consider transmetatarsal amputation of the forefoot in CLTI
patients who would require more than two digital ray
amputations to resolve distal necrosis, especially when the
hallux is involved.
2 (Weak) C (Low) Elsherif,114 2017
9.2 Offer primary amputation to CLTI patients who have a pre-
existing dysfunctional or unsalvageable limb, a poor
functional status (eg, bedridden), or a short life expectancy
after shared decision-making with the patient and health
care team.
1 (Strong) C (Low) Aziz,115 2015
Siracuse,116 2015
9.3 Consider secondary amputation for patients with CLTI who
have a failed or ineffective reconstruction and in whom no
further revascularization is possible and who have
incapacitating pain, nonhealing wounds, or uncontrolled
sepsis in the affected limb after shared decision-making
with the patient and health care team.
2 (Weak) C (Low) Reed,117 2008
9.4 Consider revascularization to improve the possibility of healing
an amputation at a more distal functional amputation level
(eg, AKA to BKA), particularly for patients with a high
likelihood of rehabilitation and continued ambulation.
2 (Weak) C (Low) Rollins,118 1985
Miksic,119 1986
9.5 Consider a TKA or AKA in patients who are nonambulatory for
reasons other than CLTI (ie, bedridden patients with ﬂexion
contracture, dense hemiplegia, cancer) and are unlikely to
undergo successful rehabilitation to ambulation.
2 (Weak) C (Low) Ayoub,120 1993
Taylor,121 2008
9.6 Involve a multidisciplinary rehabilitation team from the time a
decision to amputate has been made until successful
completion of rehabilitation has been achieved.
1 (Strong) C (Low) Webster,122 2012
9.7 Continue to observe CLTI patients who have undergone
amputation at least yearly to monitor progression of disease
in the contralateral limb and to maintain optimal medical
therapy and risk factor management.
1 (Strong) C (Low) Bradley,123 2006
Glaser,124 2013
Research priorities
9.1 Identify the best noninvasive test to predict the optimal level of amputation with respect to primary healing.
9.2 Determine whether the primary healing rates, postproceduremobility with prosthesis, and quality of life data justify a TKA over
an AKA.
9.3 Investigate whether there is a difference in stump healing between the skew ﬂap, long posterior ﬂap, and equal anterior and
posterior ﬂap techniques of BKA.
9.4 Investigate whether the quality of life after partial foot amputations is inferior to or even better than after BKA or AKA.
9.5 Determine the optimal early prosthesis ﬁtting and rehabilitation strategies for independent ambulation.
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SURVEILLANCE AFTER INFRAINGUINAL
REVASCULARIZATION FOR CLTI
This section reviews evidence for adjunctive medical
therapies, surveillance, reintervention, and postproce-
dural care after infrainguinal revascularization for CLTI.
Medical therapies
All patients who have undergone revascularization for
CLTI should continue with best medical therapies to
slow the progression of atherosclerosis and mitigatethe adverse impact of risk factors as recommended in
Section 4. In addition, the role of speciﬁc pharmaco-
therapy for maintaining the beneﬁts of revascularization
has been the subject of a number of studies.
Endovascular interventions. Long-term antiplatelet
therapy remains a cornerstone to reduce atherothrom-
botic events and to improve patency and limb salvage
rates after peripheral interventions.35,135 Contemporary
management involves the choice between single anti-
platelet therapy and DAPT. Aspirin has been a mainstay
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Clopidogrel is also effective as a single agent.35,567 Use
of DAPT after intervention has become standard in the
treatment of CAD134,568 and has migrated to other arenas
of vascular intervention. Clopidogrel is a prodrug
requiring conversion by cytochrome P450 enzymes, the
activity of which may be affected by genetic poly-
morphisms or drug-drug interactions. It has been esti-
mated that between 4% and 30% of individuals treated
with conventional doses of clopidogrel do not attain the
full antiplatelet response.569 Of note, it has been reported
that patients with PAD may have a higher prevalence of
resistance to clopidogrel than coronary intervention
patients.136
Despite an absence of level 1 evidence, DAPT is
frequently employed for 1 to 6 months after peripheral
interventions.134,136 The Clopidogrel and Aspirin in the
Management of Peripheral Endovascular Revasculariza-
tion (CAMPER) study was designed to compare aspirin
with DAPT but was stopped because of poor enroll-
ment.137,570 The MIRROR trial was a double-blind RCT
comparing clinical outcomes of aspirin and placebo vs
aspirin and clopidogrel for 6 months after FP interven-
tion. Of the 80 patients who were randomized, 42%
had CLTI.136 Decreased target lesion revascularization
was observed in patients randomized to the DAPT
arm, although there was no signiﬁcant difference in
patency rate. A meta-analysis suggested that DAPT
might be associated with a reduced risk of major ampu-
tations after revascularization, with increased bleeding
risk vs monotherapy.297 A propensity-adjusted analysis
from the Vascular Quality Initiative associated DAPT
use with improved survival after revascularization for
CLTI.571 The efﬁcacy of DAPT may depend on multiple
factors, including procedure-related, anatomic, and
patient factors. Subgroups of patients who may derive
more beneﬁt from DAPT include those with complex
disease patterns, those with prior failed interventions,
and those at lower risk of bleeding complications (eg,
younger patients). Adequately powered RCTs are
needed to better deﬁne the risks and beneﬁts of DAPT
after peripheral intervention as well as optimal dosing
and duration of treatment.
The phosphodiesterase inhibitor cilostazol has anti-
platelet and antiproliferative properties, and several
studies have suggested that it may reduce the incidence
of restenosis after catheter interventions. Iida et al572 re-
ported that cilostazol treatment reduced angiographic
restenosis after FP intervention (angioplasty with provi-
sional stenting) in an open label randomized trial of
200 patients, of whom 90% had intermittent claudica-
tion. A meta-analysis suggested an association between
cilostazol use and reduced rates of in-stent restenosis af-
ter FP stenting in “high-risk” patients, pooling studies that
included 75% claudicants.573 Conversely, an open labelRCT found no effect of cilostazol treatment in reducing
restenosis after IP interventions for severe limb
ischemia.574 No clear recommendation can be made at
present regarding the potential beneﬁt of cilostazol after
endovascular interventions for CLTI.
Vein and prosthetic bypass grafts. After vein graft im-
plantation, patency of the graft is likely to be enhanced
by lifestyle modiﬁcations and medical therapy. Most
studies of vein graft patency include patients with both
CLTI and claudication. Meta-analyses from prospective
studies130,131 along with multiple case series demonstrate
a consistent association between the avoidance of
smoking and enhanced vein graft patency. Statin medi-
cations have not been evaluated in randomized trials for
enhancement of vein graft patency, although some
retrospective studies suggest that they may be of
beneﬁt.125,126 In a cohort study, statin use was not asso-
ciated with better limb outcomes, although overall sur-
vival was improved.129
Although antiplatelet agents are commonly used, there
is inconclusive evidence that they speciﬁcally enhance
lower extremity vein graft patency. A Dutch trial of
2690 patients randomized to oral anticoagulants (target
international normalized ratio of 3-4.5) or 80 mg of
aspirin per day after lower extremity bypass found better
vein graft patency at 12 and 24 months for the oral anti-
coagulants on subgroup analysis.575 However, there were
twice as many bleeding complications in the
anticoagulant-treated patients. In contrast, a multicenter
U.S. trial comparing warfarin plus aspirin with aspirin
alone found no improvement in vein graft patency and
a higher rate of bleeding in the combined treatment
arm.576 A study of 56 patients with poor-quality venous
conduits compared aspirin alone with a combination of
aspirin and warfarin and found improved patency in
the aspirin plus warfarin group.577 Finally, a systematic re-
view found no effect of aspirin or dipyridamole
compared with placebo on vein graft patency at 1
year.127,128 Vein graft patients receiving aspirin or aspirin
plus clopidogrel have similar patency, and there is a
higher rate of mild to moderate bleeding with DAPT.132
A more recent systematic review concluded that anti-
platelet therapy has a beneﬁcial effect on primary
patency of peripheral bypass grafts compared with pla-
cebo or no treatment.128 It appears, then, that there is
limited evidence to support a speciﬁc antithrombotic
regimen in patients after vein bypass grafting for CLTI.
Single antiplatelet therapy, recommended as standard
for long-term PAD management, should be continued
in these patients. Treatment with warfarin may be
considered in patients with high-risk vein grafts (eg,
spliced vein conduit, poor runoff) who are not at
increased risk for bleeding.
In contrast, there is consistent evidence supporting the
use of antiplatelet therapy in patients who have
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views have supported the use of aspirin and other anti-
platelets in maintaining lower extremity bypass graft
patency, and greater beneﬁts have been seen with pros-
thetic grafts.127,128 Other studies have demonstrated
similar ﬁndings.133 In particular, one randomized trial
(Clopidogrel and Acetylsalicylic Acid in Bypass Surgery
for Peripheral Arterial Disease [CASPAR]) showed that
DAPT with clopidogrel and aspirin led to signiﬁcantly
improved patency in prosthetic grafts but not in venous
grafts.132 However, this was accompanied by an
increased risk of mild to moderate bleeding. Another
study demonstrated that the use of anticoagulants
such as vitamin K antagonists did not improve the pros-
thetic graft patency, although they were beneﬁcial in
venous conduits.575,578 In a single-center study, investiga-
tors suggested the use of therapeutic vitamin K antago-
nists to prolong the patency of prosthetic grafts with low
velocities.579
Surveillance and reintervention
After endovascular treatment. Despite the high initial
technical success rates of endovascular interventions,
early failure of these minimally invasive procedures is
common.100,365,580-583 This has led to high rates of sec-
ondary interventions and questions of clinical efﬁcacy to
support them.
Currently, guidelines support DUS surveillance and pro-
phylactic reintervention for asymptomatic vein graft ste-
nosis to promote long-term patency.138,584-589 Conversely,
strategies for surveillance and guidelines for reinterven-
tion after angioplasty have primarily been left up to the
individual practitioner. There are many determinants of
failure after angioplasty, including indication (claudica-
tion vs CLTI), lesion length, lesion severity (occlusion vs
stenosis), calciﬁcation, location, concomitant inﬂow and
outﬂow vessel disease, use of stents, and residual stenosis
or recoil at the time of the initial procedure. As a result,
predicting which interventions are more prone to failure
has proved challenging, and there is scarce evidence to
support indications for repeated interventions in CLTI.
Modalities for surveillance include clinical follow-up
visits (assessment of symptoms, inspection of the ex-
tremity, pulse examination), ABI measurements, and
DUS scan (PSV measurement and velocity ratio). Other
imaging modalities, such as DSA, CTA, and MRA, are
not reasonable for surveillance because of invasiveness,
cost, and limited access as well as exposure to ionizing
radiation and contrast dye and potential risks from the
procedure itself.
Surveillance by clinical follow-up alone may be insufﬁ-
cient to detect restenosis as patients may remain asymp-
tomatic until the target artery has occluded, akin to
bypass grafts. Likewise, ABI measurement alone haslimited value, given the difﬁculty in determining the level
of restenosis, the limitation in diabetics with calciﬁed ves-
sels, and the variability of correlation when there is a drop
in ABI (>0.15) with lesion severity.590,591 The addition of
DUS provides anatomic information using direct visuali-
zation of the vessel as well as physiologic information
based on spectral waveforms, pressure, and velocity
measurements. The combination of PSV and velocity ra-
tio measurements offers high positive predictive value for
identifying moderate and severe restenosis when it is
correlated with angiography.592,593
The value of DUS in a postprocedural surveillance pro-
gram needs to be balanced by the potential harm asso-
ciated with performing unnecessary procedures on
asymptomatic restenotic lesions that may have an other-
wise benign natural history. The cost associated with
maintaining such a program should also be considered.
One strategy is to pursue DUS surveillance at regular in-
tervals (3-6 months) and to consider reintervention for se-
vere recurrent asymptomatic lesions (>70%) before they
progress to complete occlusion. This approach is sup-
ported by data suggesting that restenotic lesions are
markers of subsequent failure.142,594,595
Several studies have shown that reintervention on
occluded lesions brings higher rates of distal emboliza-
tion and subsequent reocclusion in comparison to
intervening on restenotic but patent vessels.596,597
Although these seem to be reasonable incentives for
surveillance, DUS may not identify all of these lesions
before failure; for example, not all angioplasty site reoc-
clusions are preceded by severe restenotic le-
sions.141,598,599 To date, there are inadequate data
demonstrating clinical beneﬁt of a DUS surveillance
program after endovascular intervention for CLTI. Still,
there are likely to be subgroups of patients who may
beneﬁt more than others from close surveillance and
early reintervention. These may include patients who
have experienced multiple failed angioplasties; pa-
tients who have previously undergone failed bypasses
or for whom conduits are unavailable; patients who
had presented with severe ischemia (eg, WIfI grade 3),
unresolved tissue loss, or appearance of new inﬂow le-
sions; and patients with known poor runoff or long
target vessel occlusions that are prone to failure.
Vein and prosthetic bypass grafts. Vein grafts primar-
ily fail when stenotic lesions develop within the venous
conduit or at anastomotic sites of the conduit to the
inﬂow and outﬂow arteries. Stenotic lesions can also
develop in the outﬂow artery remote from the distal
anastomotic site. Approximately one-third of lower ex-
tremity vein grafts develop lesions that threaten graft
patency, and most occur within 2 years of graft place-
ment. Vein grafts are never entirely free of the risk for
development of intragraft or anastomotic stenosis. The
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conduits, with nonsaphenous or spliced venous conduits,
and in grafts with anastomosis to more distal (tibial or
pedal) arteries. Surveillance of lower extremity autolo-
gous vein grafts is based on this natural history and as-
sumes that a patent, hemodynamically uncompromised
reconstruction is optimal for wound healing and limb
viability. Secondary reconstructions for thrombosed
lower extremity vein grafts are technically more complex
and less durable than revision of a failing but patent
bypass.
Vein graft surveillance programs may be solely clinical
or clinical and vascular laboratory based. The TASC II
working group recommended that patients treated
with lower extremity vein grafts be observed for at least
2 years with a surveillance program consisting of an inter-
val history to detect new symptoms, pulse examination,
and measurement of resting and postexercise ABI,
when possible.156 Most vascular laboratory-based surveil-
lance programs focus on DUS detection of stenotic le-
sions within the graft or at the anastomotic sites.
Although there is considerable information on DUS sur-
veillance of lower extremity vein grafts for CLTI, there
are few prospective data.
The Vein Graft Surveillance Randomised Trial (VGST), a
prospective trial from the United Kingdom, random-
ized 594 patients with patent vein grafts 30 days after
surgery to either clinical surveillance or combined
DUS surveillance and clinical surveillance. The majority
of operations (two-thirds) were femoral-popliteal by-
passes for CLTI. Conduits were ipsilateral reversed
saphenous vein in >90%. Thus, technical complexity
of surgery in the VGST may not reﬂect that of open re-
constructions performed for CLTI in the modern endo-
vascular era. At 18 months, the investigators found no
differences in primary, primary assisted, or secondary
patency between the two surveillance strategies.589 A
smaller study from Sweden randomized 156 patients
with lower extremity arterial reconstructions to inten-
sive surveillance, including DUS scanning (n ¼ 79), or
routine clinical surveillance (n ¼ 77). There were 40 pol-
ytetraﬂuoroethylene grafts, equally distributed be-
tween the two groups. Only two grafts in each group
were performed for claudication, and two-thirds were
to the popliteal artery. Among the vein grafts in the
study, there was improved assisted primary and sec-
ondary patency in the intensive surveillance group
that had DUS scanning.585
The beneﬁt of a vein graft surveillance program with
DUS scanning is suggested in large single-institution
case series as well as in one large multi-institution pro-
spective study.79,138,140,600,601 These studies and others
have demonstrated large differences between primary
patency and assisted primary patency of vein graftsmonitored with a DUS-based surveillance program.139
They also demonstrate that electively revised vein grafts
have excellent long-term patency, even comparable to
that of grafts that have never undergone revision. In
contrast, salvage of vein grafts that have already throm-
bosed is associated with markedly reduced secondary
patency. Improved quality of life has been associated
with maintained patency of vein grafts performed for
CLTI.233 Despite these observations, it must be acknowl-
edged that the clinical beneﬁt of DUS-based surveillance
after vein bypass for CLTI is still unclear. A systematic re-
view found low-quality evidence for DUS surveillance of
infrainguinal vein grafts.602
The underlying principle of clinical surveillance of vein
grafts is that recurrence of symptoms, change in pulse
status, or decrease in ABI >0.15 indicates an at-risk graft
that should be considered for revision. It is also sug-
gested that vein grafts with >70% stenosis identiﬁed
by DUS scanning be considered for revision as such le-
sions are unlikely to improve and associated grafts
have an adverse natural history.138,600 These lesions are
deﬁned by an associated PSV of >300 cm/s, a PSV ratio
(deﬁned as PSV at the lesion divided by PSV in a prox-
imal segment) of >3.5, or a midgraft PSV <45 cm/s.
Vein graft stenoses treated with open surgical tech-
niques (patch angioplasty or interposition grafting)
have excellent long-term patency and associated limb
salvage.139 The technical success and short-term patency
of surveillance-detected lesions treated with catheter-
based techniques are high, although long-term data
are lacking. In general, longer lesions and lesions
detected within 3 months of graft implantation are
best treated surgically. Short lesions and those treated
after 3 months of graft implantation may be treated
either surgically or with catheter-based techniques, pri-
marily balloon angioplasty, and possibly with drug-
coated balloons.603,604 With either mode of treatment,
recurrence of stenosis within the vein graft or its anasto-
moses is possible. Thus, continued surveillance after rein-
tervention is indicated to detect recurrent and new
stenotic lesions. After treatment of a vein graft stenosis,
the treated graft should undergo surveillance at intervals
similar to those for primarily placed grafts.139 Treatment
of recurrent lesions in previously revised vein grafts can
also provide continued long-term patency and limb
salvage.139
Long-term patency of infrainguinal prosthetic bypass
grafts is inferior to that of venous bypass grafts. Evidence
as to the efﬁcacy of prosthetic graft surveillance pro-
grams is more inconclusive. In one study, 69 patients
with infrainguinal prosthetic bypasses were assessed by
ultrasound after 4 weeks and every 3 months thereafter
(total follow-up was 3 years).605 The ultrasound examina-
tion appeared to be of limited value, with 12 of 14 failing
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of 118 above-knee prosthetic grafts, most bypass occlu-
sions again occurred without previously detected le-
sions.606 A quarter of patients developed a graft-related
stenosis detected by ultrasound. Successful intervention
of the stenotic lesions was associated with a lower
bypass occlusion rate of 21% at 2 years (vs 41% for the
entire series). Hence, in the authors’ opinion, ultrasound
surveillance was justiﬁed. In another study of 89 grafts
in 66 patients (FP and femorotibial), speciﬁc criteria for
DUS proved predictive for patency of prosthetic tibial by-
passes but not of popliteal bypasses.607 These criteria
included PSV >300 cm/s at graft anastomoses, adjacent
PSV ratio >3.0, uniform PSVs <45 cm/s, and monophasic
ﬂow throughout the graft.
One study sought to describe modes of failure and
associated limb loss after infrainguinal polytetraﬂuoro-
ethylene bypass grafting as well as beneﬁts of warfarin
on graft patency.579 The study involved 121 patients
(86% with CLTI) with 131 infrainguinal (above-knee and
below-knee) bypasses. Of these, 77% of the below-
knee bypasses had anastomotic adjuncts (vein cuff or
patch). Postoperative DUS was performed at 1 month,
4 months, and 7 months and then twice yearly. Multi-
variate analysis showed that low graft ﬂow (midgraft
velocity <45 cm/s) was more commonly associated
with graft failure than stenosis detected by DUS.Recommendations
10.1 Continue best medical therapy for PAD, including the long
term use of antiplatelet and statin therapies, in all patien
who have undergone lower extremity revascularization.
10.2 Promote smoking cessation in all CLTI patients who have
undergone lower extremity revascularization.
10.3 Consider DAPT (aspirin plus clopidogrel) in patients who ha
undergone infrainguinal prosthetic bypass for CLTI for a
period of 6 to 24 months to maintain graft patency.
10.4 Consider DAPT (aspirin plus clopidogrel) in patients who ha
undergone infrainguinal endovascular interventions for
CLTI for a period of at least 1 month.
10.5 Consider DAPT for a period of 1 to 6 months in patients
undergoing repeated catheter-based interventions if the
are at low risk for bleeding.
10.6 Observe patients who have undergone lower extremity vei
bypass for CLTI on a regular basis for at least 2 years with
clinical surveillance program consisting of interval histor
pulse examination, and measurement of resting APs and
TPs. Consider DUS scanning where available.Therapeutic anticoagulation with warfarin increased
patency in patients with low-ﬂow grafts but not in pa-
tients with high-ﬂow grafts.579
A consensus document from Mohler et al608 supports
surveillance of prosthetic reconstructions at baseline
and at 6-month intervals, similar to vein reconstructions.
DUS imaging criteria were recommended for patients af-
ter femoral-femoral bypass grafting, particularly for those
with a PSV >300 cm/s in the inﬂow iliac artery and a
midgraft velocity <60 cm/s predictive of graft failure.609
When DUS-directed intervention was performed,
patency at 5 years (assisted patency) was 88%. Patency
appeared to be improved in comparison to most reports
in the literature of patency without surveillance. DUS sur-
veillance of prosthetic grafts does not reliably detect
correctable lesions that precede failure as it does in
vein bypass grafts. Instead, surveillance may serve as a
predictor of graft thrombosis by the detection of midg-
raft velocities below 45 cm/s. Prosthetic grafts with low
velocity may beneﬁt from warfarin to improve patency,
which may justify surveillance. The use of warfarin was
recommended if the mean graft velocity was below 60
cm/s to reduce the incidence of expanded polytetra-
ﬂuoroethylene bypass graft thrombosis.579 No speciﬁc
recommendations can be made, however, regarding sur-
veillance and reintervention for prosthetic grafts, and this
information can only serve as a guideline.Grade Level of evidence Key references
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1 (Strong) A (High) Hobbs,130 2003
Willigendael,131 2005
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Continued.
Recommendations Grade Level of evidence Key references
10.7 Observe patients who have undergone lower extremity
prosthetic bypass for CLTI on a regular basis for at least 2
years with interval history, pulse examination, and
measurement of resting APs and TPs.
Good practice statement
10.8 Observe patients who have undergone infrainguinal
endovascular interventions for CLTI in a surveillance
program that includes clinical visits, pulse
examination, and noninvasive testing (resting APs and
TPs).
Good practice statement
10.9 Consider performing additional imaging in patients
with lower extremity vein grafts who have a decrease
in ABI $0.15 and recurrence of symptoms or change
in pulse status to detect vein graft stenosis.
Good practice statement
10.10 Offer intervention for DUS-detected vein graft lesions
with an associated PSV of >300 cm/s and a PSV
ratio >3.5 or grafts with low velocity (midgraft
PSV <45 cm/s) to maintain patency.
1 (Strong) B (Moderate) Mills,138 2001
10.11 Maintain long-term surveillance after surgical or
catheter-based revision of a vein graft, including DUS
graft scanning where available, to detect recurrent
graft-threatening lesions.
1 (Strong) B (Moderate) Landry,139 2002
Nguyen,140 2004
10.12 Consider arterial imaging after endovascular
intervention for failure to improve (wound healing,
rest pain) or a recurrence of symptoms to detect
restenosis or progression of pre-existing disease.
2 (Weak) C (Low) Bui,141 2012
10.13 Consider reintervention for patients with DUS-detected
restenosis lesions >70% (PSV ratio >3.5, PSV
>300 cm/s) if symptoms of CLTI are unresolved
or on a selective basis in asymptomatic patients
after catheter-based interventions.
2 (Weak) C (Low) Humphries,142 2011
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Treatment of lower extremity tissue loss both acutely
and in the longer term is complex and mandates a
team approach. Physicians, surgeons, and nurses must
work collaboratively rather than in individual silos of
care.610-612 In these cases, wound healing is protracted,
with the median time to healing ranging from 147 days
for forefoot wounds to 188 days for midfoot wounds
and 237 days for hindfoot wounds.613 The likelihood and
duration of healing are also determined by the presence
of concomitant infection and ischemia.192
The Threatened Limb Classiﬁcation System from the
SVS has been validated in several studies.68-70,164,166 It is
a promising, pragmatic means to assess the likelihood
of morbidity for at-risk legs and to communicate severity.
The structure of the WIfI system is designed using a scale
of none (0), mild (1), moderate (2), or severe (3), similar to
the TNM system in cancer assessment.10,68,69,164 The sys-
tem can be visualized as three intersecting rings of risk,enabling the team to collectively identify which risk is
more dominant at any given time.
Tissue loss-dominant conditions. The primary issue af-
ter revascularization in CLTI is often management of tis-
sue loss (wound healing). Therapy is based primarily on
appropriate débridement, ofﬂoading, and a simple
moisture-retentive dressing strategy.233 Pressure off-
loading is one of the single most important and yet
neglected aspects of therapy. Whereas the total contact
cast remains the gold standard for ofﬂoading nonin-
fected, nonischemic wounds, other techniques may also
be considered, depending on available resources.614,615
More signiﬁcant degrees of tissue loss may require a
strategy of ﬁlling the defect followed by skin graft-
ing.616,617 Once the wound heals and the patient is no
longer “tissue loss dominant,” care then shifts to maxi-
mizing ulcer-free and activity-rich days in diabetic foot
remission.618 This may include protecting the tissue by
external (shoes, insoles, and inﬂammation monitoring)
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and rehabilitation) means.619-622 The role and timing of
foot amputations (eg, digital, forefoot, or midfoot) are dis-
cussed in Section 9.
Ischemia-dominant conditions. The management
and monitoring of ischemia play a central role in healing
as well as in recurrence and involve regular vascular
assessment and monitoring for potential intervention.
Infection-dominant conditions. Infection is often the
primary factor leading to amputation, accentuated by
tissue loss and ischemia. Addressing this triad involves
surgical and medical therapy based on established
criteria. Each member of the wound care team must
work to categorize, stage, and grade the severity of
each component of the “wound triad” initially and at all
follow-up encounters. Appropriate and regular docu-
mentation of the wound status is crucial, including dia-
grams and photographs to document progress. Often,
one or more of these conditions can be found to bemore
“dominant” and can then be targeted for care. These
conditions are dynamic and will change over time. Dur-
ing follow-up, recurrence may be related to tissue loss
(deformity, inappropriate shoes, or change in activity). As
a result, nonhealing may be due to ongoing or recurrent
ischemia, and intervening in the development of an
infection may require additional surgical or medical
intervention.
Level of Key
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pedal wounds.










1 (Strong) A (High) Elraiyah,143 201611. STUDY DESIGNS AND TRIAL END POINTS IN
CLTI
IDEAL: A framework for research
The evidence base underpinning the surgical and
endovascular management of CLTI is weak compared
with that available for coronary interventions and phar-
macologic cardiovascular risk reduction. In addition,
methodologies (phase 1 to 4 trials) that have been suc-
cessfully used by the pharmaceutical industry togenerate level 1 evidence cannot be easily transferred
to the evaluation of revascularization strategies for CLTI,
and so different approaches are required. The Idea,
Development, Exploration, Assessment, and Long-term
study (IDEAL) framework provides a system for evalu-
ating new surgical and interventional therapies that
can be adapted for use in CLTI (Table 11.1).623-627
Recommendation11.1 Use a research framework such as the IDEAL for
gathering new data and evidence on the surgical and
endovascular management of CLTI.Depending on the stage of surgical innovation, the
IDEAL framework describes a wide range of different
methodologies that can be used to provide varying levels
of evidence that serve different purposes. However, once
the assessment stage has been reached, RCTs remain by
far the most reliable means of comparing the clinical
effectiveness and cost-effectiveness of alternative treat-
ment strategies and should be the method of choice
whenever it is practically and ﬁnancially feasible. Funding
of such trials by governmental or professional organiza-
tions to assess existing or new technologies further en-
hances the value of the resulting data by avoiding
actual or perceived commercial sponsor bias. Still, RCTs
have limitations, including cost, long completion times,
potentially incomplete applicability to populations of pa-
tients outside the deﬁned inclusion criteria, and
restricted ability to address epidemiologic study
questions.
As a result, a number of alternative methodologic ap-
proaches are available and can be employed in certain
circumstances.628 For example, large administrative da-
tabases and prospective registries (particularly
population-based ones) have the beneﬁt of relative low
cost, simplicity, and improved external validity, although
they can carry a substantial risk of treatment bias and
confounding. Given that the observed treatments are
typically not randomly assigned but rather chosen on
the basis of a mix of the patient’s characteristics and
the provider’s inclination, reliable comparisons between
dissimilar groups can be a problem. Additional risks
include important sampling errors and improper or
imprecise assignment of causality to a particular
observed end point, although some of these limitations
can be mitigated by employing multivariate analysis.
Still, the increasing use of registries designed to capture
the outcomes of patients with vascular disease reﬂects
their value in identifying trends in practice patterns.
Added value can be found in capturing the experience
of particular subsets of patients undergoing deﬁned
treatments or techniques. However, because registries
are highly dependent on robust follow-up and capture
of detailed information of the patient on a consistent
Table 11.1. IDEAL: Stages of surgical and endovascular innovation for chronic limb-threatening ischemia (CLTI)
Stage 1. Idea 2a. Development 2b. Exploration 3. Assessment 4. Long-term study
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RCT, Randomized controlled trial.
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bias that can paint an unreliable picture with regard to
the clinical effectiveness and cost-effectiveness of a
particular treatment strategy.
Recommendation11.2 Encourage funders, journal reviewers, and editors to
prioritize prospective, multicenter, controlled, and
preferably randomized studies over retrospective
case series, studies using historical controls, or
other less rigorous research methodologies.Objective performance goals OPGs
The SVS Critical Limb Ischemia Working Group devel-
oped a standardized set of outcome measurements,
OPGs, derived from CLTI patients undergoing open
bypass in several RCTs.162 The OPGs include major
adverse limb events (MALE) and postoperative death as
a measure of early safety and AFS to deﬁne longer
term clinical effectiveness. Additional safety and efﬁcacy
OPGs were created for speciﬁc outcome variables of in-
terest, and risk-stratiﬁed guidelines based on clinical,
anatomic, and conduit criteria were identiﬁed for
deﬁned subgroups. The main aim of the OPG initiative
was to establish benchmark values against which novel
endovascular therapies could be initially evaluated
without undertaking full RCTs. However, without good-
quality RCTs, OPGs cannot be refreshed and, over time,will increasingly come to rely on historical controls. As
such, RCTs are still required to determine both the clin-
ical effectiveness and cost-effectiveness once safety and
efﬁcacy OPGs have been met.
Recommendation11.3 When RCTs are not feasible, use the OPG
benchmarks from the SVS’s Critical Limb
Ischemia Working Group to evaluate the efﬁcacy
of novel endovascular CLTI techniques and
devices.RCTs
An appropriately designed RCT remains the optimal
means of providing critical conﬁrmatory evidence before
the widespread adoption of novel interventions.629-631
The paucity of such studies in CLTI,13-15,632 however, un-
derscores the many challenges that aspiring investiga-
tors face, particularly in trying to complete trials on
time and on budget.
Trial design. The adaptive features of a pragmatic trial
design allow investigators greater ﬂexibility with regard
to speciﬁc treatment decisions. They will also generally
lead to results that are more universally applicable,
particularly in time-intensive and laborious studies that
unfold during a period of potentially changing treatment
paradigms. Conversely, a nonpragmatic design can more
deﬁnitively generate supportive evidence for a particular
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direct comparisons within a given revascularization
strategy. One should determine to what degree a
particular study is targeting real-world applicability and
balance the theoretical, statistical, and practical impact
of choosing one design over another.
Inclusion and exclusion criteria. Therapeutic goals can
differ according to whether the CLTI patient presents
with ischemic rest pain only or withminor or major tissue
loss. More important, the goals in all CLTI patients differ
signiﬁcantly from those in patients presenting with IC.
Therefore, it should be clear that it is rarely if ever appro-
priate to combine IC patients and CLTI patients in the
same study. Similarly, it is clearly inappropriate to extrap-
olate data gathered in patients with IC to those with CLTI
and vice versa.
Because CLTI represents a wide spectrum of disease, it
is important that trials describe patients who are
enrolled in terms of limb threat (Sections 1 and 3) and
anatomic burden of disease (Section 5). Amputation
rates are signiﬁcantly higher in patients with tissue loss
than in those with rest pain. This makes the group of pa-
tients with tissue loss a potentially more attractive one
for a study in terms of being able to demonstrate the
clinical effectiveness and cost-effectiveness of a new
intervention with an achievable sample size and within
a realistic time. However, as the severity of tissue loss pro-
gresses, opportunities to detect therapeutic beneﬁt may
begin to decrease as some patients with advanced dis-
ease will inevitably progress to amputation or death
regardless of the intervention provided. As such, the
CLTI patient group, in which there is a real prospect of
showing true beneﬁt for a new intervention, may be
more limited than is often initially appreciated.
Recommendations11.4 To facilitate sufﬁcient enrollment, limit RCT
exclusion criteria to those that are deemed
essential to trial integrity.11.5 Design RCTs, prospective cohort studies, and
registries that are speciﬁc to CLTI.11.6 Use an integrated, limb-based threatened limb
classiﬁcation system (eg, WIfI) and a whole limb
anatomic classiﬁcation scheme (eg, GLASS) to
describe the characteristics and outcomes of CLTI
patients who are enrolled.Outcomes
Efﬁcacy vs effectiveness. It is important to distinguish
between clinical efﬁcacy and clinical effectiveness. Clin-
ical efﬁcacy is the patient beneﬁt observed under ideal
circumstances. Does the procedure work in a selected
group of homogeneous patients when it is performedby a selected group of clinicians? This is best demon-
strated by an explanatory trial. Clinical effectiveness is
the patient beneﬁt observed from a procedure in the
real world. It is best demonstrated by a pragmatic trial.
With regard to CLTI, although the majority of published
(usually industry-funded) trials fall into the clinical efﬁ-
cacy category, the results are often presented and over-
interpreted as if they represent clinical effectiveness. This
has incorrectly led to new treatments being adopted as
the standard of care solely on the basis of limited evi-
dence gathered in highly selected patients and centers.
Types of end points. Most CLTI trial end points can be
broadly divided into the following categories:
1. Objective clinical: AFS, MALEs
2. Subjective clinical: patient-reported outcomes mea-
sures (PROMs), including generic and disease-
speciﬁc HRQL instruments633
3. Hemodynamic: ankle and toe pressures and indices
4. Anatomic: patency; target lesion, vessel, and limb
revascularization
To describe the overall quality of revascularization for
CLTI, RCTs should use a menu of outcomes derived
from all four of the categories (Table 11.2).
It is also important for RCTs to include a full health eco-
nomic analysis for the cost-effectiveness of the compar-
ator interventions to be determined. This is preferably
based on quality-adjusted life-years. It is then up to
each health care system to determine whether and
how such data should be used in relation to individual
“willingness to pay” thresholds, which are typically based
on economic, societal, and political considerations. For
example, in the United Kingdom, bearing in mind the
proportion of gross domestic product that the country
has decided to spend on health care and the Depart-
ment of Health’s agreed social value judgments, the Na-
tional Health Service will not usually fund interventions
that are associated with an incremental cost-
effectiveness ratio in excess of £20,000 per quality-
adjusted life-year. This ﬁgure represents the United King-
dom’s willingness to pay threshold.
Objective clinical outcomes. AFS has been recom-
mended as a suitable primary CLTI efﬁcacy end point
by TASC II, the U.S. FDA, the UK National Institute for
Health and Care Excellence, and the SVS Critical Limb
Ischemia Working Group. It has been used in a number
of CLTI RCTs, including Project of Ex-vivo Vein graft En-
gineering via Transfection III (PREVENT III),634 all three
BASIL trials, and BEST-CLI. As with most end points,
however, AFS has its limitations. For example, AFS does
not distinguish between transfemoral and transtibial
amputation, and because the performance and timing
of amputation can be discretionary and not easily blin-
ded, AFS does not necessarily capture the full clinical
Table 11.2. Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL-2), Balloon vs Stenting in Severe Ischaemia of the
Leg (BASIL-3), and Best Endovascular vs Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI) trial end
points
End points BASIL-2 and BASIL-3 BEST-CLI
Primary AFS MALE-free survival
Secondary Freedom from all-cause mortality
In-hospital and 30-day morbidity and mortality
MALE
MACE
Relief of ischemic pain
Psychological morbidity
HRQL: generic and disease-speciﬁc instruments
Reintervention and crossover intervention rates
Healing of tissue loss (ulcers, gangrene)
Extent and healing of minor amputations
Hemodynamic changes; absolute APs and TPs,
ABI, TBI
HRQL (VascuQoL and EQ-5D)
Health economic analysis
Freedom from all-cause mortality
RAFS
Freedom from MALE and POD
AFS
Freedom from myocardial infarction
Freedom from stroke
Freedom from reinterventions (major and minor) in index leg
No. of reinterventions (major and minor) per limb salvaged
Freedom from hemodynamic failure
Freedom from clinical failure
Freedom from CLTI
HRQL (VascuQoL and EQ-5D)
Health economic analysis
ABI, Ankle-brachial index; AFS, amputation-free survival; APs, ankle pressures; CLTI, chronic limb-threatening ischemia; EQ-5D, EuroQol-5 Dimension
questionnaire; HRQL, health-related quality of life; MACE, major adverse cardiac event; MALE, major adverse limb event; POD, perioperative death;
RAFS, reintervention- and amputation-free survival; TBI, toe-brachial index; TPs, toe pressures; VascuQoL, Vascular Quality of Life questionnaire.
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the severity of pain and use of analgesia, the success of
healing of minor amputations and tissue loss, and the
requirement for reintervention are all important clinical
parameters not characterized by AFS. In addition, its
appropriateness in patients with rest pain only has been
questioned, and as a composite, AFS life tables do not
distinguish between effect of the intervention on limb
salvage and overall mortality. Therefore, whereas it is
reasonable to use AFS and other related composite end
points, such as MALEs, as the determinants of sample
size calculations, they should be accompanied by a
range of single, composite, objective, and subjective
clinical end points.
Subjective outcomes. Given the growing appreciation
of the importance of the patients’ perception of their
treatment experience, incorporating HRQL and PROMs
into trial designs is strongly recommended. A number
of well-validated generic HRQL instruments are now
available in a range of languages. These include the 12-
Item Short-Form Health Survey and the EuroQol-5
Dimension questionnaire as well as more disease-
speciﬁc instruments, such as the Vascular Quality of Life
tool. Some researchers have advocated that future RCTs
be based on anticipated PROMs and HRQL beneﬁts.
Hemodynamic outcomes. Measuring hemodynamic
parameters in CLTI patients can be challenging because
CLTI is deﬁned in part by the hemodynamic conse-
quences of the disease (Section 1). Thus, it is important
to attempt to describe the outcome of various interven-
tions for CLTI in terms of their impact on hemodynamic
measures, including ankle and toe pressures and indices.
Anatomic outcomes. Anatomic outcomes such as
patency have been widely used in regulatory trialsdesigned to obtain premarketing authorizations despite
the well-recognized problematic relationship between
these outcomes and clinical success. The related
outcome measures of clinically driven target lesion and
target vessel revascularization are inappropriate in the
context of CLTI, given the frequency of complex multi-
level disease and the high degree of subjectivity sur-
rounding decisions to reintervene. Patency as an
outcome metric is further limited by the lack of
consensus with regard to deﬁnitions after endovascular
interventions. The role of patency and other anatomic
end points within CLTI trial methodology needs to be
better deﬁned.
Recommendations11.7 Describe outcomes in CLTI trials using a combination of
objective and clinically relevant events, subjective
PROMs and HRQL assessments, and anatomic and
hemodynamic end points.11.8 Require regulatory trials aimed at obtaining premarket
approval for devices for use in CLTI to study CLTI patients
and to present data on objective and clinically relevant
end points, PROMs and HRQL assessments, and
anatomic and hemodynamic end points.Follow-up. Determining the end points as well as the
frequency and time during which they will be collected
will depend on the study aims, design, and budget. Given
the importance of evaluating the impact of comparator
interventions on the natural history of CLTI, a follow-up
period of at least 2 to 3 years is strongly recommended
as it is unlikely that 6-month or 12-month follow-up pe-
riods will provide adequate assessment of clinical
durability.
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proportions or by cumulative outcome estimates using
the Kaplan-Meier analysis. Absolute proportions pro-
vide the most transparent and reliable outcome mea-
sure. Unfortunately, because they evaluate identical
follow-up periods in all participants, they also limit
follow-up to the observation period of the last included
patient. In contrast, cumulative estimates can integrate
variable follow-up periods, thereby avoiding loss of
available information. These estimates, however, are
based on speciﬁc assumptions and are therefore
vulnerable to attrition bias.635,636 Consequently, incom-
plete follow-up might lead to relevant but easily
missed false outcome estimates that can affect study
groups differently.637 To evaluate the risk of attrition
bias, completion of follow-up should be measured
independently of the study design and systematically
declared against a predeﬁned study end date using
the follow-up index or the C index.
Recommendation11.9 Follow up patients in trials for a time
sufﬁcient (this will usually be >2 years) to allow
appropriate comparison of the impact of the
different interventions on the natural history of
CLTI. Measure and declare completeness of
follow-up coverage to quantify risk of attrition
bias.Time-to-event analysis. Given the chronic and recur-
rent nature of CLTI, there is a compelling need to
develop end points that move beyond the historical
paradigm of a simple time-to-ﬁrst-event analysis. End
points such as AFS can reliably capture the centrally
important end-stage events of limb amputation and
death. Likewise, MALE and other end points focused on
reintervention or other patient-related outcomes can
capture the early clinical impact of treatment failure.
Unfortunately, these and other time-to-ﬁrst-event end
points collectively may present an incomplete assess-
ment of the total impact various CLTI treatment stra-
tegies over time.
The primary goal of a time-integrated measure for CLTI
disease severity should be to more accurately assess
long-term relief from commonly occurring multiple
events in a manner that is analogous to disease-free sur-
vival after cancer treatment. Without such a time-
integrated approach, even an otherwise well designed
CLTI trial may prove to be an incomplete and potentially
misleading assessment of overall clinical effectiveness
and cost-effectiveness. As an example, consider two
CLTI patients with ulceration.d Patient 1 has an endovascular intervention that heals
his wound but after 2 months has recurrent symp-
toms and restenosis with a second intervention at 4
months. He develops another recurrence with pain
and two gangrenous digits at 6 months. The patient
subsequently requires a bypass graft at 7 months
and a transmetatarsal amputation of the foot, result-
ing in clinical stabilization for 2 years. Outcomes: no
death; no major amputation; time to ﬁrst reinterven-
tion, 4 months; time to initial healing, 2 months;
time to MALE, 7 months.
d Patient 2 receives a bypass graft that heals his wound
by 3 months. At 7 months, he presents with an asymp-
tomatic graft stenosis and undergoes a surgical revi-
sion (3-cm interposition graft). He remains clinically
stable for 2 years. Outcomes: no death; no major
amputation; time to ﬁrst reintervention/MALE, 7
months; time to initial healing, 3 months.
Patient 1 had clinical recurrences and two reinterven-
tions and spent most of the year with symptoms. Pa-
tient 2 had a prophylactic reintervention and spent
most of the year symptom free. A CLTI trial using
only AFS and MALE as end points would have failed
to differentiate these two notably different clinical
experiences.
Recommendation11.10 Include a time-integrated measure of clinical disease
severity (such as freedom from CLTI) in the CLTI trial
design to describe the total impact of comparator
CLTI interventions.Sample and effect size
CLTI patients who are entered into the “nonactive
treatment” (placebo) group in RCTs often have out-
comes that are better than expected compared with
similar patients who are treated outside of research
conditions. This makes it more difﬁcult to demonstrate
differences in clinical effectiveness and cost-
effectiveness among the comparator interventions for
CLTI. As a result, researchers must avoid the potential
pitfall of basing the power calculation for their trial on
an unrealistically large effect size. It is widely agreed
that it is poor science and unethical to embark on a trial
when there is no realistic prospect of answering the
question being posed. An overpowered trial is equally
undesirable as it is a misuse of resources, and patients
may be disadvantaged by continuing to receive a treat-
ment that is likely of little or no value or even potentially
harmful to them. Despite this understanding, the CLTI
literature is characterized by studies that present highly
94S Conte et al Journal of Vascular Surgery
June Supplement 2019questionable, post hoc, subgroup analyses. To guard
against this, all CLTI protocols along with full statistical
analysis plans should be published in peer-reviewed
journals to allow independent, public, and transparent
scrutiny.
Recommendation11.11 Publish all CLTI trial protocols together with the full
statistical analysis plans in peer-reviewed journals to
allow independent, public, and transparent scrutiny
and to prevent nonreporting of negative trials.Recommendation
11.14 Assess the quality of evidence in CLTI research using
frameworks such as GRADE that consider multiple
certainty domains and are not based solely on study
design.Beyond the pivotal RCT
Given thechallenges inherent inevaluatingthewidearray
of novel endovascular modalities for CLTI, comparative tri-
als of varying size and scope canbeeffective in establishing
the utility of a particular technique, device, or overall revas-
cularization strategy. As described within the OPGs,
focused superiority or noninferiority RCTs can also be
used to test a novel intervention against more established
alternatives, and the safety and efﬁcacy of new technolo-
gies can be effectively studied in a timely fashion. However,
once the pivotal RCTs havebeen successfully completed, it
is important that ongoing surveillance be rigorously under-
taken with the use of well-designed, large, prospective,
observational studies, including disease- or procedure-
based national registries. Of note, some countries require
manufacturers and importers to submit reports of device-
related deaths, serious injuries, or malfunctions to the
appropriate regulatory bodies.
Also important is cooperation among publicly and
industry-funded investigators in designing and perform-
ing RCTs. Currently, this is happening with the BASIL
and BEST-CLI trials, which will serve to facilitate subse-
quent individual patient data analyses, meta-analyses,
and subgroup analyses. Ultimately, this type of data
sharing will provide a powerful framework for reﬁning
OPGs and validating the use of tools to better deﬁne pa-
tient, limb, lesion, and anatomic risk in CLTI patients,
such as WIfI and GLASS.
Recommendations11.12 Conduct postmarketing surveillance data collection
using well-designed, large observational studies
and registries.11.13 Share clinical trial data to allow subsequent
individual patient data analyses, meta-analyses,
and subgroup analyses; updating of OPGs; and
validation of decision-making tools, such as the
WIfI system and GLASS.Strength of recommendation and level of evidence
Multiple methods to systematically assess the quality of
research have been proposed and used by various bodies.
Whereas each method has its advantages anddisadvantages, the continued use of multiple methodolo-
gies that each produces slightly different strengths of
recommendationonanygiven topic leads to inconsistency
andconfusion.Asa result, there is a strongmovementglob-
ally to use the GRADE system as ameans of rating the level
of evidence and thereby deﬁning the appropriate strength
of resulting recommendations.638 The GVG on CLTI also
endorse the use of GRADE. Thus, it is in the best interests
of public and commercial researchers who want their
research to have maximum impact on practice to ensure
that their studies are designed in such a way as to score
well using the GRADE criteria.Research priorities11.1 Design well-constructed RCTs that address clinically
relevant issues regarding the management of CLTI.11.2 Clarify angiosome-based vs indirect tibial
revascularization.11.3 Identify the relative value of endovascular vs surgical
therapy.11.4 Validate speciﬁc anatomic scenarios outlined within
GLASS.11.5 Validate the WIfI system across speciﬁc grade levels.11.6 Develop a reliable, real-time assessment tool for
postintervention foot and wound perfusion.11.7 Develop consensus deﬁnitions of postintervention
patency and standardized patency-based end points
relevant to CLTI interventions and trials.12. CREATING A CENTER OF EXCELLENCE FOR
AMPUTATION PREVENTION
The major causes of amputation are related to diabetes
and CLTI. Of the 200 million people worldwide with PAD,
CLTI affects at least 2% to 3%.1 Whereas revascularization
is the treatment of choice in preventing limb loss, pro-
cedure bias, lack of specialty training, market forces,
and lack of consensus deﬁnitions remain major obstacles
in achieving the best possible outcomes for CLTI care.639
The CLTI patient is particularly complex. Patients with
PAD have an increased risk of CAD and cerebrovascular
disease and an elevated risk of 5-year mortality.640 Histor-
ically, CLTI was primarily sequalee of smoking and a diet
high in saturated fats. However, in the last few decades,
the rise in CLTI has followed the global epidemic of dia-
betes. Because of this changing epidemiology, this sec-
tion focuses mainly on establishing and monitoring
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concepts presented herein can be applied to all CLTI
teams.
Diabetes-related CLTI is only one part of diabetic foot
syndrome, which is a common but complex group of
complications from diabetes. These include neuropathy,
ulceration, Charcot foot, soft tissue and bone infection,
and PAD including CLTI and gangrene. It is well known
that diabetes increases the risk of myocardial infarction by
50% and stroke by 25%; however, the greatest increased
risk is fora footor legamputation.618Diabetic foot syndrome
is also a costly comorbidity representing approximately
one-third of the total cost of diabetes.641 One study found
the mean 1-year cost from a public payer perspective in
the United States to be $44,200.642 Roughly 75% of the
cost was due to inpatient hospitalizations, for which the
average lengthof stay forDFUand lowerextremity amputa-
tion exceeded that of myocardial infarction, stroke, and
diabetic ketoacidosis.643-645
The patient with diabetic foot syndrome has a poor
prognosis. It is frequently associated with loss of quality
of life, work, independence, and income for both the pa-
tient and the primary caregiver. The relative 5-year mor-
tality rate after a lower extremity amputation is a
staggering 70%.646 For patients with DFU, it is 55%; and
for patients with PAD alone, the 5-year relative mortality
rate is 32%.647 Thus, although diabetes is an endocrine
disease, common complications of diabetes are related
to microvascular or macrovascular disease. For this
reason, diabetic foot syndrome should be more appro-
priately thought of as part of the cardiovascular compli-
cations of diabetes.
Many institutions and government agencies have
responded to the growing complexity, options, and sub-
specialization of treating medical conditions by creating
disease-speciﬁc Centers of Excellence. A Center of Excel-
lence is a virtual or physical location with a team of high-
ly skilled experts who are often involved in research and
innovation to advance their ﬁeld.648 Whereas there have
been experts in the ﬁeld of PAD who have opined on
what a Center of Excellence for CLTI, diabetic foot care,
or amputation prevention might encompass, there are
currently no governmental agencies or professional soci-
eties that have established such guidelines.
Center of Excellence. In 2010, building on the work of
the International Working Group on the Diabetic Foot,
three tiers of care were proposed for an amputation pre-
vention teamdbasic, intermediate, and Center of Excel-
lence (Table 12.1).649 The basic model of care is
performed in an ofﬁce setting with a general practitioner,
internist, or endocrinologist and a specialist nurse. An
intermediate model of care is set in a hospital or multi-
disciplinary clinic and consists of various specialists to
heal wounds and to prevent limb loss. This model is
similar to a wound care center in the United States or adiabetic foot clinic in Europe. A Center of Excellence
model is typically found in a tertiary care hospital with a
predetermined team of specialists operating under
clinical practice pathways, policies, and procedures. The
Center of Excellence has advanced diagnostics and can
intervene rapidly to prevent limb loss.
Currently, in many countries, there are no criteria
required to designate oneself a Center of Excellence for
health care. Anyone or any institution can use the termi-
nology, and doing so does not guarantee that excellent
care is being delivered. Based on experience in creating
Centers of Excellence, a set of criteria are proposed to
determine Center of Excellence designation in CLTI and
amputation prevention, as outlined in Table 12.2.
Team setting, components, and function. No single
specialist possesses all the necessary skills to manage
diabetic foot syndrome. Therefore, it is important to
create a team of specialists with the required skills.
Whereas some of the services required to treat CLTI
and to prevent amputation can be performed in the
outpatient setting, many needed services are intensive
and require access to an acute care hospital.
An understanding of the natural history of amputation
in diabetes can assist in determining how to build an
effective team (Fig 12.1).650 Diabetes leads to peripheral
neuropathy, although the timing of its onset is related
to long-term control of blood glucose level. Peripheral
neuropathy leads to unfelt repetitive trauma and in
combination with foot deformity causes DFU.651
Approximately half of these patients have signiﬁcant
PAD with their DFU. Still, more often than not, infection
serves as the ﬁnal event leading up to the
amputation.652
Fitzgerald et al610 described the seven essential skills for
limb salvage teams. These were modiﬁed to identify nine
skills needed for the comprehensive management of dia-
betic foot. Table 12.3 lists the essentials skills as well as the
type of specialist who should be added to the team to
complete a given task. The simplest method to construct
a team for a Center of Excellence is to ensure that each of
these skills is covered by an expert on the team. In addi-
tion, several authors have described an irreducible mini-
mum to the team that includes vascular surgery and
surgical podiatry. These two specialties have been nick-
named the “toe and ﬂow” team.610,649
Team-driven protocols. It is simply not enough tohave a
designated team. The team must be used in an effective
manner, and outcomes should be monitored in a struc-
tured fashion. Fig 12.2 illustrates a useful pathway in
setting up the structure of the team, establishing goals,
and ensuring that the goals aremet. PublishedCPGs from
medical and surgical societies establishbestpractices, but
they are not always feasible for practice in all settings.
Current CPGs exist for PAD in diabetes, diabetic foot
Table 12.1. The three tiers of care for amputation prevention and diabetic foot care centers
Clinical level of care Setting Potential clinicians Role
Basic model of care General practitioner’s ofﬁce,








Close collaboration with a referral
center












Active collaboration with other
departments in the hospital
and extramural facilities













Collects and reports outcomes;
facilitates regional education
Adapted from Rogers LC, Andros G, Caporusso J, Harkless LB, Mills JL Sr, Armstrong DG. Toe and ﬂow. J Am Podiatr Med Assoc 2010;100:342-8.
Table 12.2. Criteria for Center of Excellence designation in chronic limb-threatening ischemia (CLTI) or amputation
prevention
Center of Excellence criteria Description
Multidisciplinary team of specialists Specialists who can surgically andmedically manage PAD and infections and provide the
general or intensive medical care needed for the complex CLTI patient
Protocol-driven care A team that follows written, evidence-based clinical practice pathways, policies, and
procedures
Outcomes monitoring and reporting Establishes a process for data collection and reports that data to the community or in the
literature
Methods of improvement Establishes a process for continual improvement based on outcomes and new
techniques or therapies
Educational resource Serves as an educational resource for the medical community through mentoring,
publishing, and symposia
PAD, Peripheral artery disease.
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ment of the diabetic foot and the Charcot foot, and pre-
vention of diabetic foot problems.158,653-658Whereas these
CPGs can serve as a template, localities are encouraged to
create their own clinical practice pathways speciﬁc to the
facility or system in which they practice.
The clinical practice pathways are used to identify the
team structure and patient ﬂow, when to engage variousmembers, and what to do if the patient is not improving
as expected. Policies and procedures are then created to
assist providers and staff in complying with the pathway.
Quality assurance goals are also created for measurable
policies and procedures. Certain outcomes are self-
explanatory, such as limb salvage rate, whereas others
should be followed to ensure the quality of care deliv-
ered by the Center of Excellence. These can include the
Fig 12.1. The elevating risk of the “stairway to an amputa-
tion” or the natural history of diabetes-related amputa-
tions. (Adapted from Rogers LC, Armstrong DG. Podiatry
care. In: Cronenwett JL, Johnston KW, editors. Rutherford’s
vascular surgery. 7th ed. Philadelphia: Saunders Elsevier;
2010. p. 1747-60.)
Table 12.3. The nine essential skills to prevent amputa-
tions in diabetes and the possible specialty responsible
Essential skills Possible team members




















The ability to perform wound
assessment and staging or









The ability to perform site-speciﬁc
bedside and intraoperative









































Adapted from Fitzgerald RH, Mills JL, Joseph W, Armstrong DG. The
diabetic rapid response acute foot team: 7 essential skills for targeted
limb salvage. Eplasty 2009;9:e15.
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foot wounds, healing percentage, and quality of life mea-
sures. Table 12.4 lists the most important measurable
outcomes for limb salvage and their calculation. These
data may not always be easy to track. Existing electronic
health record systems are lacking in their ability to track
and to report most of these or other custom measures.
Centers of Excellence often resort to developing their
own software or keeping track of data manually in
spreadsheets.
Finally, performance improvement plans must be
drafted and initiated when the quality assurance goals
are not met. Fig 12.3 shows an example of how this system
would be applied to vascular disease screening in DFUs.
Team impact. In 2005, the World Health Organization
and the International Diabetes Federation declared
that up to 80% of diabetes-related amputations are
preventable.660,661 Currently, the only intervention to
address this has been the formation of multidisciplinary
teams to prevent unnecessary amputations. In fact, the
multidisciplinary team to prevent diabetes-related am-
putations dates back to at least 1934, when Elliott P.
Joslin, an endocrinologist in Boston, established his team
to treat diabetic gangrene.662
In the United States, an organized team in a public hos-
pital reduced lower extremity amputations 72% during 2
years. In the Veterans Affairs medical centers, several fac-
tors were signiﬁcant in the reduction of lower extremity
amputations, including use of a specialized team and
establishment of a high-risk foot clinic.663,664 In a military
medical center, amputations were reduced by 82% as a
result of a specialized limb preservation service.665
Another report showed a reduction improvement in
diabetes-related foot outcomes with an integrated inter-
disciplinary team in a large academic medical center.666
In several other studies, adding podiatry to the team was
found to be helpful in reducing amputations andsigniﬁcantly reducing the cost associated with diabetic
foot.641,663,667,668
The impact of a limb salvage team is not limited to any
geographic area. In The Netherlands, investigators re-
ported a 34% nationwide reduction in amputations after
setting up multidisciplinary teams.669 In Brazil, the
Fig 12.2. A schematic on how to organize the diabetic foot
care within a multidisciplinary team.
Table 12.4. Major outcome measures for chronic limb-
threatening ischemia (CLTI) and amputation prevention
Quality assurance
measure Calculation
Limb salvage rate No. of total patients  No. of major
amputations (BKA or AKA)
No. of total patients
Major to minor
amputation ratio
No. of major amputations performed
(BKA or AKA)




No. of wounds healed




No. of DFUs healed
Total No. of DFUs  palliative care
patients
Median days to heal,
all wounds
Calculate days to heal for all wounds.
Exclude amputated and palliative care
patients.
Median days to heal,
DFUs
Calculate days to heal for all DFUs.




No. of NIVSs performed




No. of open bypass patients  No. of
open bypass failures




No. of endovascular patients  No. of
endovascular failures
No. of endovascular patients
AKA, Above-knee amputation; BKA, below-knee amputation; DFUs,
diabetic foot ulcers; NIVSs, noninvasive vascular studies.
Palliative care patients are deﬁned as those in whom healing is not the
treatment goal, that is, terminal or hospice patients.
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wide is leading to improved care.670 In Italy, investigators
reported a reduction in hospitalizations and amputa-
tions in the diabetic foot after implementing a multidis-
ciplinary referral team.670,671 In Spain, a multidisciplinary
foot team reduced amputations during 3 years
compared with the previous 6 years.672 The United
Kingdom has also seen reduced amputations secondary
to better-organized diabetic foot care with specialized
clinics that follow multidisciplinary care pathways and
protocols.673,674 Lastly, in Finland, a decrease in major
amputations was correlated with rising interest in limb
salvage and an increase in distal vascular procedures.675
In a subsequent study, researchers reported a reduction
in amputations and length of stay when inpatient care
was reorganized.676
Summary. Centers of Excellence can be implemented
with a well-organized team approach to diabetic foot
syndrome and, in particular, the foot with CLI. Creating
an integrated team whose primary focus is limb
salvage and that receives all referrals for suspected CLTI
is key. Teams can improve processes, time to inter-
vention, and outcomes. The setting and structure of the
team will ultimately depend on the availability and
local need. However, to be most successful, Centers of
Excellence should have team members who are
capable of performing the nine essential skills as out-
lined in Table 12.3.
Centers of Excellence have published pathways and
policies and procedures to determine the function and
involvement of various members. Equally important to
setting up the team is measuring the Center’s perfor-
mance. This is best accomplished with concrete quality
assurance goals and the implementation of aperformance improvement plan to be used when these
goals are not met.
13. GLOBAL PERSPECTIVES IN CLTI
The preceding sections of this guideline make recom-
mendations regarding the diagnosis and treatment of
CLTI based on data published in peer-reviewed journals
and, where such data are lacking, consensus expert
opinion. Vascular specialists managing CLTI across the
globe serve the needs of diverse communities and cul-
tures, working within a wide range of health care envi-
ronments. Most vascular specialists will strive to keep
up to date with the published evidence base and are
greatly facilitated in doing so through the use of mod-
ern information technology systems. However, the real-
ity is that most publications on CLTI are written in
English, and the data contained therein
Fig 12.3. An example of using the organized care model for peripheral artery disease (PAD) screening in diabetic
foot ulcers (DFUs). CPG, Clinical practice guideline; CPP, clinical practice pathway; P&P, policies and procedures;
PI, performance improvement; QA, quality assurance.
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mainly HICs (western Europe, North America, Japan),
that have mature, well-resourced health and social
care systems as well as clinical research infrastructure.
Most vascular specialists treating patients with CLTI do
not, of course, work in such favorable environments. As
such, they often have to adapt foreign “evidence-based
recommendations” to their own particular situation to
provide the best possible care to their patients with
the resources available. The GVG authors recognize
this and, speciﬁcally, that some of the recommenda-
tions contained within this guideline are likely to remain
aspirational for many vascular specialists working in
diverse health care settings across the globe. The au-
thors therefore thought it important to examine the
state of CLTI care from a broader perspective. To that
end, a questionnaire enquiring about the presentation,
diagnosis, and management of CLTI was sent to
vascular specialists (n ¼ 50) working in a range of lower,
middle, and higher income countries. This sectionprimarily comprises a description of the responses
received (n ¼ 22), supported by published locoregional
data where available. The authors and the Steering
Committee of the GVG appreciate and recognize these
contributors for providing survey responses for this Sec-
tion (Table 13.1).
Whereas the information provided may not be consid-
ered the highest quality from an epidemiologic perspec-
tive, a number of important global issues emerged from
the responses. This brief overview highlights the urgent
need for better data on the impact of CLTI and how it
is managed around the world. The majority of responses
derive from a few key opinion leaders from Latin Amer-
ica, Asia, and Africa; thus, the following discussion may
not reﬂect concerns of other populations, providers,
and nations.
Deﬁnition and classiﬁcation. Clinical criteria, history,
and examination are the mainstays of CLTI diagnosis
across the world, with the use of adjunctive
Table 13.1. Contributors
Country Name Afﬁliation
Argentina Dr Juan Esteban Paolini President, Argentine Association of Angiology and Cardiovascular
Surgery, Caba
Brazil Dr Tulio Pinho Navarro Vascular and Endovascular Surgery, Belo Horizonte-MG
China Dr Jinsong Wang Vascular and Endovascular Surgery, Guangzhou, Guangdong
Colombia Dr Alberto Munoz Vascular and Endovascular Surgery, Bogota; Secretary General,
WFVS-ALCVA (Latin American Society for Vascular Surgery and
Angiology)
Costa Rica Dr Roger Jimeìnez Juaìrez Vascular and Endovascular Surgery, San Jose
Cuba Dr Alejandro Hernandez Seara National Institute of Angiology and Vascular Surgery, Havana
Ecuador Dr Victor Hugo Jaramillo Vergara Chief of Vascular Surgery Department, Hospital Carlos Andrade
Marín, Quito
El Salvador Dr Andres Reynaldo Hernandez Morales Vascular Department Chairman, Institute Salvadorien del Seguro
Social
India Dr Varinder Bedi Head of Department of Vascular and Endovascular Surgery, Sir
Gangaram Hospital, New Delhi
India Dr P. C. Gupta Head of Department of Vascular and Endovascular Surgery, CARE
Hospital, Hyderabad
India Dr Kalkunte R. Suresh Jain Institute of Vascular Sciences, Bangalore
Japan Dr Tetsuro Miyata Professor, Vascular and Endovascular Surgery, Tokyo
Malaysia Dr Yew Pung Leong Vascular and endovascular surgeon, The Vascular Centre, Sunway
Medical Centre, Kuala Lumpur
Mexico Dr José Antonio Muñoa Prado Vascular and Endovascular Surgery, Chiapa
New Zealand Dr Thodur Vasudevan Vascular surgeon; Chair, Board of Vascular Surgery, Waikato
Hospital, Hamilton
Paraguay Dr Agustin Saldivar Orrego President of Paraguayan Society of Angiology and Vascular Surgery
Peru Dr Fernando Batista Sanchez Vascular and Endovascular Surgery, Lima
South Africa Dr Martin Veller Dean, Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg
Spain Dr Melina Vega de Ceniga Senior consultant, Angiology and Vascular Surgery, Hospital de
Galdakao-Usansolo, Bizkaia
Sri Lanka Dr Mandika Wijeyaratne Consultant vascular surgeon, Colombo
Tanzania Dr Zulﬁqarali G. Abbas Consultant physician, Dar es Salaam; Chairman, Pan-African
Diabetic Foot Study Group; Vice President, D-Foot International
Uruguay Dr Marcelo Diamant President of ALCVA (Asociación Latinoamericana de Cirugía
Vascular y Angiología); vascular and endovascular surgeon
All the respondents are vascular surgeons.
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ing to be highly variable. ABI testing was used by all
except one respondent. However, although all respon-
dents regularly dealt with diabetic vascular disease
and the acknowledged limitations of APs in that
setting, only two used TPs; none used TcPO2 routinely.
All (except one who exclusively used WIfI) used either
the Fontaine or Rutherford classiﬁcation for staging,
approximately in equal numbers. About one-third of
respondents described employing WIfI in addition to
another clinical classiﬁcation system. In summary,
therefore, across most of the world, there appears to be
limited adherence to any one published deﬁnition or
staging system for CLTI.Epidemiology and risk factors. Although accurate
country-speciﬁc epidemiologic data are sparse, there
seems little doubt that the increasing prevalence of DM
(Fig 13.1) together with the growing use of tobacco and
population aging is resulting in a signiﬁcant increase in
CLTI and amputations across much of the world, espe-
cially in LMICs.677
In 2013, Fowkes et al1 undertook a meta-analysis of 34
studies to compare the prevalence and risk factors be-
tween HICs and LMICs. This is well outlined in Section 2
of this document, but it is worth recalling some of the
key presented data. They concluded, “Globally, 202
million people were living with peripheral artery disease
in 2010, 69.7% of them in LMIC, including 54.8 million in
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gion. During the preceding decade, the number of indi-
viduals with peripheral artery disease increased by
28.7% in LMIC and 13.1% in HIC. Also of note is the per-
centage of increase of PAD is higher in women than
men in LMIC which is opposite of HIC.” The increase in
PAD burden observed in women and in the younger,
economically productive age groups is especially worri-
some (Table 13.2).
The data on country-speciﬁc incidence of PAD and CLTI
are sparse in these LMICs, unlike in HICs. There are no
relevant epidemiologic data from large regions, but the
updated data from Abbas are tabulated for perspective,
reﬂecting PAD in diabetics in sub-Saharan Africa
(Table 13.3).
Lacking ﬁrm epidemiologic data, recent estimates of
CLTI prevalence have used extrapolations from demo-
graphic and other available disease prevalence data,
yielding global estimates of between 20 and 40 million
individuals afﬂicted. About two-thirds of these are pro-
jected to be in LMICs. Unfortunately, documented data
to support this are difﬁcult to ﬁnd in any indexed, peer-
reviewed journals.
According to the survey respondents, the risk factors for
CLTI in their regions are largely as expected, but DM is a
predominant cause, more than in HICs. The prevalence
reported by respondents varied from 40% to 90%. Inter-
estingly, a cultural preference for walking barefoot or a
lack of appropriate footwear is a signiﬁcant problem in
some countries. Approximately 60% to 80% of all the
PAD patients seen by the respondents present with
CLTI. The average age was around 65 years, and about
70% were men. Most respondents reported that 70%
to 100% of CLTI patients presented with tissue loss; in
three countries, it was <50%. Primary amputation was
performed in 10% to 40% of CLTI patients, this being
mainly (25%-90%) because of delayed presentation or
referral. Only two countries reported a primary amputa-
tion rate of <10%. Postprocedural amputation rates
were reported at around 5% to 10%, although two coun-
tries reported much higher rates (60%-70%) because of
late presentation or aggressive disease patterns
encountered.
Diagnostic evaluation. DUS appears to be used almost
universally, although three respondents preferred to pro-
ceed directly to other imaging modalities. Only ﬁve re-
spondents performed DSA as their primary imaging
modality. The remainder opted for MRA and CTA in
about equal numbers. In patients with renal impairment,
DSA was preferred by most, with half opting for iodin-
ated contrast agents with appropriate renal protection
measures and the other half favoring CO2 angiography.
Two respondents performed only noninvasive testing in
such patients before intervention.Medical and noninterventional management (with or
without revascularization). Respondents reported wide-
spread routine use of antiplatelet and lipid-lowering
agents. ACEIs, vasoactive drugs (such as cilostazol and
pentoxifylline), and anticoagulants were used selectively.
IV prostanoids and vasodilators were used by some as
adjuncts to revascularization and in those with non-
reconstructible disease. Use of arterial assist devices
(compression pump), HBOT, and SCS was uncommon.
Lumbar sympathectomy was performed by a third of
respondents, possible in patients with Buerger's disease
(not speciﬁed).
Anatomic classiﬁcation, risk stratiﬁcation, and pre-
dictors of limb salvage. The almost uniform answer to
the question How satisﬁed are you with present systems?
was “somewhat satisﬁed.” Interestingly, only six respon-
dents used TASC to inform decisions about revasculariza-
tion strategies and procedures in patients with CLTI.
There was strong support for a new approach to patient
and limb risk stratiﬁcation and for a new anatomic clas-
siﬁcation system.REVASCULARIZATION
Although, overall, there has been a shift toward endo-
vascular intervention, there is considerable variation in
practice across the respondentsdvarying from 5% to
80% for both endovascular and “open” procedures! All
stated that the preferred conduit for both above-knee
and below-knee bypass continues to be autogenous
vein. Prosthetic grafts are used selectively above the
knee, but none advocate their use for distal bypass.
None of the respondents endorsed “routine stenting” in
the femoral-popliteal region, and all endovascular op-
tions (balloon angioplasty, DCB, stenting) are used selec-
tively. Balloon angioplasty is preferred for endovascular
intervention in infrapopliteal vessels; four respondents
selectively use DCB, but none were in favor of stents
below the knee.
Postprocedural surveillance and follow-up. All the re-
spondents said they had deﬁned follow-up protocols
for patients undergoing infrainguinal revascularization.
All patients (surgical and endovascular) are observed at
least every 3 months for a year and then at variable in-
tervals thereafter. Clinical evaluation and ABI are the
mainstays of surveillance. Use of other noninvasive
methods (PVR, DUS) is variable. Speciﬁc protocols for
vein and prosthetic bypass grafts seem to be standard-
ized per available data in a minority of centers. Approach
to surveillance-detected lesions is similarly variable but
mostly dictated by the patient’s symptoms rather than
by the result of physiologic testing. Arteriography is
reserved for clinically signiﬁcant lesions. Postprocedural
drug therapy, for example, with antiplatelet and
Fig 13.1. International Diabetes Federation global diabetes projections. (From the International Diabetes Feder-
ation. IDF diabetes atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.)
Table 13.2. Estimated number of people living with pe-
ripheral artery disease (PAD)
Age, years
Rate of change (%), 2000-2010
HICs LMICs Worldwide
25-29 3.02 11.91 10.34
30-34 1.52 7.62 5.82
35-39 4.12 22.49 16.19
40-44 3.28 32.05 22.59
45-49 7.14 25.83 20.51
50-54 12.15 42.40 32.37
55-59 31.31 55.53 47.49
60-64 16.85 29.90 25.06
65-69 4.90 20.29 14.35
70-74 8.02 29.73 20.05
75-79 11.68 41.36 26.75
80-84 51.98 45.77 48.92
85-89 34.80 47.86 39.84
$90 37.22 58.82 44.09
Total 13.08 28.67 23.51
HICs, High-income countries; LMICs, Low- and middle-income
countries.
Adapted from Fowkes FG, Rudan D, Rudan I, Aboyans V, Denen-
berg JO, McDermott MM, et al. Comparison of global estimates of
prevalence and risk factors for peripheral artery disease in 2000
and 2010: a systematic review and analysis. Lancet 2013;382:
1329-40.
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published recommendations. Because most CLTI pa-
tients had tissue loss, almost all the centers provided
intensive wound services within their department as part
of a multidisciplinary team approach. Nearly all agreed
that wound infection is a signiﬁcant determinant of
outcome after revascularization and possible cause of
amputation even after successful revascularization.
Health economics. CLTI has a serious adverse eco-
nomic impact on patients, their families, and wider com-
munities right across the world but especially so in
LMICs. Although these countries are often grouped
together, the division betweenmiddle income and lower
income is variable and imprecise. Furthermore, there is
often considerable inequality within each LMIC, and re-
spondents reported that most patients with CLTI (30%-
90%) appear to come from the poor socioeconomic
backgrounds. The following data from the Indian Na-
tional Sample Survey Ofﬁce could represent the situation
in many LMICs678:
1. Only 18% of the urban population and 14% the of rural
population are covered by some form of health
insurance.
2. Governmental health expenditure is <2% of gross do-
mestic product overall.
Table 13.3. Prevalence (%) of peripheral artery disease
(PAD) in diabetics
Country 1990-2000 2000-2010 2010
Benin NA NA 42
Ethiopia 11.6 NA NA
Ivory Coast NA NA 22
Malawi 15 NA NA
Nigeria NA 54 52
South Africa 10.2 8.2 30
Sudan 10 NA NA
Tanzania 12.5 21 26
Uganda NA NA 39
Zambia NA NA 41
NA, Not available.
Adapted from Abbas ZG, Archibald LK. Recent international develop-
ment: Africa. In: Boulton AJ, Cavanagh P, Rayman G, editors. The foot in
diabetes. 4th ed. Hoboken, NJ: John Wiley & Sons; 2006. p. 379-385).
Updated by Dr Abbas (Tanzania) with review of regional data and
literature.
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come or savings” (68%) and “borrowings” (25%) to
fund hospitalization expenses.
4. Around 1% of the poor in rural areas have to sell their
physical assets to meet health expenditure, and >5%
seek help of friends and relatives. This is also in line
with earlier studies showing that millions are pushed
into poverty each year by medical expenditure and
that such expenses are among the leading causes of
indebtedness among the poor.
5. In cities, people rely much more on their income or
savings (75%) than on borrowings (18%) to fund
their treatment. Previous studies have repeatedly
shown that India has one of the most privatized
health care systems in the world, with out-of-
pocket expenses accounting for the bulk of medical
spending.
In India, the cost of IP bypass is U.S. $1500 to $3000, and
costs of balloon angioplasty are similar. The use of a stent
or DCB would add another U.S. $500 to $1000, and
wound care adds at least U.S. $500. Such out-of-pocket
expenses are probably unaffordable for most CLTI pa-
tients. Importantly, these costs depend on recycling of
single-use devices like sheaths, angioplasty balloons, and
guidewires. Without such practice, the cost would in-
crease by at least 50%, and far fewer patients, especially
poorer ones, would have access to treatment, resulting
in much greater loss of life and limb. Recycling of single-
use devices (not just vascular devices) is common in
Asia, Africa, Latin America, and eastern Europe, and proper
regulation of the practice, including appropriate consent
procedures, is important to mitigate patient harm.679
Summary of global perspectives. Based on the re-
sponses to the questionnaire and the limited publishedand unpublished data at times, we can draw the
following conclusions.
1. CLTI is a signiﬁcant and increasing global problem,
especially in LMICs, where the incidence in women
appears to be rising more quickly than in men.
2. Diabetes and unabated smoking are the major causes
of CLTI globally.
3. Although vascular specialists try to follow the pub-
lished evidence base, economic and social constraints
mean that the approach to CLTI must to tailored to
the working environment.
4. CLTI and diabetic foot problems are associated with
high amputation rates in LMICs because of delayed
presentation and referral and limited access to afford-
able care.
5. Economic constraints are an important limitation in
the adoption of advanced vascular technologies, and
practical issues such as recycling of single-use devices
require oversight from a public health perspective.
6. Few countries maintain national registries or other
CLTI data sets.
7. Most countries do not have a standardized approach
to CLTI, with considerable locoregional variation in
practice.
8. Most countries do not have well-organized and sup-
ported vascular societies where best practice and
research can be shared and disseminated.Dissemination and implementation. A large number
of vascular specialists from around the world have
contributed to the GVG, and that global involvement
sets the present guideline document apart from all pre-
vious consensus statements. The paradigms and tools,
such as WIfI, PLAN, and GLASS, set out in the GVG will,
it is hoped, meet the needs of the global vascular com-
munity as expressed by our questionnaire respondents.
However, some guideline recommendations will not be
achievable by vascular specialists working in LMICs. The
GVG recommendations should not, therefore, be viewed
as an inﬂexible global “standard of care.” Following pub-
lication, it will be important to disseminate the GVG as
quickly and widely as possible, simultaneously through
a range of different channels, and to obtain validation
and feedback from the global community. Dissemina-
tion will be assisted by publication of the full GVG as a
supplement to the Journal of Vascular Surgery and Euro-
pean Journal of Vascular and Endovascular Surgery, pub-
lication of an executive summary with the
recommendations in a range of other journals in a num-
ber of different languages, presentations at conferences,
and free online access to the documents linked from so-
cieties’ web pages.
ADDENDUM
As this guideline goes to press (April, 2019), the safety of
paclitaxel-eluting devices for the treatment of peripheral
arterial disease has come under intense scrutiny. The
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this issue to the vascular community, has unanimously
approved the statement below. Given time constraints,
this statement was not reviewed by the entire GVG
Writing Group. This statement was approved by the three
major sponsoring societies (ESVS, SVS, WFVS).
STATEMENT ON THE SAFETY OF
PACLITAXEL-ELUTING DEVICES FOR THE
TREATMENT OF CLTI
Recently the safety of paclitaxel (PTX)-eluting devices
for the treatment of patients with peripheral arterial dis-
ease (PAD) has come into question. A meta-analysis of
randomized controlled trials investigating these devices
in the femoral and/or popliteal arteries identiﬁed an
increased mortality at two years and beyond in patients
treated with the PTX devices versus controls.680 These tri-
als largely enrolled patients with intermittent claudica-
tion, with a small minority (11%) being within the
spectrum of CLTI. Ongoing efforts from regulatory bodies
and other independent groups seek to further clarify the
validity of these observations. In the interim the US Food
and Drug Administration has urged caution in the use of
PTX devices for treatment of PAD.
The GVG Steering Committee believes that the risks
and beneﬁts of treatments for CLTI, including drug-
eluting devices, need to be examined with appropriately
controlled, prospective studies that are speciﬁc to the
CLTI population. In this regard, the execution of random-
ized controlled-trials involving PTX-eluting devices in
CLTI, with appropriate safety monitoring and regulatory
oversight, are important to the vascular community.
Such trials should incorporate appropriate informed con-
sent discussions with subjects, including the potential
increased risk of mortality, and should mandate long-
term follow-up for at least 2 years. Outside of such trials,
given the indeterminate risk and efﬁcacy of these devices
in patients with CLTI, and the availability of alternative
modalities, we believe appropriate caution should be
exercised.
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Recommendations 1.1 and 1.2








by computer and was
prestratiﬁed for the presence
of DM and bilateral symptoms
of CLI.
No signiﬁcant difference was seen in
terms of pain score, number of
amputations, or death.
Wang,2 2016 Noninvasive screening tests for
the prediction of wound
healing and the risk of
amputation in DFUs
Various tests Various tests Systematic review and meta-
analysis of 37 observational
studies
For the TcPo2 test, the pooled DOR
was 15.81 (95% CI, 3.36-74.45) for
wound healing and 4.14 (95% CI,
2.98-5.76) for the risk of
amputation. ABI was also
predictive but to a lesser degree of
the risk of amputations (DOR, 2.89;
95% CI, 1.65-5.05) but not of wound
healing (DOR, 1.02; 95% CI, 0.40-
2.64). It was not feasible to perform
meta-analysis comparing the
remaining tests. The overall quality
of evidence was limited by the risk
of bias and imprecision (wide CIs
due to small sample size).
Brownrigg,3 2016 Prognostic markers
in the prediction
of wound healing or
amputation among patients
with foot ulcers in DM
Various tests Various tests Systematic review and meta-
analysis of 11 observational
studies on 9 markers of PAD
Skin perfusion pressure $40 mm Hg,
TP $30 mm Hg (and $45 mm Hg),
and TcPo2 $25 mm Hg were
associated with at least a 25%
higher chance of healing. AP <70
mm Hg and ﬂuorescein toe
slope <18 units each increased the
likelihood of major amputation by
around 25%.








The AFS at 12 months was 87%, 81%,
81%, and 62% in the very-low-risk,
low-risk, moderate-risk, and very-
high-risk groups, respectively (P ¼
.106). The difference was
statistically signiﬁcant between the
very-low-risk and high-risk groups
(HR, 3.4; 95% CI, 1.1-10.3; P ¼ .029).
Ward,5 2017 93 patients who presented to a
public hospital with CLI
The prognostic value
of WIfI
None Retrospective adjusted analysis On multivariable analysis, increasing
WIfI amputation score (OR, 1.84;
95% CI, 1.0-3.39) was associated
with increased risk of 1-year major
amputation rate.






None Retrospective adjusted analysis WIfI mean score was predictive in the
entire cohort (HR, 1.4; 95% CI, 1.1-1.7),
the bypass-only cohort (HR, 1.5; 95%
CI, 1.1-1.9), and the endovascular-
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Recommendations 3.4, 3.5, and 3.6
Lijmer,7 1996 441 patients with suspected PADNoninvasive tests for
assessing PAD
None Retrospective adjusted analysis
with blinded readers
For assessing PAD (lesions $50%),
determining an ABI is justiﬁed
(ROC area, 0.95 6 0.02). For disease
localized to the AI segment,
performing a single test, the
femoral pulsatility index, is
sufﬁcient (ROC area, 0.80 6 0.04).
For disease including the FP and IP
segments, a combination of tests is
necessary.







A strong association was found
between DM and high ABI (OR,
16.0; P < .001). When ABI ranges
were compared with TBI and Pk-PT
results, those with ABI #0.9 and
ABI $1.4 presented similar patterns
of abnormalities. Pk-PT or TBI or
both were abnormal in >80% of
cases in both ABI #0.9 and $1.4
groups. The ABI vs TBI relationship
appeared linear in nondiabetic
patients but had an inverted J
shape in diabetic patients,
suggesting that high ABI masked
leg ischemia.
Saluan,9 2018 556 patients from
the Cohorte des Patients
ARTériopathes hospitalized for
PAD. Patients with CLI were
enrolled according to the
TASC II deﬁnition and followed




AP, systolic TP, and
forefoot TcPo2
3 comparative tests The cohort selection was
considered adequate
(consecutive sampling) and
low risk for selection bias, but
outcome assessment was not
adjusted or blinded.
AP failed to identify 42% of patients
with CLI. After 1 year, 27% of
medical and 17% of surgical
patients had undergone major
amputation. TP <30 mm Hg
predicted major amputation in the
whole sample and in the medical
group (OR, 3.5 [1.7-7.1] and 5 [2-12.4],
respectively), but AP did not.
TcPo2 <10 mm Hg also predicted
major amputation (OR, 2.3 [1.5-3.5]
and 3.8 [2.1-6.8]). The best
predictive thresholds for major
amputation were systolic TP <30
mm Hg and TcPo2 <10 mm Hg.
None of these methods performed
before surgery was able to predict
outcome in the revascularized
patients.
Recommendations 3.7 and 3.8
Larch,10 1997 50 patients with FP obstruction
were examined immediately
before planned PTA
Color DUS DSA Consecutive sample, 2 readers,
cross-sectional design
The sensitivity of color DUS for
detecting a hemodynamically
relevant arterial lesion (stenosis or
occlusion) was 100% in the PT
artery, 78% in the AT artery, and
92% in the peroneal artery.
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Visser,11 2000 31 diagnostic studies Gadolinium-
enhanced MRA
Color-guided DUS Diagnostic meta-analysis,
medium risk of bias, adjusted
analysis
Pooled sensitivity for MRA (97.5%;
95% CI, 95.7%-99.3%) was higher
than that for DUS (87.6%; 95% CI,
84.4%-90.8%). Pooled speciﬁcities
were similar: 96.2% (95% CI, 94.4%-
97.9%) for MRA and 94.7% (95% CI,
93.2%-96.2%) for DUS.
Adriaensen,12 2004 73 patients with symptomatic
PAD
CT DSA Randomized, unblinded Further imaging was recommended
more often after CT than after DSA
(P ¼ .003). Analysis of trends
demonstrated increasing
conﬁdence in CT and stable
conﬁdence in DSA.
Collins,13 2007 Symptomatic lower limb PAD DUS MRA and CTA Systematic review and meta-
analysis of 113 observational
studies of moderate quality
For the detection of stenosis >50% in
the whole leg, MRA (14 studies) had
the highest diagnostic accuracy,
with sensitivity ranging from 92%
to 99.5% and speciﬁcity from 64%
to 99%. CTA (7 studies) was slightly
inferior to MRA, with a sensitivity
ranging from 89% to 99% and
speciﬁcity from 83% to 97%, but
better than DUS (28 studies), which
had a sensitivity ranging from 80%
to 98% and speciﬁcity from 89% to
99%.
Hingorani,14 2004 33 inpatients with chronic lower
extremity ischemia




No differences were noted between
intraoperative ﬁndings and
arteriography. Two of the 3
differences between duplex
arteriography and contrast
arteriography were thought to be
clinically signiﬁcant, whereas 9 of
the 12 differences between MRA
and contrast arteriography were
thought to be clinically signiﬁcant.
On the basis of these data in this
series, MRA does not yet seem to
be able to obtain adequate data on
IP segments, at least not for this
highly selected population. When
severe tibial calciﬁcation or very low
ﬂow states are identiﬁed, contrast
arteriography may be necessary for
patients undergoing duplex
arteriography.






Contrast arteriography Consecutive series, comparative,
nonrandomized, low risk of
bias overall
Additional contrast arteriography
imaging was required for
procedural planning in 102
patients. The areas not visualized
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popliteal (17), and IP (221). Factors
associated with increased need to
obtain contrast arteriography
included DM (P < .001), IP
calciﬁcation (P < .001), older age
(P ¼ .01), and limb-threatening
ischemia (P < .001).
Met,16 2009 957 patients with IC or CLI CTA DSA Systematic review and meta-
analysis of 20 nonrandomized
studies of moderate quality
The sensitivity of CTA for detecting
>50% stenosis or occlusion was
95% (95% CI, 92%-97%), and
speciﬁcity was 96% (95% CI, 93%-
97%). CTA correctly identiﬁed
occlusions in 94% of segments, the
presence of >50% stenosis in 87%
of segments, and absence of
signiﬁcant stenosis in 96% of
segments.
Recommendation 4.1
The Study Group of Critical
Chronic Ischemia of the
Lower Extremities,17 1997
522 patients with chronic CLI Various predictors None Prospective observational study
with linkage to census
information, unblinded
Besides age $70 years (RR, 1.94; 95%
CI, 1.37-2.70), only a history of stroke
(RR, 1.82; 95% CI, 1.19-2.79) and








None Prospective observational study,
consecutive sample
Multivariate analysis conﬁrmed the
independent role of age, history of
stroke, renal insufﬁciency, and
dialysis. Combined treatment with
ACE and statin appeared to reduce
mortality.
Armstrong,19 2014 739 patients with claudication or
CLI who underwent diagnostic
or interventional lower
extremity angiography











low risk of bias
After adjustment for baseline
covariates, patients adhering to all
four guideline-recommended
therapies had decreased MACEs
(HR, 0.64; 95% CI, 0.45-0.89), MALEs
(major amputation, thrombolysis,
or surgical bypass; HR, 0.55; 95% CI,
0.37-0.83), and mortality (HR, 0.56;
95% CI, 0.38-0.82) compared with
patients receiving fewer than four





involving 135,000 patients in
comparisons of antiplatelet
therapy vs control and 77,000
in comparisons of different
antiplatelet regimens
Antiplatelet Control Meta-analysis of randomized
trials of various risk of bias
Allocation to antiplatelet therapy
reduced the combined outcome of
any serious vascular event by about
one-quarter; nonfatal myocardial
infarction was reduced by one-
third, nonfatal stroke by one-
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quarter, and vascular mortality by
one-sixth (with no apparent
adverse effect on other deaths).
Absolute reductions in the risk of
having a serious vascular event per
1000 were 36 among patients with
previous myocardial infarction, 38
among patients with acute
myocardial infarction, 36 among
those with previous stroke or
transient ischemic attack, 9 among
those with acute stroke, and 22
among other high-risk patients.
Antithrombotic Trialists’
Collaboration,21 2009
Meta-analysis of 6 primary
prevention trials and 16
secondary prevention trials
Aspirin No aspirin Meta-analysis of individual
participant data from
randomized trials at varying
risk of bias
In the primary prevention trials,
aspirin allocation yielded a 12%
proportional reduction in serious
vascular events (0.51% aspirin vs
0.57% control per year; P ¼ .0001).
Aspirin allocation increased major
gastrointestinal and extracranial
bleeds (0.10% vs 0.07% per year;
P < .0001).
In the secondary prevention trials,
aspirin allocation yielded a greater
absolute reduction in serious
vascular events (6.7% vs 8.2% per
year; P < .0001), with a
nonsigniﬁcant increase in
hemorrhagic stroke but reductions
of about a ﬁfth in total stroke
(2.08% vs 2.54% per year; P ¼ .002)
and in coronary events (4.3% vs
5.3% per year; P < .0001).
In both primary and secondary
prevention trials, the proportional
reductions in the aggregate of all
serious vascular events seemed















international trial at low risk of
bias
Patients treated with clopidogrel had
an annual 5.32% risk of ischemic
stroke, myocardial infarction, or
vascular death compared with
5.83% with aspirin.
Hiatt,23 2017 13,885 patients with symptomatic
PAD, with an ABI of #0.8 or




Clopidogrel (75 mg once daily) Double-blinded randomized trial
at low risk of bias
Patients in both groups had similar
rates of reduction in cardiovascular
(CV) events (CV death, myocardial
infarction, ischemic stroke) and
rates of major bleeding. CV events
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patients receiving clopidogrel (HR,
1.02; 95% CI, 0.92-1.13; P ¼ .65), acute
limb ischemia occurred in 1.7% of
the patients (HR, 1.03; 95% CI, 0.79-
1.33; P ¼ .85), and major bleeding
occurred in 1.6% (HR, 1.10; 95% CI,
0.84-1.43; P ¼ .49).
Recommendation 4.5
Anand,24 2018 7470 patients with PAD of the
lower extremities (previous
peripheral bypass surgery or
angioplasty, limb or foot
amputation, IC (with objective
evidence of PAD), of the
carotid arteries (previous
carotid artery revascularization
or asymptomatic carotid artery
stenosis of at least 50%) or
CAD with an ABI of <0.9
Oral rivaroxaban (2.5




day (5 mg with
aspirin placebo
once a day), or




3 arms Multicenter, blinded patients and
investigators, RCT at low risk of
bias
Rivaroxaban plus aspirin compared
with aspirin alone reduced the
composite end point of CV death,
myocardial infarction, or stroke (126
[5%] of 2492 vs 174 [7%] of 2504;
HR, 0.72; 95% CI, 0.57-0.90; P ¼
.0047) and MALEs including major
amputation (32 [1%] vs 60 [2%]; HR,
0.54; 95% CI, 0.35-0.82, P ¼ .0037).
Rivaroxaban plus aspirin combination
increased major bleeding
compared with the aspirin alone
group (77 [3%] of 2492 vs 48 [2%] of
2504; HR, 1.61; 95% CI, 1.12-2.31; P ¼
.0089).
Recommendation 4.6
Anand,25 2007 2161 patients with PAD Antiplatelet agent þ
oral anticoagulant
agent
Antiplatelet therapy alone RCT Treating 1000 patients with
combination therapy compared
with antiplatelet therapy alone for
3 years would lead to 24 fewer CV
events but 28 more episodes of life-
threatening bleeding, a net
increase in serious adverse
outcomes.
Recommendation 4.7
Mills,26 2011 Meta-analysis of 10 RCTs
enrolling 41,778 patients
High-dose statin Low- or medium-dose statin RCTs at low risk of bias No difference in mortality or CV
mortality. High dose reduced
composite end points of CV death
and nonfatal myocardial infarction




20,536 adults (aged 40-80 years)
with coronary disease, other




Placebo Blinded randomized trial All-cause mortality was signiﬁcantly
reduced (1328 [12.9%] deaths
among 10,269 allocated to
simvastatin vs 1507 [14.7%] among
10,267 allocated to placebo; P ¼
.0003) because of a highly
signiﬁcant 18% proportional
reduction in the coronary death
rate (587 [5.7%] vs 707 [6.9%]; P ¼
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.0005), a marginally signiﬁcant
reduction in other vascular deaths
(194 [1.9%] vs 230 [2.2%]; P ¼ .07),
and a nonsigniﬁcant reduction in
nonvascular deaths (547 [5.3%] vs
570 [5.6%]; P ¼ .4).
Meade,28 2002 1568 men (aged




Placebo Double-blinded randomized trialBezaﬁbrate did not reduce the
incidence of coronary heart disease
and stroke (RR, 0.96; 95% CI, 0.76-
1.21). There were 90 and 111 major
coronary events in the active and
placebo groups, respectively (RR,
0.81; 95% CI, 0.60-1.08), of which 64
and 65 were fatal (RR, 0.95; 0.66-
1.37) and 26 and 46 were nonfatal
(RR, 0.60; 95% CI, 0.36-0.99).
Beneﬁcial effects on nonfatal
events were greatest in men
aged <65 years at entry, in whom
beneﬁt was also seen for all
coronary events (RR, 0.38, 95% CI,
0.20-0.72). There were no
signiﬁcant effects in older men.
There were 60 strokes in those
receiving active treatment and 49
in those receiving placebo (RR, 1.34;
95% CI, 0.80-2.01). There were 204
and 195 deaths from all causes in
the two groups, respectively (RR,
1.03; 95% CI, 0.83-1.26). Bezaﬁbrate
reduced the severity of IC for up to
3 years.
Leng,29 2000 7 RCTs (698 patients with lower
limb atherosclerosis)
Lipid-lowering therapy Systematic review
of 7 RCTs at low
risk of bias
The follow-up period varied from 4
months to 3 years. The overall
quality of the included trials was
high. The trials were
heterogeneous in terms of
inclusion criteria, type of drugs
used, and outcomes measured.
Lipid-lowering therapy produced a
marked but nonsigniﬁcant
reduction in mortality (OR, 0.21;
95% CI, 0.03-1.17) but little change
in nonfatal events (OR, 1.21; 95% CI,
0.80-1.83). In two trials, there was a
signiﬁcant overall reduction in
disease progression on
angiography (OR, 0.47; 95% CI,
0.29-0.77). The changes in ABI and
walking distance were inconsistent,
although trials showed a general
improvement in symptoms that
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Aung,30 2007 18 randomized controlled trials
(10,049 patients with PAD)
Lipid-lowering therapy Systematic review of 18 RCTs The pooled results from all eligible
trials indicated that lipid-lowering
therapy had no statistically
signiﬁcant effect on overall
mortality (OR, 0.86; 95% CI, 0.49-
1.50) or on total CV events (OR, 0.8;
95% CI, 0.59-1.09). However,
subgroup analysis, which excluded
PQRST, showed that lipid-lowering
therapy signiﬁcantly reduced the
risk of total CV events (OR, 0.74; CI,
0.55-0.98). This was primarily due to
a positive effect on total coronary
events (OR, 0.76; 95% CI, 0.67-0.87).
Greatest evidence of effectiveness
came from the use of simvastatin
in people with a blood cholesterol
level$3.5 mmol/L (Heart Protection
Study). Pooling of the results from
several small trials on a range of
different lipid-lowering agents
indicated an improvement in total
walking distance (WMD, 152 m;
95% CI, 32.11-271.88) and pain-free
walking distance (WMD, 89.76 m;
95% CI, 30.05-149.47) but no
signiﬁcant impact on ABI (WMD,
0.04; 95% CI, 0.01 to 0.09).
Rodriguez,31 2017 509,766 patients (aged 21-84
years) in the Veterans Affairs
health care system with two or
more visits for atherosclerotic










During a mean follow-up of 492 days,
there was a graded association
between intensity of statin therapy
and mortality, with 1-year mortality
rates of 4.0% (5103/126,139) for those
receiving high-intensity statin
therapy, 4.8% (9703/200,709) for
those receiving moderate-intensity
statin therapy, 5.7% (1632/28,765)
for those receiving low-intensity
statin therapy, and 6.6% (4868/
73,728) for those receiving no statin
(P < .001). After adjustment for the
propensity to receive high-intensity
statins, the HR for mortality was
0.91 (95% CI, 0.88-0.93) for those
receiving high- vs moderate-
intensity statins. The magnitude of
beneﬁt of high- vs moderate-
intensity statins was similar for an
incident cohort HR of 0.93 (95% CI,
0.85-1.01). For patients aged 76 to
84 years, the HR was 0.91 (95% CI,
0.87-0.95). Patients treated with
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maximal doses of high-intensity
statins had lower mortality (HR,
0.90; 95% CI, 0.87-0.94) compared
with those receiving submaximal
doses.
Recommendation 4.8
SPRINT,32 2015 9361 persons with a systolic blood
pressure of 130 mm Hg or
higher and an increased CV




Target of <140 mm Hg Randomized trial at low risk of
bias
Signiﬁcantly lower rate of the primary
composite (CV) outcome in the
intensive-treatment group than in
the standard-treatment group
(1.65% per year vs 2.19% per year;
HR with intensive treatment, 0.75;
95% CI, 0.64-0.89; P < .001). All-
cause mortality was also
signiﬁcantly lower in the intensive-
treatment group (HR, 0.73; 95% CI,
0.60-0.90; P ¼ .003).
Bavry,33 2010 2699 PAD patients observed for a
mean of 2.7 years
Blood pressure target NA All-cause death, nonfatal myocardial
infarction, or nonfatal stroke
occurred least frequently among
PAD patients treated to an average
systolic blood pressure of 135 to 145
mm Hg and an average diastolic
blood pressure of 60 to 90 mm Hg.
PAD patients displayed a J-shaped
relationship with systolic blood
pressure and the primary outcome,
although individuals without PAD
did not. PAD patients may require
a different target blood pressure
than those without PAD.
ACCORD Study Group,34 2010 4733 participants





Standard therapy, targeting a
systolic pressure of <140 mm
Hg
Low risk of bias, precise Targeting a systolic blood pressure
of <120 mm Hg compared
with <140 mm Hg did not reduce
the rate of a composite outcome of
fatal and nonfatal major CV events.
Moise,35 2016 The objective of this study was to
project the potential value of
adding intensive systolic blood
pressure goals in high-risk
patients to the JNC7 or JNC8
guidelines in a contemporary
population of untreated
hypertensive individuals aged
35 to 74 years.
NA NA Simulation and
state-transition (Markov
cohort) model of incidence,
prevalence, mortality, and
costs of CVD
Adding intensive systolic blood
pressure goals for high-risk patients
prevents an estimated 43,000 and
35,000 annual CVD events
incremental to JNC8 and JNC7,
respectively. Intensive strategies
save costs in men and are cost-
effective in women compared with
JNC8 alone. At a willingness to pay
threshold of $50,000 per quality-
adjusted life-years gained, JNC8 þ
intensive had the highest
probability of cost-effectiveness in
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intensive the highest probability of
cost-effectiveness in men (100%).
Assuming higher drug and
monitoring costs, adding intensive
goals for high-risk patients
remained consistently cost-
effective in men but not always in
women.
Recommendation 4.9
Nathan,36 2005 1441 patients with type 1 DM Intensive therapy Conventional
therapy
Randomized trial
at low risk of bias
Intensive treatment reduced the risk
of any CVD event by 42% (95% CI,
9%-63%; P ¼ .02) and the risk of
nonfatal myocardial infarction,
stroke, or death from CVD by 57%
(95% CI, 12%-79%; P ¼ .02).
van Dieren,37 2014 7768 patients with type 2 DM Intensive glycemic
control
Standard control Randomized trial
at low risk of bias
Feasible intensive control of DM
There was no signiﬁcant reduction in
macrovascular disease, but a trend
was seen toward fewer myocardial
infarctions with more intensive
glucose control.
Selvin,38 2004 13 observational studies (1699
patients with type 1 DM and
7435 patients with type 2 DM)
NA NA Meta-analysis of 13 prospective
cohort studies
The pooled RR for CVD was 1.18; this
represented a 1-percentage point
increase in glycosylated
hemoglobin level (95% CI, 1.10-1.26)
in persons with type 2 DM. Results
in persons with type 1 DM were
similar but had a wider CI (pooled
RR, 1.15; 95% CI, 0.92-1.43).
Recommendation 4.10




Other glucose-lowering drugs Meta-analysis of
trials at overall
low risk of bias
Compared with metformin,
sulfonylurea (SMD, 0.18; 95% CI,
0.01-0.34), thiazolidinedione (SMD,
0.16; 95% CI, 0.00-0.31), dipeptidyl
peptidase 4 inhibitor (SMD, 0.33;
95% CI, 0.13-0.52), and a-
glucosidase inhibitor (SMD, 0.35;
95% CI, 0.12-0.58) monotherapy
was associated with higher
hemoglobin A1c levels.
Sulfonylurea (OR, 3.13 [95% CI, 2.39-
4.12]; RD, 10% [95% CI, 7%-13%])
and basal insulin (OR, 17.9 [95% CI,
1.97-162]; RD, 10% [95% CI, 0.08%-
20%]) were associated with
greatest odds of hypoglycemia.
Recommendation 4.11
Nawaz,40 1998 33 inpatients receiving
metformin
Contrast angiography Retrospective case series Twenty-nine patients had a normal
serum creatinine concentration
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before the procedure and none
had a rise after angiography. Four
patients had an abnormal serum
creatinine concentration before
angiography; all four patients
showed signiﬁcant deterioration
and all four patients died, two of
unrelated causes and two of acute
renal failure and acidosis.
Goergen,41 2010 Systematic review of 5 CPGs on
use of contrast medium in
patients taking metformin
Contrast angiography NA NA Recommendations were inconsistent
regarding need to withhold
metformin in patients with normal
vs abnormal renal function. Not all
guidelines included a speciﬁc time
period. A 48-hour withholding
period was the most common
recommendation. Supporting
evidence was of low quality, and
connection between evidence and
recommendations was unclear.
Recommendation 4.12
Blomster,42 2016 20 countries worldwide
participating in the Action in





daily smokers, and 3124 former
smokers)
Smoking Nonsmoking Prospective observation of
a trial, low risk
of bias
Daily smoking was associated with
increased risk of major CV events
and mortality. Men and women
had similar HRs for most
subcomponents of outcomes.
Newhall,43 2017 Vascular surgery practices Brief smoking
cessation
intervention
Control sites Cluster randomized trial at low
risk of bias
Compared with usual care, patients in
the intervention group were more
likely to express interest in quitting
and to acknowledge their addictive
behaviors, and when resurveyed 3
months after intervention, they had
larger declines in nicotine
dependence and health effects
domains.
Athyros,44 2013 1600 patients with established
coronary heart disease, mean
follow-up 3 years (RCT of
statins)
Atorvastatin No atorvastatin Low risk, RCT The relative effects of statins were
similar in smokers and nonsmokers
(absolute effects were higher in
smokers).
Blomster,42 2016 11,140 patients with type 2 DM
aged $55 years and in CV risk
at the time of randomization.
NA NA Low risk, cohort Daily smoking was associated with
increased risk of all primary and
secondary outcomes with the
exception of major cerebrovascular
disease.




Patients were observed for 4.5 years.
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Evaluation (HOPE) trial, with
either CVD or DM with at least
one additional risk factor (2728
never-smokers, 5241 former
smokers, 936 current smokers)
smokers, had adjusted RRs for CV
death of 1.65 (95% CI, 1.28-2.14), for
myocardial infarction of 1.26 (95%
CI, 1.01-1.58), for stroke of 1.42 (95%
CI, 1.00-2.04), and for total mortality
of 1.99 (95% CI, 1.63-2.44).
Recommendation 4.13
Kondo,46 2011 25,464 healthy Japanese men,
with no known diseases and





Fewer total CVD events were
observed with an increasing
duration of quitting, with a
statistically signiﬁcant reduction in
mortality with quitting for $4 years.







referral to quit line
Usual smoking cessation care Cluster randomized trial without
baseline assessment
More patients in the intervention
group reported “a lot” or “some”
interest in quitting after their initial
appointment with the vascular
surgeon (95.4% vs 85.7%; P ¼ .05).
At 3-month follow-up, 37% of those
with a strong desire to quit were
successful compared with 23% of
those with a weak desire.
Recommendations 6.3, 6.4, and 6.5
Schanzer,47 2008 Patients who underwent
infrainguinal vein bypass
surgery for CLI; two data sets
were used: the PREVENT III
randomized trial (n ¼ 1404)







For a given risk category, the
AFS estimate was consistent
between the derivation and
validation sets.
Stratiﬁcation of the patients in three
risk categories yielded three
signiﬁcantly different Kaplan-Meier
estimates for 1-year AFS (86%, 73%,
and 45% for low-, medium-, and
high-risk groups, respectively).
Bradbury,48 2010 2020 patients with severe lower
limb ischemia due to
infrainguinal disease who
survived for 2 years after
intervention (BASIL trial)
Bypass surgery ﬁrst Balloon angioplasty ﬁrst Multivariate Cox model based on
RCT at low risk of bias
evaluating the effect of
baseline variables
Baseline factors that were signiﬁcant
were BASIL randomization
stratiﬁcation group, below-knee
Bollinger angiogram score, BMI,
age, DM, creatinine level, and
smoking status. The factors that
contributed to the Weibull
predictive model were age,
presence of tissue loss, serum
creatinine concentration, number
of AP measurements detectable,
maximum AP measured, history of
myocardial infarction or angina,
history of stroke or transient
ischemia attack, below-knee
Bollinger angiogram score, BMI,
and smoking status.
Meltzer,49 2013 4985 individuals after bypass
surgery for CLI from the
National Surgical Quality
Improvement Program
Bypass surgery None Retrospective data analysis from




Higher model scores were
signiﬁcantly associated with higher
rates of mortality, all major
morbidities, and 30-day major
morbidity and mortality.
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Simons,50 2016 7754 patients with
CLI from the national SVS VQI
database
Bypass surgery None Retrospective data analysis from
a registry with adequate
outcome and exposure
ascertainment
Three prediction models had similar
discriminative performance: BASIL,
Finland National Vascular
(Finnvasc) registry, and modiﬁed
PREVENT III. A novel VQI-derived
model had improved
discriminative ability with a C index
of 0.71.






None Retrospective data analysis from




In the validation data set, the 30-day
postoperative mortality/
amputation rates in patients with
scores of 0, 1, 2, 3, and 4 were 4.8%,
7.5%, 10.1%, 15.9%, and 22.2%,
respectively (P < .0001); mortality
rates were 0.7%, 2.3%, 4.2%, 5.5%,
and 14.8%, respectively (P < .0001);
and major amputation rates were
4.6%, 5.3%, 6.4%, 11.0%, and 14.0%,
respectively (P ¼ .011).
Recommendation 6.10
Lavery,52 2008 162 patients with large, chronic,
nonischemic diabetic foot
wounds after partial foot
amputation.
NA NA Reanalysis of RCT, moderate risk
of bias
Early changes in percentage of
wound area reduction were
predictive of ﬁnal healing at 16
weeks.
Sheehan,53 2003 203 patients with DFUs NA NA Reanalysis of RCT, moderate risk
of bias
The percentage change in foot ulcer
area after 4 weeks of observation is
a robust predictor of healing at 12
weeks.
Snyder,54 2010 250 control group patients from
two RCTs of human ﬁbroblast-
derived dermal substitute for
treating DFUs
NA NA Reanalysis of data from two RCTsRegardless of baseline size category,
DFUs with <50% persistent area of
reduction at 4 weeks were less
likely to heal by 12 weeks than
DFUs with $50% persistent area of
reduction (P # .001). Sensitivity and
speciﬁcity were higher with cutoff
of 4 weeks than weeks 1 to 3.
Cardinal,55 2008 241 DFUs from patients enrolled
in RCTs on topical wound
treatments
NA NA Reanalysis of data from two RCTsWound margin advance, initial
healing rate, percentage wound
surface area reduction, and wound
healing trajectories (all P < .001)
were powerful predictors of
complete wound healing at 12
weeks. Wounds with poor healing
progress by these criteria at 4
weeks were highly likely to remain
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Recommendation 6.11
Abu Dabrh,56 2015 13 studies enrolling 1527 patients
with CLI
Natural history None Meta-analysis of observational
studies at increased risk of bias
During a median follow-up of 12
months, all-cause mortality rate
was 22% (CI, 12%-33%) and major
amputation rate was 22% (CI, 2%-
42%). Worsened wound or ulcer
was found at 35% (CI, 10%-62%).
The quality of evidence was low
because of increased risk of bias
and inconsistency.
Recommendations 6.6, 6.12, 6.13, and 6.14
Cull,57 2014 139 patients with foot wounds





The WIfI clinical stage was predictive
of 1-year limb amputation (stage 1,
3%; stage 2, 10%; stage 3, 23%; stage
4, 40%) and wound nonhealing
(stage 1, 8%; stage 2, 10%; stage 3,
23%; stage 4, 40%).
Zhan,58 2015 201 patients with threatened
limbs





The amputation group had a
signiﬁcantly higher prevalence of
advanced stage 4 patients (P <
.001), whereas the limb salvage
group presented predominantly as
stages 1 to 3. Patients in clinical
stages 3 and 4 had a signiﬁcantly
higher incidence of amputation
(P < .001), decreased AFS (P < .001),
and delayed wound healing time
(P < .002) compared with those in
stages 1 and 2.
Darling,59 2015 596 limbs of
patients undergoing
an IP angioplasty for CLI
Angioplasty NA Retrospective cohort identiﬁed
using administrative codes,
consecutive sample, adjusted
analysis, no blinded outcome
adjudication
One-unit increase in the WIfI
composite score is associated with
a decrease in wound healing (HR,
1.2; 95% CI, 1.1-1.4) and an increase in
the rate of stenosis (HR, 1.2; 95% CI,
1.1-1.4) and major amputations (HR,
1.4; 95% CI, 1.2-1.8).




gathered registry data of
consecutive patients
Increased WIfI stage was associated
with MALEs (P ¼ .018), reduced
limb salvage (P ¼ .037), and
decreased AFS (P ¼ .048). PREVENT
III risk score category was
associated with mortality (P < .001)
and AFS (P < .001).
Robinson,61 2017 280 threatened limbs. NA NA Retrospective
analysis of prospectively
gathered registry data of
consecutive patients, adjusted
analysis
Increasing WIfI stage was associated
with decreased 1-year Kaplan-
Meier limb salvage (stage 1, 96%;
stage 2, 84%; stage 3, 90%; and
stage 4, 78%; P ¼ .003) and AFS
(P ¼ .006).
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Recommendation 6.17





Patients who had similar
procedures in the 12 months
before the use of vein
mapping
Pre-post nonrandomized study Preoperative mapping was found to
be accurate in 50 of 51 patients
(98%). Vein size as determined by
B-mode ultrasound correlated well
with angiograms, R ¼ 0.85 overall
with R >0.9 in the last 7 months of
the study. Wound complications
occurred in 2% of the patients who
had preoperative mapping and in
17% of the historical controls.
Wengerter,63 1990 239 IP reversed great saphenous
vein graft bypasses placed for
critical ischemia during a 7-
year period
NA NA Nonrandomized prospective
cohort study, unblinded
A pattern of increasing graft patency
and limb salvage was noted as the
minimum external diameter
increased from <3.0 mm to $4.0
mm.








Vein diameter and conduit type were
the dominant technical
determinants of early and late graft
failure.
Recommendations 6.20, 6.21, 6.22, 6.23, and 6.24
Harward,65 1995 450 patients undergoing lower
extremity arterial
reconstruction
NA NA Retrospective unblinded cohort
study
The majority of complications and
deaths occurred in patients
undergoing aortic inﬂow plus
complex outﬂow procedures
(profundaplasty or composite
bypass conduits), in which the
morbidity and mortality rates were
84.2% and 47.4%, respectively,
compared with rates of 45.7% and
2.9% (P < .01) after all other inﬂow/
outﬂow procedures. The increased
difﬁculty of these complex
procedures is reﬂected in the
signiﬁcantly greater blood loss and
operative times (1853 mL and 10.0
hours) compared with similar
values (1125 mL and 7.7 hours; P <
.01) for all other inﬂow/outﬂow
procedures.
Zukauskas,66 1995 1953 aortofemoral
reconstructions were
performed during a 6-year
period




arterial occlusive disease is a safe
and effective method of treating
critical limb ischemia.
Recommendation 6.25





NA Uncontrolled studies Technical success was achieved in
86% to 100% of the patients.
Clinical symptoms improved in
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described in seven studies and
ranged from 1.2% to 6.7%.
Complications were reported in 3%
to 45% of the patients. The most
common complications were distal
embolization, access site
hematomas, pseudoaneurysms,
arterial ruptures, and arterial
dissections.







Technical success was achieved in
92.8% of patients (95% CI, 89.8%-
95.0%; 749 cases). Primary patency
at 12 months was 88.7% (95% CI,
85.9%-91.0%; 787 cases). Subgroup
analyses demonstrated a technical
success rate of 93.7% (95% CI,
88.9%-96.5%) and a 12-month
primary patency rate of 89.6% (95%
CI, 84.8%-93.0%) for TASC C lesions.
For TASC D lesions, these rates
were 90.1% (95% CI, 76.6%-96.2%)
and 87.3% (95% CI, 82.5%-90.9%),
respectively.




Multicenter prospective cohort The primary patency rate for the total
patient population was 97.4%. The
primary patency rates at 12 months
for the TASC II class A and TASC II
class B (C) lesions were,
respectively, 98.3% and 96.6%.
Recommendation 6.26
Indes,70 2013 Meta-analysis of 29 open bypass
studies (3733 patients) and 28
endovascular treatment
studies (1625 patients) in AI
occlusive disease
Direct open bypass Endovascular treatment Mostly observational
comparative studies
Mean length of hospital stay was 13
days for open bypass vs 4 days for
endovascular treatment
procedures (P < .001). The open
bypass group experienced more
complications (18.0% vs 13.4%; P <
.001) and greater 30-day mortality
(2.6% vs 0.7%; P < .001). At 1 year, 3
years, and 5 years, pooled primary
patency rates were greater in the
open bypass group vs the
endovascular cohort (94.8% vs
86.0%, 86.0% vs 80.0%, and 82.7%
vs 71.4%, respectively; all P < .001);
the same was true for secondary
patency (95.7% vs 90.0% [P ¼ .002],
91.5% vs 86.5% [P < .001], and 91.0%
vs 82.5% [P < .001], respectively).
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Chiu,71 2010 29 bypass studies Bypass Endovascular treatment Systematic review of mostly
observational studies
Operative mortality rate was 4.1% for
AFB, 2.7% for IFB, and 2.7% for AI
endarterectomy. Systematic
morbidity rate was 16%, 18.9%, and
12.5%. Local morbidity rate was
6.3% for AFB, 5.7% for IFB, and 2.4%
for AI endarterectomy. Graft-
related morbidity/intervention
failure rates were 3.1%, 4.2%, and
3.8%. Eight studies reported
infection rates after AFB, with a
combined rate of 0.4%. The 5-year
patency rates for patients with CLI
were 79.8% for AFB, 74.1% for IFB,
and 81.7% for AI endarterectomy.
Ricco,72 2008 143 patients with unilateral iliac
artery occlusive disease and
disabling claudication
Crossover bypass Direct bypass Primary patency at 5 years was higher
in the direct bypass group than in
the crossover bypass group
(92.7% 6 6.1% vs 73.2% 6 10%; P ¼
.001). Assisted primary patency and
secondary patency at 5 years were
also higher after direct bypass than
after crossover bypass (92.7% 6
6.1% vs 84.3% 6 8.5% [P ¼ .04] and
97.0% 6 3.0% vs 89.8% 6 7.1% [P ¼
.03], respectively). Patency at 5
years after crossover bypass was
signiﬁcantly higher in patients
presenting with no or low-grade
SFA stenosis than in patients
presenting with high-grade ($50%)
stenosis or occlusion of the SFA
(74.0% 6 12% vs 62.5% 6 19%; P ¼
.04). In both treatment groups,
patency was comparable using
polytetraﬂuoroethylene and
polyester grafts. Overall survival was
59.5% 6 12% at 10 years.
Recommendation 6.27
Kang,73 2008 65 limbs in 58 patients with
occlusive disease of the CFA
CFA endarterectomy NA Retrospective, unblinded,
adjusted analysis
Technical success was achieved in
100% of the cases. The 1- and 5-year
primary patencies were 93% and
91%, respectively.
Ballotta,74 2010 117 patients CFA endarterectomy NA Retrospective, unblinded,
unadjusted analysis
There were no perioperative deaths or
major complications. The 7-year
rates of freedom from further
revascularization and survival were
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Recommendation 6.28
Chang,75 2008 171 patients (mean age, 67 6 10







Technical success occurred in 98% of
patients. Clinical improvement was
seen in 92% of patients. Mean ABI
increased from 0.38 6 0.32 to
0.72 6 0.24. Median length of stay
was 2 days (range, 1-51 days). The
30-day mortality was 2.3%, and 5-
year survival was 60%. The 5-year
primary, primary assisted, and
secondary patencies were 60%,
97%, and 98%, respectively.
Endovascular reintervention was
required in 14% of patients; inﬂow
surgical procedures were required
in 10%. By logistic regression
analysis, use of stent grafts
compared with bare stents was
associated with signiﬁcantly higher
primary patency (87% 6 5% vs
53% 6 7%; P < .01).
Recommendation 6.29
Baumann,76 2011 98 patients with symptomatic
obstructions of the CFA
Endovascular therapy NA Consecutive series, adjusted
analysis
Primary sustained clinical
improvement rates at 3, 6, 12, and
24 months were 55%, 55%, 40%,
and 0% in CLI patients and 81%,
75%, 68%, and 52% in claudicants,
respectively. Limb salvage rates at
24 months were 94% in CLI
patients and 100% in claudicants.
Bonvini,77 2011 97 patients with symptomatic
obstructions of the CFA




Failuresddeﬁned as a ﬁnal
angiographic result with a >30%
residual stenosisdwere observed
on 26 occasions (7.2%). In-hospital
major (ie, requiring surgery) and
minor (ie, treated percutaneously
or conservatively) complications
occurred in 5 (1.4%) and 18 (5.0%)
procedures, respectively.
Gouëfﬁc,78 2017 117 patients with de novo
atherosclerotic lesions of the
CFA
Stenting Surgery Randomized trial, moderate risk
of bias
Primary outcome (mortality and
complications) occurred in 16 of 61
patients (26%) in the surgery group
and 7 of 56 patients (12.5%) in the
stenting group (OR, 2.5; 95% CI, 0.9-
6.6; P ¼ .05). The mean duration of
hospitalization was signiﬁcantly
lower in the stenting group (3.2 6
2.9 days vs 6.3 6 3 days; P < .0001).
At 24 months, the sustained clinical
improvement, the primary patency
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rate, and the target lesion and
extremity revascularization rates
were not different in the two
groups.







Survival was 92.9% at 1 year and 87.2%
at 3 years. AFS, freedom from loss of
patency or death, and
reintervention-free survival were
93.5%, 83%, and 87.5% at 1 year,
respectively. Multivariable
predictors of mortality were tissue
loss, COPD, ESRD, urgent case, and
age, whereas aspirin use and
nonwhite race were protective.
Tissue loss, rest pain, COPD, ESRD,
stent use, nonambulatory status,
and female sex were predictive of
major amputation, whereas aspirin
use, P2Y12 antagonist use, statin
use, and initial technical success
were protective.
Recommendations 6.32, 6.40, and 6.41





NA Noncomparative meta-analysis Prosthetic bypass outcomes were
notably inferior to vein bypass in
terms of amputation and patency
outcomes, especially for below-
knee targets at 2 years and beyond.
DESs demonstrated improved
patency over BMSs in IP arteries
(primary patency, 73% vs 50% at 1
year), which was at least
comparable to balloon angioplasty
(66% primary patency), albeit
within an anatomically restricted
cohort of CLTI patients. Survival,
major amputation, and AFS at 2
years were broadly similar between
endovascular interventions and
vein bypass, with prosthetic bypass
having higher rates of limb loss.
Recommendations 6.33, 6.34, 6.35, 6.36, and 6.37
See Abu Dabrh,56 2015; Zhan,58 2015; Darling,59 2015; Causey,60 2016; Robinson,61 2017
Recommendation 6.38
Chae,81 2016 Meta-analysis of 727 patients








studies at increased risk of bias
Overall limb salvage (OR, 2.209; P ¼
.001) and wound healing rates (OR,
3.290; P ¼ .001) were signiﬁcantly
higher in patients who received
angiosome-targeted angioplasty.
The revision rate was not

































Supplementary Table (online only). Continued.
Study Population Intervention Comparison Methodologic quality Results
Jongsma,82 2017 Meta-analysis of 19 cohort studies





Indirect revascularization Nonrandomized studies at low
risk of bias
Direct revascularization signiﬁcantly
improved wound healing (RR, 0.60;
95% CI, 0.51-0.71), major
amputation (RR, 0.56; 95% CI, 0.47-
0.67), and AFS rates (RR, 0.83; 95%
CI, 0.69-1.00).
Biancari,83 2014 Systematic review and meta-







studies at increased risk
of bias
The risk of unhealed wound was
signiﬁcantly lower after direct
revascularization (HR, 0.64; 95% CI,
0.52-0.8; I2, 0%; four studies
included) compared with indirect
revascularization. Direct
revascularization was also
associated with signiﬁcantly lower
risk of major amputation (HR, 0.44;
95% CI, 0.26-0.75; I2, 62%; eight
studies included). Pooled limb
salvage rates after direct and
indirect revascularization were
86.2% vs 77.8% at 1 year and 84.9%
vs 70.1% at 2 years, respectively. The
analysis of three studies reporting
only on patients with DM
conﬁrmed the beneﬁt of direct
revascularization in terms of limb
salvage (HR, 0.48; 95% CI, 0.31-0.75;
I2, 0%).
Sumpio,84 2013 Systematic review of 11 case
series (1616 patients, 1757
limbs)
Revascularization Mostly retrospective case series
at increased risk of bias
Ten studies compared direct and
indirect revascularization. Five
studies reported that limb salvage
rate was higher with direct
revascularization than with indirect
revascularization (93% vs 72%; P ¼
.02). Five of eight studies that
reported wound healing rates
found a signiﬁcant increase with
direct revascularization compared
with indirect revascularization;
however, length of follow-up varied
between these studies. Mean time
to healing was not signiﬁcantly
different in direct revascularization
compared with indirect
revascularization when analyzed by
three studies. One study found a
signiﬁcant increase in AFS in direct
revascularization compared with
indirect revascularization
(evaluated by three studies). Seven
studies with a predominantly
diabetic population reported limb
salvage as a primary outcome, and
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Azuma,85 2012 228 patients (249 limbs) with CLTIBypass NA Retrospective consecutive case
series
The complete healing of ischemic
wounds was achieved in 211 limbs
(84.7%). ESRD (OR, 0.127; P < .001),
DM (OR, 0.216; P ¼ .030), Rutherford
category 6 with heel ulcer/
gangrene (OR, 0.134; P < 0.001),
Rutherford category 6 except heel
(OR, 0.336; P ¼ .025), and low
albuminemia (OR, 0.387; P ¼ .049)
were negative predictors of wound
healing. Regarding the angiosome,
the healing rate in the indirect
revascularization group was slower
than in the direct revascularization
group, especially in patients with
ESRD (P < .001). However, the
healing rates of the direct and
indirect revascularization groups
were similar after minimizing
background differences with
propensity score methods (P ¼
.185).
Recommendation 6.39





NA Noncomparative meta-analysis Prosthetic bypass outcomes were
notably inferior to vein bypass in
terms of amputation and patency
outcomes, especially for below-
knee targets at 2 years and beyond.
DESs demonstrated improved
patency over BMSs in IP arteries
(primary patency, 73% vs 50% at 1
year), which was at least
comparable to balloon angioplasty
(66% primary patency), albeit
within an anatomically restricted
cohort of CLTI patients. Survival,
major amputation, and AFS at 2
years were broadly similar between
endovascular interventions and
vein bypass, with prosthetic bypass
having higher rates of limb loss.
Schillinger,86 2006 104 patients with severe
claudication or CLTI due to
stenosis or occlusion of the
SFA
Stenting Angioplasty RCT Secondary stenting was performed in
17 of 53 patients (32%) in the
angioplasty group, in most cases
because of a suboptimal result
after angioplasty. At 6 months, the
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was 24% in the stent group and
43% in the angioplasty group (P ¼
.05); at 12 months, the rates on DUS
were 37% and 63%, respectively
(P ¼ .01). Patients in the stent group
were able to walk signiﬁcantly
farther on a treadmill at 6 and 12
months than those in the
angioplasty group.




Multicenter RCT The stent graft group had a
signiﬁcantly higher technical
success rate (95% vs 66%; P <
.0001) and 1-year primary vessel
patency rate at DUS (65% vs 40%;
P ¼ .0003). A patency beneﬁt was
seen for lesions at least 3 cm long.
At 12 months, chronic limb
ischemia status was 15% further
improved for the stent graft group
(P ¼ .003). There were no signiﬁcant
differences between treatment
groups with regard to the
occurrence of early or late major
adverse events.
Dake,88 2011 474 patients with FP PAD (236
primary DES; 238 angioplasty)
DES PTA, provisional BMS Multinational RCT There were 120 patients who had
acute PTA failure and underwent
secondary random assignment to
provisional DES (n ¼ 61) or BMS (n ¼
59). Primary end points were the 12-
month rates of event-free survival
and patency in the primary DES
and PTA groups. Compared with
the PTA group, the primary DES
group exhibited superior 12-month
event-free survival (90.4% vs 82.6%;
P ¼ .004) and primary patency
(83.1% vs 32.8%; P < .001), satisfying
the primary hypotheses. In the
secondary evaluations, the primary
DES group exhibited superior
clinical beneﬁt compared with the
PTA group (88.3% vs 75.8%; P <
.001); the provisional DES group
exhibited superior primary patency
(89.9% vs 73.0%; P ¼ .01) and
superior clinical beneﬁt (90.5% and
72.3%; P ¼ .009) compared with
the provisional BMS group; and the
stent fracture rate (both DES and
BMS) was 0.9% (4/457).
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Rosenﬁeld,89 2015 476 patients with symptomatic









Single-blinded, multicenter RCT At 12 months, the rate of primary
patency among patients who had
undergone angioplasty with the
drug-coated balloon was superior
to that among patients who had
undergone conventional
angioplasty (65.2% vs 52.6%; P ¼
.02). The proportion of patients free
from primary safety events was
83.9% with the drug-coated
balloon and 79.0% with standard
angioplasty (P ¼ .005 for
noninferiority). There were no
signiﬁcant between-group
differences in functional outcomes








vein and 5 polytetra
ﬂuoroethylene
grafts)
DUS NA Prospective evaluation of
consecutive sample,
unblinded and not adjusted
The 30-day primary patency was 99%
(129/130) for FP grafts and 93% (78/
84) for femorodistal grafts.
Secondary patency was 100% (130/
130) and 96% (81/84), respectively.
Primary patency was 89% (16/18) for
those grafts that required
intraoperative revision based on
arteriographic ﬁndings.
Bandyk,91 1994 368 patients after carotid
endarterectomy, infrainguinal
vein bypass, or visceral or renal
reconstruction
DUS NA Uncontrolled and
nonrandomized series
DUS identiﬁed technical (residual
plaque, stricture) or intrinsic
defects (platelet thrombus, distal
thrombosis) requiring revision in 37
(10%) of the reconstructions; low
(<0.5%) complication rate.
Recommendation 7.1
Ubbink,92 2013 Six studies comprising nearly 450
patients with inoperable
chronic CLI
SCS Standard care Controlled nonblinded studies Overall, no signiﬁcantly different
effect on ulcer healing was
observed with the two treatments.
Complications of SCS treatment
consisted of implantation
problems (9%; 95% CI, 4%-15%) and
changes in stimulation requiring
reintervention (15%; 95% CI, 10%-
20%). Infections of the lead or pulse
generator pocket occurred less
frequently (3%; 95% CI, 0%-6%).
Overall risk of complications with
additional SCS treatment was 17%
(95% CI, 12%-22%), indicating a
number needed to harm of 6 (95%
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study) at 2 years were V36,500 (SCS
group) and V28,600 (conservative
group). The difference (V7900) was
signiﬁcant (P < .009).
Recommendation 7.2
Karanth,93 2016 Cochrane review showing no
trials; critical lower limb
ischemia due to
nonreconstructible PAD
LS Standard care NA No trials
Recommendation 7.3










Meta-analysis of randomized and
nonrandomized studies at
increased risk of bias
None of the non-revascularization-
based treatments were associated
with a signiﬁcant effect on
mortality. IPC (OR, 0.14; 95% CI,
0.04-0.55) and spinal cord
stimulators (OR, 0.53; 95% CI, 0.36-
0.79) were associated with reduced
risk of amputation. The quality of
evidence was low because of
increased risk of bias and
imprecision.
Recommendation 7.4
Vietto,95 2018 33 randomized controlled trials
with 4477 participants
Prostanoids Other agents or placebo Meta-analysis of randomized
trials at increased risk of bias
Low-quality evidence suggests no
clear difference in the incidence of
CV mortality between patients
receiving prostanoids and those
given placebo (RR, 0.81; 95% CI,
0.41-1.58).
High-quality evidence suggests that
prostanoids have no effect on the
incidence of total amputations
compared with placebo (RR, 0.97;
95% CI, 0.86-1.09).
Adverse events were more frequent
with prostanoids than with
placebo (RR, 2.11; 95% CI, 1.79-2.50;
moderate-quality evidence).
Recommendation 7.5
Smith,96 2012 8 trials enrolling
269 participants
Naftidrofuryl Other agents or placebo Meta-analysis of randomized
trials at increased risk of bias
The effect of naftidrofuryl was
statistically nonsigniﬁcant on pain,
rest pain, skin necrosis, or mean
ankle systolic pressure.
Recommendation 7.6
Kranke,97 2015 12 trials enrolling
269 participants
HBOT Usual care Meta-analysis of randomized
trials at increased risk of bias
HBOT increased ulcer healing rate in
diabetics without signiﬁcant effect
on other outcomes. Data
speciﬁcally in CLI were limited.
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Game,98 2016 Systematic review
of 30 studies, including
13 HBOT trials
HBOT 11 RCTs and 2 retrospective
cohort studies at increased risk
of bias
Studies have conﬂicting results. It is
not yet clear which patients would
beneﬁt from HBOT.
Santema,99 2018 120 patients with
DM with an ischemic wound
HBOT Usual care RCT After 12 months, 28 index wounds
were healed in the standard care
group vs 30 in the standard care
with HBOT group (RD, 3%; 95% CI,
14 to 21). AFS was achieved in 41
patients in the standard care group
and 49 patients in the standard
care with HBOT group (RD, 13%;
95% CI, 2 to 28). In the standard
care with HBOT group, 21 patients
(35%) were unable to complete the
HBOT protocol as planned. Those
who did had signiﬁcantly fewer
major amputations and higher AFS
(RD for AFS, 26%; 95% CI, 10-38).
Recommendation 8.1










Meta-analysis of randomized and
nonrandomized studies at
increased risk of bias
None of the non-revascularization-
based treatments were associated
with a signiﬁcant effect on
mortality. IPC (OR, 0.14; 95% CI,
0.04-0.55) and spinal cord
stimulators (OR, 0.53; 95% CI, 0.36-
0.79) were associated with reduced
risk of amputation. The quality of
evidence was low because of
increased risk of bias and
imprecision.




Placebo Randomized controlled trials No signiﬁcant differences were
observed in major amputation
rates (RR, 0.91; 95% CI, 0.65-1.27),
survival (RR, 1.00; 95% CI, 0.95-1.06),
and AFS (RR, 1.03; 95% CI, 0.86-1.23)
between the cell-treated and
placebo-treated patients. The ABI
(mean difference, 0.11; 95% CI, 0.07-
0.16), TcPo2 measurements (mean
difference, 11.88; 95% CI, 2.73-21.02),
and pain score (mean difference,
0.72; 95% CI, 1.37 to 0.07) were
signiﬁcantly better in the
treatment group than in the
placebo group.
Recommendation 9.1






Digital amputation Nonrandomized comparative
observational study,
consecutive sample
The median time to major
amputation was (400 6 IQR 1205
days) in the digital amputation
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891 days in the transmetatarsal
amputation group (P ¼ .974); 29.9%
of digital amputations and 15.7% of
transmetatarsal amputations in
diabetic patients required minor
amputations or revision procedures
(P ¼ .04). Median length of hospital
stay was (20 days; IQR, 27 days) in
the digital amputation group and
(17 days; IQR, 17 days) in the
transmetatarsal amputation group
(P ¼ .17). Need for readmission was
48.1% in digital amputation
patients compared with 50% in
transmetatarsal amputation
patients (P ¼ .81). Quality of time
spent without symptoms of disease
or toxicity of treatment was (315
days; IQR, 45 days) in the digital
amputation group and (346 days;
IQR, 48 days) in the transmetatarsal
amputation patients (P ¼ .099).
Recommendation 9.2
Siracuse,102 2015 110,279 patients undergoing
major vascular surgery





Compared with a matched cohort of
high-risk non-DNR patients, those
with DNR orders suffered
equivalent rates of postoperative
morbidity but markedly increased
mortality.
Aziz,103 2015 16,678 patients underwent
emergency vascular
operations





DNR patients were more likely to
have higher rates of graft failure
(8.7% vs 2.4%; adjusted P < .01) and
failure to wean from mechanical
ventilation (14.9 % vs 9.9%; adjusted
P < .001). DNR status was
associated with a 2.5-fold rise in 30-
day mortality (35.0% vs 14.0%; 95%
CI, 1.7-2.9; adjusted P < .001).
Recommendation 9.3
Reed,104 2008 33 Patients who had undergone
BKA or AKA after failed lower
extremity revascularization
NA NA Survey with 39% nonresponse
rate
If faced with a similar scenario, 85%
(28/33 patients) of amputees would
do everything to save the leg; 54%
(18/33) of patients actively used a
prosthesis, and 91% (30/33) resided
at home.
Recommendation 9.4






After profundaplasty, ischemic ulcers
healed in 9 of 17 (53%) patients.
Rest pain was relieved in 6 of 19
(32%), and areas of ischemic
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necrosis healed in 7 of 20 (35%).
Cumulative patency of the deep
femoral artery was 49% at 3 years
but fell to 21% at 5 years, whereas
cumulative limb salvage was 49%
and 36%, respectively. Eleven of the
required 28 amputations were
performed in the immediate
postoperative period.
Profundaplasty was used to lower
the amputation level and to
preserve the knee joint in six
patients. The other ﬁve early
amputations occurred in severely
ischemic limbs without distal
vessels suitable for bypass. The
profundaplasty remained patent in
all 19 patients who underwent BKA,
and 16 (84%) became ambulatory
with a prosthesis.
Miksic,106 1986 282 PFA reconstructions NA NA Uncontrolled
surgical case
series
An inﬂow correction was necessary in
60.3% of PFA reconstructions.
Factors that bear on the success or
failure of profundaplasty were
evaluated. These were AI inﬂow,
extent of disease in the PFA, runoff
in the distal popliteal-tibial system,
and extent of the ischemic lesion.
Of the failures, most were due to
established gangrene, obstructions
throughout the whole length of the
PFA, or poor popliteal-tibial runoff
system. The cumulative limb
salvage at 2 years was 86.8% in
limbs subjected to an inﬂow
correction procedure and
profundaplasty but only 56.5% in
repair of the PFA alone.
Recommendation 9.5
Ayoub,107 1993 32 patients with TKAs for
ischemia
NA NA Uncontrolled consecutive
surgical case
series
Average length of stay was 8.7 days.
One patient required a revision to
AKA. There were no other major
complications.
Taylor,108 2008 309 BKA patients NA NA Uncontrolled consecutive
surgical case
series
Patients with CAD (OR, 0.465; 95% CI,
0.289-0.747), cerebrovascular
disease (OR, 0.389; 95% CI, 0.154-
0.980), and impaired ambulatory
ability before BKA (OR, 0.310; 95%
CI, 0.154-0.623) were less likely to


































Supplementary Table (online only). Continued.
Study Population Intervention Comparison Methodologic quality Results
ambulation, and survival for at least
6 months) with BKA. Patients with
impaired ambulation combined
with another factor had only a 20%
to 23% probability of successful
outcome, and patients with all
three had a 10.4% probability of
success.
Recommendation 9.6
Webster,109 2012 Individuals undergoing their ﬁrst
major lower limb amputation





At 4 months, unsuccessful prosthetic
ﬁtting was signiﬁcantly associated
with depression, prior arterial
reconstruction, DM, and pain in the
residual limb. At 12 months, 92% of
all patients were ﬁtted with a
prosthetic limb, and individuals
with transfemoral amputation
were signiﬁcantly less likely to have
a prosthesis ﬁtted. Age older than
55 years, diagnosis of a major
depressive episode, and history of
renal dialysis were associated with
fewer hours of prosthetic walking.
Recommendation 9.7
Glaser,110 2013 1715 patients undergoing lower
extremity amputation




Cox proportional hazards regression
analysis revealed that ESRD (HR,
3.9; 95% CI, 2.3-6.5), chronic renal
insufﬁciency (HR, 2.2; 95% CI, 1.5-
3.3), atherosclerosis without
diabetic neuropathy (HR, 2.9; 95%
CI, 1.5-5.7), atherosclerosis with
diabetic neuropathy (HR, 9.1; 95%
CI, 3.7-22.5), and initial major
amputation (HR, 1.8; 95% CI, 1.3-2.6)
were independently predictive of
subsequent contralateral major
amputation.
Bradley,111 2006 107 vascular amputees (mean





On analysis, 41% were prescribed a
statin and 39% were prescribed a
statin and 60% an antiplatelet
agent. Whereas 39% of these
patients were receiving both drugs,
32% had been prescribed neither.
Recommendations 10.1, 10.2, 10.3, 10.4, and 10.5 (also see evidence for 4.7 and 4.8)
Bedenis,112 2015 16 studies with 5683 randomized
participants
Nine different treatment groups
were evaluated: aspirin or
aspirin and dipyridamole (DIP)
vs placebo or nothing (six
Antiplatelets Other approaches Meta-analysis of
trials at low to moderate risk
of bias
Graft patency was improved in the
aspirin or aspirin-DIP treatment
group (OR, 0.42; 95% CI, 0.22-0.83;
P ¼ .01; 952 participants).
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studies); aspirin or aspirin-DIP
vs pentoxifylline (two studies);
aspirin-DIP vs indobufen (one
study); aspirin or aspirin-DIP vs
vitamin K antagonists (two
studies); aspirin-DIP vs low-
molecular-weight heparin
(one study); ticlopidine vs
placebo (one study); aspirin vs
PGE1 (one study); aspirin vs
naftidrofuryl (one study); and
clopidogrel and aspirin vs
aspirin alone (one study).
Abbruzzese,113
2004




Statins No statins Retrospective comparative study,
not blinded, adjusted analysis
Perioperative mortality (2.6%) and
major morbidity (3.2%) were not
different between groups. There
was no difference in primary
patency (74% 6 5% vs 69% 6 6%;
P ¼ .25), limb salvage (92% 6 3% vs
90% 6 4%; P ¼ .37), or survival
(69% 6 5% vs 63% 6 5%; P ¼ .20) at
2 years. However, patients taking
statins had higher primary-revised
(94% 6 2% vs 83% 6 5%; P < .02)
and secondary (97%6 2% vs 87%6
4%; P < .02) graft patency rates at 2
years. Of all factors studied by
univariate analysis, only statin use
was associated with improved
secondary patency (P ¼ .03) at 2
years. This was conﬁrmed by
multivariate analysis.
Henke,114 2004 293 patients (338 infrainguinal
bypass procedures
NA NA Retrospective case series Statin drugs were taken by 56% of
patients, ACE inhibitors by 54% of
patients, and antiplatelet agents or
warfarin sodium (Coumadin) by
93% of patients. Statin drug use
was independently associated with
increased graft patency (OR, 3.7;
95% CI, 2.1-6.4) and with decreased
amputation rate (OR, 0.34; 95% CI,
6.15-0.77). Kaplan-Meier analysis
showed that only ACE inhibitors
were associated with lower
mortality (P ¼ .05).
Suckow,115 2015 2067 infrainguinal bypass
patients, from the Vascular
Study Group of New England




Despite higher comorbidity burdens,
long-term survival was better for
patients taking statins in crude (RR,
0.7; P < .001), adjusted (HR, 0.7; P ¼
.001), and propensity-matched
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subgroup analysis, a survival
advantage was evident in patients
taking statins with CLI (5-year
survival rate, 63% vs 54%; log-rank,
P ¼ .01) but not with claudication
(5-year survival rate, 84% vs 80%;
log-rank, P ¼ .59). Statin therapy
was not associated with 1-year rates
of major amputation (12% vs 11%;
P ¼ .84) or graft occlusion (20% vs
18%; P ¼ .58) in CLI patients.
Perioperative myocardial infarction
occurred more frequently in
patients taking a statin in crude
analysis (RR, 2.2; P ¼ .01) but not in
the matched cohort (RR, 1.9; P ¼
.17).
Brown,116 2008 Systematic review
of randomized





No antiplatelet treatment Moderate risk of
bias overall
The administration of a variety of
platelet inhibitors resulted in
improved venous and artiﬁcial graft
patency compared with no
treatment. However, analyzing
patients for graft type indicated
that those patients receiving a
prosthetic graft were more likely to
beneﬁt from administration of
platelet inhibitors than patients
treated with venous grafts.
Willigendael,117 2005 Meta-analysis of data from 29
studies
NA NA Moderate risk of
bias overall
The effect of smoking on graft
patency in the randomized clinical
trials and other prospective studies
had a 3.09-fold (2.34-4.08; P <
.00001) increase in graft failure.
There is a dose-response
relationship, with decreased
patency in heavy smokers
compared with moderate smokers.
Smoking cessation restores
patency rates toward the never-
smokers group.




Usual care Moderate risk of
bias overall
Cochrane reviews have shown
beneﬁts of nicotine replacement
therapy as well as a small but
signiﬁcant beneﬁt from brief
physician advice compared with no
advice (OR, 1.69). More frequent
advice may be marginally more
effective.









The primary efﬁcacy end point was a
composite of index graft occlusion
or revascularization, above-ankle
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amputation of the affected limb, or
death. In the overall population,
the primary end point occurred in
149 of 425 patients in the
clopidogrel group vs 151 of 426
patients in the placebo (plus
aspirin) group (HR, 0.98; 95% CI,
0.78-1.23). In a prespeciﬁed
subgroup analysis, the primary end
point was signiﬁcantly reduced by
clopidogrel in prosthetic graft
patients (HR, 0.65; 95% CI, 0.45-
0.95; P ¼ .025) but not in venous
graft patients (HR, 1.25; 95% CI,
0.94-1.67; not signiﬁcant). A
signiﬁcant statistical interaction
between treatment effect and graft
type was observed (P
[interaction] ¼ .008). Although
total bleeds were more frequent
with clopidogrel, there was no
signiﬁcant difference between the
rates of severe bleeding in the
clopidogrel and placebo (plus
aspirin) groups (2.1% vs 1.2%).
Gassman,120 2014 165 bypasses in patients with
multiple comorbidities (79%
CLTI)
Preoperative aspirin NA Case series Preoperative and postoperative
aspirin use was associated with
increased 2-year secondary
prosthetic graft patency over
control (preoperative, 78% vs 44%
[P < .002]; postoperative, 72% vs
50% [P < 0.01]). Preoperative
aspirin use was associated with an
improvement in the rate of
amputation (OR, 0.44; 95% CI,
0.198-0.997) and stenosis (OR ¼
0.45; 95% CI, 0.217-0.956).
Bhatt,121 2006 15,603 patients with clinically










The primary efﬁcacy end point was a
composite of myocardial infarction,
stroke, or death from CV causes.
The rate of the primary efﬁcacy end
point was 6.8% with clopidogrel
plus aspirin and 7.3% with placebo
plus aspirin (RR, 0.93; 95% CI, 0.83-
1.05; P ¼ .22). The respective rate of
the principal secondary efﬁcacy
end point, which included
hospitalizations for ischemic
events, was 16.7% and 17.9% (RR,
0.92; 95% CI, 0.86-0.995; P ¼ .04),
































Supplementary Table (online only). Continued.
Study Population Intervention Comparison Methodologic quality Results
1.7% and 1.3% (RR, 1.25; 95% CI, 0.97-
1.61; P ¼ .09). The rate of the primary
end point among patients with
multiple risk factors was 6.6% with
clopidogrel and 5.5% with placebo
(RR, 1.2; 95% CI, 0.91-1.59; P ¼ .20),
and the rate of death from CV
causes also was higher with
clopidogrel (3.9% vs 2.2%; P ¼ .01).
In the subgroup with clinically
evident atherothrombosis, the rate
was 6.9% with clopidogrel and
7.9% with placebo (RR, 0.88; 95%
CI, 0.77-0.998; P ¼ .046).





Placebo plus aspirin Double-blinded, placebo-
controlled RCT
Clopidogrel plus aspirin inhibits
platelet function more than aspirin
alone. Platelet function in the
clopidogrel group was signiﬁcantly
suppressed compared with
baseline at 1 hour, 24 hours, and 30
days after endovascular
intervention (stimulated ﬁbrinogen
binding by 53.9%, 51.7%, and 57.2%,










Aspirin and placebo Blinded trial at low risk of bias At 6 months, clopidogrel patients had
signiﬁcantly lower rates of target
lesion revascularization compared
with placebo patients (2 [5%] vs 8
[20%]; P ¼ .04). After stopping
clopidogrel-placebo after 6
months, there was no signiﬁcant
difference in target lesion
revascularization at 12 months after
treatment (9 [25%] clopidogrel vs
12 [32.4%] placebo; P ¼ .35).
Mortality was 0 vs 1 in the placebo
group at 6 months (P ¼ .32) and
0 vs 3 at 12 months (P ¼ .08).
Dual antiplatelet therapy reduces
peri-interventional platelet
activation and improves functional
outcome without higher bleeding
complications.




Placebo and aspirin Blinded trial at low risk of bias Clopidogrel and aspirin inhibited
platelet function more than aspirin
alone in patients with claudication
before and after angioplasty.
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Recommendation 10.10
Mills,125 2001 156 autogenous infrainguinal vein
grafts in 142 patients
DUS surveillance NA Uncontrolled and not blinded The incidence of graft thrombosis
was 3% per year (mean follow-up,
27.5 months). Intermediate lesions
developed in 32 grafts (20%).
Among these 32 grafts with
intermediate stenoses, 63%
progressed to critical and were
revised, and 32% resolved or
stabilized.
Recommendation 10.11
Landry,126 2002 330 surgical graft revisions were






The assisted primary patency rate of
all grafts, the limb salvage rate for
patients undergoing surgery for
limb salvage indications, and the
survival rate of all patients were
87.4%, 88.7%, and 72.4%,
respectively, 5 years after the
original bypass grafting procedure;
85.7%, 83.4%, and 67.8%,
respectively, 7 years after the
original bypass grafting procedure;
and 80.4%, 75.4%, and 53.4%,
respectively, 10 years after the
original bypass grafting procedure.
A total of 180 revisions (55%) were
performed during the ﬁrst year, 110
revisions (33%) were performed
between the ﬁrst year and the ﬁfth
year, and 40 revisions (12%) were
performed on grafts older than 5
years. Lower extremity vein grafts
revised within the ﬁrst year after
bypass grafting had lesions within
the graft in 78%, in the native
arterial inﬂow in 10%, and in the
native arterial outﬂow in 12%. This
differed signiﬁcantly from the
location of lesions in revisions
performed between 1 year and 5
years and after 5 years (graft, 63%
and 62%; inﬂow, 20% and 19%;
outﬂow, 17% and 19% (P > .05, c2
test).
Nguyen,127 2004 188 vein grafts, from
a total series of 1260 bypasses,









There was no difference in patency
rate for different revision
procedures, type of vein graft,
indication for the original
procedure, or patients with DM or
renal disease. The overall limb
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years after graft revision. With Cox
proportional hazards analysis of
time to failure of the revision
procedure, the outﬂow level of the
original bypass and the time of
revision proved to be important
predictors of durability of the graft
revision. Revision of popliteal
bypass grafts resulted in a 60% 5-
year primary patency rate, whereas
revision of tibial grafts resulted in a
42% 5-year primary patency rate
(P ¼ .004; HR, 2.06). Five-year
secondary patency rates were 90%
and 76%, respectively (P ¼ .009;
HR ¼ 3.43). The timing of the graft
revision proved to be an additional
predictor. Grafts revised within 6
months of the index operation had
lower primary patency than those
with later revisions (42.9% vs 80.7%;
HR, 1.754; P ¼ .0152).
Recommendation 10.12
Bui,128 2012 94 limbs (85 patients) underwent
endovascular therapy for SFA-
popliteal disease
NA NA Prospective nonrandomized
study, consecutive sampling,
unblinded
The initial scan ﬁndings were normal
in 61 limbs (65%), and serial DUS
results remained normal in 38
(62%). In 17 limbs (28%), progressive
stenoses were detected during
surveillance. The rate of thrombosis
in this subgroup was 10%.
Moderate stenoses were detected
in 28 (30%) limbs at initial scans; of
these, 39% resolved or stabilized,
47% progressed to severe, and
occlusions developed in 14%. Five
(5%) limbs harbored severe
stenoses on initial scans, and 80%
of lesions resolved or stabilized.
Progression to occlusion occurred
in one limb (20%). The last DUS
showed that 25 limbs harbored
severe stenoses; of these, 13 (52%)
were in symptomatic patients and
thus required reintervention
regardless of DUS ﬁndings. Eleven
limbs (11%) eventually occluded.
Sensitivity and speciﬁcity of DUS to
predict occlusion were 88% and
60%, respectively.
































Supplementary Table (online only). Continued.
Study Population Intervention Comparison Methodologic quality Results
Recommendation 10.13
Humphries,129 2011 122 infrainguinal interventions for
CLI in 113 patients (53% male;
mean age, 71 years)
Early DUS Normal DUS Nonrandomized prospective
comparative study, unblinded
or adjusted
There were 50 patients who had an
abnormal ﬁnding on early DUS and
40 patients who had a normal
ﬁnding. In patients with a normal
DUS ﬁnding, the amputation rate
was 5% vs 20% in the group with
an abnormal ﬁnding (P ¼ .04).
Primary patency was 56% in the
group with a normal ﬁnding and
46% in the group with an abnormal
ﬁnding (P ¼ .18). Early DUS was able
to identify a residual stenosis not
seen on completion angiography in
56% of cases.
Recommendations 10.14 and 10.15
Elraiyah,130 2016 19 interventional studies, of
which 13 were randomized
controlled trials, including data
from 1605 patients with DFUs
using an ofﬂoading method
Ofﬂoading
approaches
Usual care The risk of bias in
the included studies was
moderate.
This analysis demonstrated improved
wound healing with total contact
casting over removable cast walker,
therapeutic shoes, and
conventional therapy. There was no
advantage of irremovable cast
walkers over total contact casting.
There was improved healing with
half-shoe compared with
conventional wound care.
Therapeutic shoes and insoles
reduced relapse rate in comparison
with regular footwear. Data were
sparse regarding other ofﬂoading
methods.
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; AFB, aortofemoral bypass; AFS, amputation-free survival; AI, aortoiliac; AKA, above-knee amputation; AP, ankle pressure; AT, anterior
tibial; BASIL, Bypass vs Angioplasty in Severe Ischaemia of the Leg; BKA, below-knee amputation; BMI, body mass index; BMS, bare-metal stent; CAD, coronary artery disease; CFA, common femoral
artery; CI, conﬁdence interval; CLI, critical limb ischemia; CLTI, chronic limb-threatening ischemia; COPD, chronic obstructive pulmonary disease; CPGs, clinical practice guidelines; CT, computed
tomography; CTA, computed tomography angiography; CV, cardiovascular; CVD, cardiovascular disease; DES, drug-eluting stent; DFUs, diabetic foot ulcers; DIP, dipyridamole; DM, diabetes
mellitus; DNR, do not resuscitate; DOR, diagnostic odds ratio; DSA, digital subtraction angiography; DUS, duplex ultrasound; ESRD, end-stage renal disease; FP, femoropopliteal; HBOT, hyperbaric
oxygen therapy; HR, hazard ratio; IC, intermittent claudication; IFB, iliofemoral bypass; IP, infrapopliteal; IPC, intermittent pneumatic compression; IQR, interquartile range; JNC, Joint National
Committee; LS, lumbar sympathectomy; MACEs, major adverse cardiac events; MALEs, major adverse limb events; MRA, magnetic resonance angiography; NA, not applicable; OR, odds ratio; PAD,
peripheral artery disease; PFA, profunda femoris artery; PGE1, prostaglandin E1; Pk-PT, posterior tibial artery peak ﬂow velocity; PREVENT III, Project of Ex-vivo Vein graft Engineering via Transfection
III; PT, posterior tibial; PTA, percutaneous transluminal angioplasty; RCT, randomized controlled trial; RD, risk difference; ROC, receiver operating characteristic; RR, relative risk; SCS, spinal cord
stimulation; SFA, superﬁcial femoral artery; SMD, standardized mean difference; SVS, Society for Vascular Surgery; TASC II, TransAtlantic Inter-Society Consensus II; TBI, toe-brachial index; TcPo2,
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